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PARKINSON'S DISEASE (PD) 
PD is one of the most common neurodegenerative disorders of the central nervous system 
(CNS). Up to 2% of the population older than 60 years of age develops PD, with aging as 
one of the major risk factors. The disease is usually characterized by typical early motor 
symptoms such as tremor, rigidity, bradykinesia, postural instability and difficulties in 
gait. Historically PD was discovered and first described by the English physician James 
Parkinson. Already in 1817 he described and published the condition in "An Essay on the 
Shaking Palsy" (Parkinson 2002). Even though the symptomatic appearance of PD was 
very extensively described in this assay, Parkinson could not know about the cellular and 
molecular basis of the disease. 
One of the most studied physiological changes linked to PD is the specific loss of 
dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) in the ventral 
midbrain. This specific and progressive cell death results in reduced dopamine secretion 
in the striatum, the target area of SN neurons, which causes the typical motor symptoms 
mentioned earlier. The initial cause of the deterioration however is yet not well understood. 
In principle one can distinguish two types of PD, one being the idiopathic form and the 
other, much less often occurring genetic or familiar, heritable form. Not much is known 
about factors that might cause idiopathic PD. Although, there are several indications that 
might explain a particularly high sensitivity of midbrain DA neurons, it is not entirely clear 
what makes SN DA neurons more vulnerable to toxic insults then other neurons. Pesticides, 
such as rotenone and paraquat or herbicides might be a risk factor (Betarbet et al. 2000; 
A. I. Brooks et al. 1999). Surprisingly, there is also evidence that cigarette smoking but also 
intake of caffeine reduces the risk of PD (Ross & Petrovitch 2001). Besides, there seems 
to be a gender-specific prevalence, since PD is more observed in males then in females 
(Shulman 2007). However, the most penetrant risk factor for idiopathic PD is advanced age. 
The risk increases with further aging since that allows the accumulation of environmental 
as well as genetic factors that favor the development of PD. 
Genetics of PD 
Over the years several genetic mutations have been linked to PD. The most widely described 
form of familial PD presents with a mutation in the SNCA gene (autosomal dominant), 
coding for the protein a-synuclein. PD specific mutations in the SNCA gene result in 
increased 13-sheet structures in a-synuclein, which in turn increases the formation of 
accumulated fibrillar structures that eventually resemble so called Lewy bodies (LBs). 
LBs are one of the cardinal physiological symptoms of PD but are also described in other 
diseases such as dementia with LBs, multiple system atrophy (MSA) and Alzheimer's 
disease (AD), which are therefore summarized under the name a-synucleinopathies. After 
the initial identification of the G209A (A53T) point mutation in pathogenic SNCA, two 
other missense mutations have been discovered, G188A (G46L) and G88C (A30P) that 
seemed to be associated to PD (Sherer et al. 2002; B. D. Lee et al. 2010). Also the occurrence 
of duplications and triplications of SNCA has been linked to familial PD (Johnson et al. 
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2004; Singleton et al. 2004; Ikeuchi et al. 2008). These studies showed that expression 
levels of a-synuclein directly correlate with the onset of the disease, since triplication 
leads to an earlier onset compared to duplications of the SNCA gene. Animal and cell 
culture studies confirmed the neurotoxicity of mutant a-synuclein, but also abundantly 
expressed wild-type a-synuclein (caused by gene multiplications) seemed to have toxic 
properties. (Conway et al. 1998; Moore et al. 2005). The notion that the neurotoxic effect of 
a-synuclein is caused by its ability and high propensity to form aggregates has been tested 
in vitro, and it appears that abundant or mutated a-synuclein tends to form J3-sheet-rich 
secondary structures that are prone to oligomerize and subsequently form multi-oligomer 
fibrillar aggregates (H. -J. Lee et al. 2002; V. M. -Y. Lee & Trojanowski 2006; Tia go Fleming 
Outeiro et al. 2007; Sharon et al. 2003). Specifically A53T and A30P mutations are the 
source for the formation of a-synuclein oligomers. It is indicated that the oligomeric 
form of a-synuclein is in fact the toxic entity in PD pathogenesis (Conway et al. 1998; 
Conway et al. 2000). Oligomeric a-synuclein is predominantly membrane-bound and 
seems to initiate the formation of soluble oligomers while PD progresses. This seeding 
effect of oligomerized protein is also found in prion-like pathologies such as scrapie and 
BSE (bovine transmissible spongiform encephalopathy) in animals and Creutzfeld-Jacob 
disease in humans. Homologies of disease spreading have been found in tissue grafts of 
PD patients several years after transplantation (Jeffrey H Kordower et al. 2008; J.-Y. Li et 
al. 2008) and have raised questions about similar properties of a-synuclein and prions 
(Angot & Patrik Brundin 2009; Angot et al. 2010). Moreover, it has been described that 
DA has a stabilizing effect on a-synuclein aggregates, which might provide indications 
why DA neurons appear to be particular susceptible in the cause of PD (Tiago F Outeiro 
et al. 2009). Taken together, a-synuclein in its mutated form(s) is considered to be one of 
the best characterized players that underlie familiar PD pathogenesis. 
A second autosomal dominant gain-of-function mutation affects the LRRK2 gene 
(leucin-rich repeat kinase 2). The most common mutation in LRRK2 linked to PD is a 
point mutation in the kinase domain (G2019S), This mutation is also found in cases of the 
sporadic form of the disease (Dachsel & Farrer 2010). Patients carrying this mutation have 
a very high risk (approx. 80%) to develop PD late in life (80+ years) regardless whether 
they carry the hetero- or homozygous form (Healy et al. 2008). LRRK2 driven PD does not 
necessarily need to present with Lewy body pathology ( Gaig et al. 2009; Marti-Masso et 
al. 2009) underlining the notion that Lewy bodies might indeed rather be a consequence 
then a cause of PD. 
Parallel to autosomal dominant PD related mutations there are several genes with 
autosomal recessive mutations that have been identified to be causative to PD as well. These 
genes encode for PINKl, parkin and DJ-1. Out of these three, mutations in parkin are 
linked to the most common form in autosomal recessive PD and usually cause an early­
onset disease. Even though several reports describe the presence of Lewy bodies in cells of 
patients, degeneration of SNc DA neurons seems to be the main pathological characteristic 
(Park et al. n.d.; Andrew J Lees et al. 2009; Hardy 2010). Because of their involvement in 
juvenile (early-onset) PD, PINKl and parkin have been studied most intensively. Drosophila 
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genetic studies have shown that Pinkl and parkin are part of a common pathway in which 
parkin acts downstream of Pinkl (Park et al. 2006; Clark et al. 2006). Both proteins are 
crucially involved in a process called mitophagy, the cellular autophagic response to 
damaged mitochondria. Thus, loss-of-function mutations in either of the genes might 
have significant disruptive effects on that process which would provide the link between 
mitochondrial dysfunction and PD. Moreover, recent studies point towards a more complex 
role of parkin by its interaction with PARIS (also known as ZNF746), a functional repressor 
with a Kruppel-associated box (KRAB) domain in its N-terminus (Shin et al. 2011). One 
of the described functions of parkin as an E3 ubiquitin ligase lies in the participation in 
the proteasomal degradation system (T. M. Dawson & V. L. Dawson 2010). Now, Shin et al. 
(2011) have shown that it ubiquitylates PARIS and that mutated parkin (as linked to PD) 
results in decreased amounts of ubiquitylated PARIS, which in turn leads to accumulation 
of PARIS, since it no longer undergoes proteasomal degradation. As it turned out there 
seems to be an inverse correlation between parkin and PARIS, meaning that increased 
parkin results in decreased PARIS and vice versa. This also had been confirmed in patients 
with sporadic PD, were PARIS levels where twice as high in the striatum and the SN. After 
the novel interaction between parkin and PARIS had been established the question arose 
what the normal targets of PARIS were. Shin and colleagues found that PARIS binds to 
the promoter of peroxisome proliferator-y (PPARy) coactivator-la in order to repress 
it. Besides, also nuclear respiratory factor-I (NRF 1) has been shown to be regulated by 
specific interaction of PARIS. Both factors, PGC-la and NRFI, are crucially involved in 
mitochondrial biogenesis (St-Pierre et al. 2006). PGC-la knock-out mice for example 
show reduced gene expression levels of cytoplasmic superoxide dismutase 1 (SODI), 
mitochondrial SOD2 and peroxisomal catalase, enzymes important to metabolize reactive 
oxygen species (ROS). Earlier, parkin had been shown to be involved in mitochondrial 
biogenesis (Kuroda et al. 2006). However, now there is evidence pointing towards a pathway 
connecting (functional) parkin to its novel interaction partner PARIS, which has indirect 
effects on ROS metabolizing enzymes (for review see Castillo-Quan 2011). 
Sensitivity of mDA neurons 
Since physiological aging appears to be one of the major risk factors for PD, one needs 
to ask what makes SNc DA neurons more vulnerable than other types of neurons that 
undergo the same process? Over the years, several hypotheses have been formulated 
in order to explain this specific character trait of mDA neurons. SNc DA neurons have 
a number of features, which clearly distinguishes them from other neurons. One of the 
most obvious differences is the presents of the polymer pigment neuromelanin, which is 
accountable for the characteristic, name-giving coloration of the SNc. Neuromelanin is 
specifically accumulated in the SN and in noradrenergic neurons of the locus coeruleus 
(Marsden 1961). These pigments contain for example dopamine or dopamine metabolites 
but also varying proteins and lipids and seem to function as cellular antioxidant and metal 
storage (Fedorow et al. 2005; J. Li et al. 2005; Bohic et al. 2008). The properties of these 
pigments seem to point to a protective function in SNc DA neurons, which are known for 
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their high oxidative processes due to high metabolic rates (for review see Double 2012). 
Another characteristic of SNc DA neurons is their function as neuronal pacemakers, which 
typically show autonomous activity, even in the absence of synaptic input, which in turn 
might be the reason for previously mentioned high metabolic rates. This constant activity 
involves Ca++ channels (also called L-type Ca++ channels) located across the membrane of 
SN neurons (Bonci et al. 1998; Puopolo et al. 2007). This is different to other neurons where 
mainly Na+ channels conduct changing membrane potentials. As a result, almost constant 
activity of the SNc DA neurons causes a drastic influx of Ca++ that usually needs to be 
maintained at basal levels (intracellular Ca++ levels are normally 10.000 times lower then 
extracellular levels). This strong Ca++ influx is then counteracted against by ATP-dependent 
Ca++ pumps. In most other neuron types such intracellular Ca ++ increase only happens 
occasionally and can be compensated with rather low metabolic expenses. However, in SNc 
DA neurons this frequent event results in a continuously high intracellular Ca++ content and 
its homeostatic levels can only be re-established at the cost of very high metabolic rates. To 
reduce cytosolic Ca++ normally the endoplasmatic reticulum (ER) and mitochondria are 
involved in the buffering process (Berridge 1998; Rizzuto & Pozzan 2006). In particular 
the accumulation of Ca++ in the mitochondrial matrix causes a significant lavishness of the 
electrochemical gradient, which is indispensable to drive oxidative phosphorylation (OP) 
processes. Besides, attempts to reduce Ca++ levels in the mitochondrial matrix also rely on 
ATP-dependent pumps. 
So together, the autologous pacemaker function of SNc DA neurons seems to result in 
an intrinsic predisposition for these neurons to become more heavily loaded with oxidative 
stress due to a need for higher metabolic rates. In turn oxidative stress ( which is considered 
a major contributor to aging) caused by elevated levels of ROS and free radicals ( due to 
increased rates of OP) seem to induce a more accelerated aging process in SNc DA neurons. 
Moreover, increased ROS generated by high rates of OP cause damage in mitochondrial 
DNA (Wallace 2005). In a healthy brain, mitochondria containing damaged DNA might 
undergo the earlier described process of mitophagy; however, if mitophagy is compromised 
or malfunctioning due to missense mutations in e.g. the genes for parkin or PINKl, the 
homeostasis maintaining process might succumb to a metabolic overload combined with 
PD specific loss-of-function mutations. 
Together, the described SNc DA neuron characteristics and the resulting cellular 
processes partly explain an increased susceptibility of these neurons. And, accompanied 
by genetic modification as described above, they most likely account for the specific and 
progressive loss of DA neurons during PD (for a schematic summary see figure 1, modified 
from Schapira 2006). 
Therapeutical approaches for PD 
Pharmacological: In the late 60's the dopamine precursor L-3,4-dihydroxiphenyalanine 
(also know as L-Dopa or levodopa) has been identified as beneficial for PD for the first 
time (Cotzias 1968). Treatment of PD with L-Dopa was, and still is the most commonly 
used approach. L-Dopa effectively restores DA levels in the brain of patients and therefore 
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Fig. I: Schematic overview of environmental and genetic factors contributing to PD. Both influence 
mitochondrial dysfunction, increased ROS production, free radicals and proteasomal dysfunction. 
Combinations of these events can lead to loss of DA neurons. 
drastically reduces all PD associated motor symptoms. However, it became clear that 
prolonged L-Dopa administration caused severe side effects. These sides effects are mainly 
motor complications ( dyskinesia) that are comparable to motor symptoms caused by PD. 
L-Dopa induced dyskinesia results from fluctuating L-Dopa levels ( due to a wearing off 
effect) in the plasma of PD patients, which leads to the extensively described "on" and "off" 
state (Shoulson et al. 1975; Marsden & Parkes 1976; A J Lees et al. 1977). In order to improve 
this fluctuation, trials have been started to investigate continuous delivery of L-Dopa, 
e.g. by intravenous injection (Hardie et al. 1984; Quinn et al. 1984). Another successful 
approach combined catecholmethyltransferase (COMT) inhibitors with L-Dopa in order to 
increase the half-life as well as the bioavailability for a single daily dose of L-Dopa (Andrew 
J Lees 2008). Furthermore, since the significant contribution of oxidative stress to PD is well 
established, other pharmacological attempts employed monoamine oxidase B (MOA-B) 
inhibitors in order to reduce the oxidative burden of the SNc neurons. The benefit from 
MOA-B treatment was mainly the neuroprotective component, which in turn allowed a 
delayed introduction of L-Dopa treatment (Olanow & Caine 1992). 
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Surgical: As early as the 1950s surgical interventions have been performed to treat 
parkinsonian symptoms. Thalamotomy (an invasive procedure in which selected parts 
of the thalamus are surgically ablated) seem to have excellent beneficial effects on the 
tremor of PD patients (Scott et al. 1970). The most applied treatment nowadays next to 
L-Dopa administration however is high-frequency deep brain stimulation (DBS). By using 
parkinsonian animal models it has been discovered that over-activity of the globus pallidus 
and the subthalamic nucleus is neutralizing motor symptoms (Benazzouz et al. 1993). A 
third surgical method to treat PD was pallidotomy, in which a small electrode is inserted in 
the globus pallidus to destroy a restricted area by a short pulse of heat (80 degrees Celsius 
for 60 seconds) (Laitinen et al. 1992; Laitinen 1995). DBS however has been applied by far 
more often and appears to be one of the most effective ways to reduce PD related motor 
symptoms. Nonetheless, these surgical interventions may reduce symptoms and therefore 
slow down the progressing disease but they do not lead to a cure. 
Gene therapy: Currently there are four studies ongoing in which gene therapy is analyzed 
as possible tool to treat PD to some extent. The preferred vectors for these studies make use 
of adeno-associated viruses and lenti viruses. Firstly, the neuroprotective effects of glia­
derived neurotrophic factor (GDNF) have been intensively studied. GNDF was shown not 
only to be neuroprotective for DA neurons, it also appeared to promote an increase in 
neuron cell body size and in the number of neurites and to stimulate their outgrowth (Lin 
et al. 1993; Stromberg et al. 1993). The neuroprotective properties of GDNF clearly reduced 
or even prevented nigrostriatal DA cell death in parkinsonian animal models ( Gash et al. 
1996; Hoffer et al. 1994; Tomac et al. 1995; J H Kordower et al. 2000) As a result of these 
promising animal studies open-label trials have been started in patients (Gill et al. 2003; 
Slevin et al. 2007). Even though these studies were encouraging, double-blind randomized 
controlled trails did not result in a comparably beneficial outcome (Lang et al. 2006; Nutt 
et al. 2003). The second gene therapy approach aimed at aromatic L-amino decarboxylase 
(AADC), which is the enzyme that converts L-Dopa to dopamine. The main goal here was to 
improve the ability of the remaining DA neurons to convert pharmacologically administered 
L-Dopa. In primate studies, human AADC gene delivery was shown to drastically reduce 
MPTP induced motor deficits (Bankiewicz et al. 2006). Based on these preclinical studies 
a phase I trial had been started on humans. AADC delivery in the putamen resulted in 
significant improvements for the patients (Christine et al. 2009). The problem however was 
that increased AADC activity still required L-Dopa administration. Attempts to circumvent 
L-Dopa treatment employed tricystronic lentiviral constructs that coded for TH, AADC 
and GCHl (GCHl functions as a crucial cofactor for TH). Also here animal model based 
studies were highly promising (Azzouz et al. 2002; Jarraya et al. 2009) and therefore 
phase I/II clinical trails are currently running but have not resulted in published data (for 
review see (Berry & Foltynie 2011). The last gene therapy approach described here aims to 
introduce glutamic acid decarboxylase (GAD), which is responsible for GABA synthesis, in 
the subthalamic nucleus in order to decrease over-activity of this particular brain area. In 
rodent and primate models behavioral recovery could be observed and subsequent phase 
I trials resulted in small improvements in a small group of PD patients (Luo et al. 2002; 
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Emborg et al. 2007; Kaplitt et al. 2007). Further research will have to show to what extent 
PD specific gene therapy really improves the course of the disease. 
Embryonic tissue grafting: Even though tissue grafting is also a form of surgical 
intervention it will be briefly discussed here in a separate section. The first clinical trials 
using fetal ventral mesencephalic (VM) tissue grafts have been conducted in the late 1980s in 
Mexico (Madrazo et al. 1988) and Sweden (Lindvall et al. 1989). Embryonic tissues had been 
isolated from abortion-derived embryos and transplanted in the striatum of patients. The 
outcome of these first attempts, however, had been poor in terms of disease improvement. 
After considerable technical improvement, several open-label trials have been performed. 
Results were highly variable but for some patients clear improvement of motor behavior 
could be seen (P Brundin et al. 2000; Freed et al. 1992; Spencer et al. 1992). However, other 
patients from the same cohort did either show only small or no improvements at all. Although 
these studies did not allow conclusions as to what extent fetal grafting benefits PD patients, 
double-blind placebo controlled transplantation experiments were performed. In one of the 
first controlled trials, 40 PD patients either received a fetal transplant or sham surgery (Freed 
et al. 2001). Scoring of motor symptoms 1 year after surgery did not reveal any significant 
improvement when comparing the treated with the untreated group. Interestingly, follow­
up analyses ( up to 4 years) revealed a significant amelioration in the commonly used unified 
PD rating score (UPDRS), particularly in patients below the age of 60. The concluding 
assumption that grafting would be more beneficial in younger subjects had to be rejected 
after a recent study (Y. Ma, Tang, et al. 2010) showed that the levels of improvement had to 
do with preoperative L-Dopa responsiveness rather than with the age of the patients. The 
reason for that seems to be the comparably high residual levels of dopamine still present in 
the putamen of these patients. As described by Ma and colleagues (Y. Ma, Tang, et al. 2010), 
beneficial effects in older patients with a good preoperative L-Dopa responsiveness were 
only seen at later time points and it was argued that this was the consequence of a slower 
recovery rate which nonetheless resulted in equally beneficial outcomes. So in conclusion, 
improvement observed in motor symptoms could not unambiguously be linked to VM 
tissue grafting. In addition and even more alarming was the observation of graft-related 
development of dyskinesias (GID - graft induced dyskinesia) in 15% of the patients after 
approx. 1 year (Olanow et al. 2001). In some of these cases GID needed to be treated with 
DBS in order to make this side effect bearable. 
When evaluating the results of all the transplantation studies conducted to date, it is 
difficult to reach a clear conclusion to what extent fetal VM tissue grafting might become 
a clinical tool to treat PD in the future. Not only the technical obstacles that are associated 
with such an intervention but also weighty ethical issues might make it impossible to 
consider this sort of approach as a feasible clinical tool. However, the knowledge gained by 
the described studies will certainly be helpful and can be translated to future technologies 
employing multipotent/pluripotent stem cells as novel tools to treat PD via intracerebral 
grafting. The implications of neural stem cells, embryonic stem cells and induced pluripotent 
stem cells as sources for PD therapy but also for disease modeling will be discussed in the 
following section. 
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Cel l  based thera py 
As indicated in the section above, the chances to use human fetal VM tissue as clinical 
source to re-establish/replace DA neurons in the striatum of PD patients appear to be 
highly unlikely. However, the specific loss of a specialized subtype of neurons in a rather 
confined area of the brain makes cell replacement strategies for PD very attractive. In 
order to circumvent both ethical and technical issues with human fetal material, extensive 
research has been done on the possible application of stem cells as source for DA neurons. 
To date the capacities of three different types of stem cells have been investigated. 
The first cell type that has been considered were neural stem cells (NSCs). In vivo, 
NSCs can be found in the developing neural tube but also in the adult brain. In the latter, 
NSCs are present in the subventricular zone (SVZ) and in the subgranular zone (SGZ) of 
the hippocampus (F H Gage 2000; Kintner 2002). NSCs are capable to self-renew and are 
multipotent, meaning they are a lineage-specific stem cell type that is able to differentiate 
into neurons, astrocytes and oligodendrocytes (Alvarez-Buylla et al. 2001 ) .  In vitro 
NS Cs can be maintained in serum-free conditions and in the presence of the mitogens 
epidermal growth factor (EGF) and basic fibroblast growth factor (FGF-2) (for review 
see e.g. (Vescovi & Snyder 1 999) . They are usually cultured as free floating aggregates (so 
called neurospheres) or as attached single layer. It has been shown that NSCs, dependent 
on their developmental stage and from where they were isolated, are able to differentiate 
into specific subtypes of neurons, for example: NSCs isolated from the spinal cord generate 
spinal cord progeny, NSCs from the forebrain preferentially form GABA-ergic neurons and 
neural precursors from the ventral mesencephalon have the capability to become mDA 
neurons (Mayer-Proschel et al. 1 997; Ling et al. 1998; Storch et al. 200 1 ) . In order to drive 
mDA differentiation in NSCs in vitro it is important to mimic the differentiation conditions 
present during embryonic DA development (for detailed description see section: midbrain 
DA neurons below) . Generally, NSCs are kept in a proliferative state in which they can 
be primed with DA specific signaling factors that are supposed to induce DA fate. Sonic 
hedgehog, fibroblast growth factor 8 and Wnt's (also referred to as "ventralization factors") 
are commonly used for DA specific induction. Upon removal of EGF/FGF-2, NSCs start 
to differentiate. Several transcription factors known to be crucially involved in mDA 
differentiation have been analyzed for their potential to facilitate NSC DA differentiation. 
Some studies, for example, indicate that overexpression of Nurrl (Wagner et al. 1 999; 
Sakurada et al. 1 999; Shim et al. 2007; J.-Y. Kim et al. 2003) or Pitx3 (O'Keeffe et al. 2008) 
or both facilitates DA differentiation in rat ventral neural precursors; on the other hand, 
there is also evidence that mouse and rat NSCs lost the capability to differentiate towards 
DA neurons (S. Chung et al. 2006; Roybon et al. 2008) .  
In chapter I I  of  this thesis we discuss the possibility to induce DA fate in non­
mesencephalic NSCs by an orchestrated activation of several transcription factors highly 
crucial for DA induction. A combination of "ventralization factors" and histone deacetylase 
inhibitors like trichostatin A (TSA) seemed to have beneficial effect on DA differentiation. 
Up to 1/3 of the differentiated NSCs adopted DA identity to some extent (Rossler et al. 
20 10).  However, the robustness of DA induction in NSCs in principle does not seem to be 
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comparable with that of ESCs and iPSCs as will be discussed below. Recently, it has been 
indicated that NSCs require Oct4 activity in order to be able to form DA neurons (Deleidi 
et al. 2011). It needs to be stressed, however, that Oct4 overexpression in NSCs is sufficient 
to induce pluripotency (J. B. Kim, Greber, et al. 2009; J. B. Kim, Sebastiano, et al. 2009), so 
that these modified cells should in fact not be considered as NSCs anymore. 
Another interesting cell type as source for DA neurons are embryonic stem cells (ESCs). 
ESCs are per definition pluripotent and can give rise to every cell type of the body. ESCs 
can be isolated from the inner cell mass of a preimplantation blastocyst and because of their 
self-renewing and proliferation capacities they can serve as an unlimited source to generate 
and study any sort of cell type. Because of their highly reliable differentiation abilities, ESCs 
have been intensively studied as source for mDA neurons. Several publications report the 
generation of DA (or DA-like) neurons from mouse, primate and human ESCs (Kawasaki et 
al. 2000; S. H. Lee, Lumelsky, Studer, Auerbach & McKay 2000a; Cho et al. 2008; Sanchez­
Pernaute et al. 2005). Specific differentiation protocols have been developed that facilitate 
in vitro generation of DA neurons. In 2000, Kawasaki et al. introduced a co-culture system 
of ESCs with stromal feeder cells (PA6 or MSS cell lines). This approach allows serum free 
differentiation conditions and results in comparably high numbers of neurons adopting a 
DA phenotype (Kawasaki et al. 2000). The effect of these feeder cells has been designated 
stromal cell-derived inducing activity (SDIA). Even though SDIA seems to work robustly, 
it is not entirely clear what the underlying beneficial agent actually is. It was suggested 
that cell-cell contact and secreted factors might trigger inhibition of bone morphogenetic 
proteins (BMPs), which normally counteracts DA differentiation in vivo. However, SDIA 
was also observed when paraformaldehyde (PFA) fixated feeder cells were used (for review 
see: Hynes & Rosenthal 2000). Also more recent differentiation protocols (see below) often 
still make use of stromal feeders in order to boost in vitro DA differentiation. 
Another DA differentiation protocol that had been developed in parallel did not 
make use of a co-culture system, instead it combined a specific sequence of defined 
factor supplementation with ESC differentiation conditions (S. H. Lee, Lumelsky, Studer, 
Auerbach & McKay 2000b). ESCs were cultured as so called embryoid bodies (EBs), free 
floating spherical structures containing embryonic germ layer tissue that can be directed 
towards neural differentiation. EBs could be expanded under conditions that favor neural 
precursor formation, DA fate priming was achieved by supplementation with Shh and 
FGF8 (for detailed description see section: midbrain DA neurons below) and subsequent 
differentiation was induced by withdraw of growth factors and supplementation with 
ascorbic acid and cAMP. 
The refinements achieved by these fairly well defined conditions have later been further 
optimized. Crucially, the aforementioned necessity to specifically inhibit BMP signaling 
in order to induce neural progenitors/DA precursors could also be accomplished by small 
molecules and specific inhibition of SMAD signaling (Chambers et al. 2009). Even further 
improvements have been made by specific induction of floor plate cells derived from ESCs 
(Fasano et al. 2010) and their subsequent highly efficient differentiation towards functional 
DA neurons (Kriks et al. 2011). 
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As for NSCs, also for ESCs the forced expression of DA specific transcription factors, 
which is supposed to increase the amount of derived DA neurons, has been investigated. 
The most promising approach was based on a study in chick embryos. Anderson et al. 
(2006) showed that the transcription factors Lmxla and Msxl are specifically expressed in 
the developing ventral midbrain of chicks. Furthermore, their study showed that ectopic 
Lmxl a  expression in the developing embryo as well as in ESCs was sufficient to generate 
DA neurons (Elisabet Andersson, Tryggvason, et al. 2006). The study provided evidence 
that Shh-induced Lmxla, in combination with Msxl (which indirectly blocks alternative 
neural fates by activation of Ngn2; for review see Burbach & Marten P Smidt 2006) was 
crucial and sufficient to induce DA specific differentiation. Following the discovery of 
Lmxla  as key factor for DA differentiation more studies seem to confirm the important role 
for Lmxla  (Friling et al. 2009; Cai et al. 2009) . However, although still debated, in vivo data 
do not seem to support a superior role for Lmxla (Nakatani et al. 20 10; Yan et al. 20 1 1 ; Q. 
Deng et al. 20 1 1 ) 
As a result of the rather robust DA differentiation capacities of ESCs, several grafting 
studies were performed in a similar way as the transplantation studies mentioned in the 
embryonic tissue grafting section (Bjorklund et al. 2002; Morizane et al. 2006; Bankiewicz et 
al. 2006; D.-W. Kim et al. 2006) .  Together these studies clearly show that cell replacement 
in neurotoxin induced lesion models by ESC-derived DA cells can restore dopamine levels 
in the brain (particularly in the striatum) and thereby cause symptomatic improvement. 
Recapitulating, ESCs seem to provide a valuable source for the in vitro generation of DA 
neurons. Resulting cells do show characteristic of bona fide ventral midbrain DA neurons 
and the possibility to utilize transgenic modifications allow purification of ESC derived DA 
neurons. However, the use of ESCs is not without complications. First of all the generation 
and isolation of ESCs (specifically human ESCs) is a matter of fierce ethical debate, even 
though already available ESC lines provide an unlimited supply. Nonetheless, the existing 
ESC lines will only serve as model systems to study PD in its cellular and molecular content. 
It is doubtful whether ESC line derived DA neurons will ever be used in cell replacement 
approaches, since they will always bear the risk of immune rejection. 
Recent developments regarding the use of induced pluripotent stem cells (iPSCs) might 
be more promising and might allow a more patient specific approach. IPSCs have been first 
described in 2006 in a keystone study by Takahashi and Yamanaka, showing the dogma­
changing possibility to convert fully differentiated somatic cells into cells that resemble 
characteristics of ESCs (Takahashi & Yamanaka 2006; Takahashi et al. 2007). With these 
capacities, iPSCs opened up new opportunities to study pluripotency. Moreover, they 
presented unprecedented applications for regenerative medicine and opportunities for in 
vitro disease modeling. 
While chapter II will provide a review on the use of iPSCs specifically focusing on 
applications for PD, the following section will briefly summarize strategies and mechanisms 
for the induction of pluripotency. 
Somatic cells ( the first studies used embryonic and adult mouse fibroblasts) can be 
reprogrammed to a pluripotent state simply by forced expression of four transcription 
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factors. These four transcription factors are Oct 4, Sox2, Klf 4 and cMyc. The initial study by 
Takahashi and Yamanaka (2006) showed that retroviral introduction of these four factors 
induced the expression of the ESC marker Fbx lS  in infected fibroblasts. FbxlS  is co­
expressed with Oct4 and Sox2 in ESCs, but appears to be dispensable for ESC self-renewal 
in mouse development (Tokuzawa et al. 2003). Approx. 14-21 days after viral transduction, 
fibroblasts in culture drastically change their morphology from typical fibroblasts, 
growing mainly in a monolayer, to a typical ESC morphology, multiplying in very dense 
and compact colonies. The first iPSCs have been shown to proliferate and self-renew, they 
were able to differentiate into cell types from all three embryonic germ layers ( endoderm, 
mesoderm and exoderm) and formed teratomas upon subcutaneous injection. The FbxlS­
selected iPSCs contributed to chimaera formation after injection into a host blastocyst, but, 
notably, were not able to contribute to the formation of the germ layer of the offspring. This 
capability is one of most stringent and crucial characteristics of pluripotent stem cells. So 
the question arose whether this first generation of iPSCs were truly pluripotent. Apparently 
the pluripotent characteristics of these cells depended on viral expression of Oct4 and Sox2, 
since endogenous expression of the crucial inducers and markers for pluripotency was not 
yet accomplished. Later studies used endogenous expression of Oct4 and Nanog as markers 
to identify pluripotent cells (Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007). 
These cells then revealed all of the molecular and biological criteria of truly pluripotent 
stem cells: firstly, similar expression profiles and chromatin configurations of Nanog and 
Oct4 to those of ESCs, secondly, induction of endogenous Nanog and Oct4 expression 
(viral gene expression has to be silenced, for more details see below), thirdly, reactivation 
of the inactivated X-chromosome and, finally, contribution to the germ line formation 
in chimeras and the ability to generate a complete embryo when injected in a tetraploid 
(4n) blastocyst. (Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007). These studies 
also showed that ectopic expression of Oct4, Sox2, Klf4 and cMyc can trigger sequential 
epigenetic changes that eventually induce pluripotency in a small fraction of cells. More 
recent evidence indicates that the reprogramming process itself mainly relies on a "optimal" 
stochastic orchestration of the four reprogramming factors (J. Hanna et al. 2009; Carey et al. 
2011). Pluripotency, eventually seems to be inducible in almost all somatic cell types after 
introducing all four factors; an optimal combination of the 4 factors, however, results into 
"high quality" fully reprogrammed iPSCs with typically a high expression of Oct4 and Klf4 
combined with a rather low expression of Sox2 and cMyc. So, for optimal reprogramming 
it appears to be crucial and highly delicate in which combination pluripotency factors are 
expressed in a somatic cell. 
A major issue in iPSC reprogramming is the use of oncogenes like cMyc and Klf4 in 
the pluripotency inducing cocktail. This would certainly be undesirable for any human 
application, be it for in vitro disease modeling or even for future cell replacement 
approaches. Therefore, it was examined whether iPSCs (from mouse and human) could be 
generated by omitting cMyc (Nakagawa et al. 2008; Wernig et al. 2008). It was demonstrated 
that pluripotency could be induced without the use of cMyc, however, it became clear that 
the oncogene would significantly enhance and accelerate the reprogramming process. 
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Furthermore, it was shown that NSCs can be reprogrammed solely by forced Oct4 expression 
(J. B. Kim, Greber, et al. 2009; J. B. Kim, Sebastiano, et al. 2009). This indicates that Oct4 
must be considered the most crucial factor for inducing pluripotency. Mechanistically, it 
is thought that initial viral delivery of Oct4, Sox2, Klf4 and cMyc induces the endogenous 
expression of Oct4, Sox2 and Nanog. Specifically OSK co-occupy their own and each 
others promoter regions in order to regulate their expression by forming an autoregulatory 
feedback loop. Concomitantly, activation of de novo DNA methyltransferases (Dnmt3a/b) 
will cause the silencing of the viral factors by DNA methylation, while promoter regions of 
endogenous factors are demethylated allowing their transcription (for schematic summery 
see figure 2 and for extended reviews on iPSCs see: (Jaenisch & Young 2008; Scheper & Sjef 
Copray 2009; J. H. Hanna et al. 2010)). Another point of view is to consider pluripotency 
factors such as Oct4, Sox and Nanog as lineage specifiers that direct commitment towards 
a specific fetal lineage, instead of mere keepers of a pluripotent ground state; in pluripotent 
cells (either ESCs or iPSCs) these factors are then supposed to be in a subtle balance (Loh 
& B. Lim 201 1). It has been shown, for example, that overexpression of Oct4 or Nanog 
pushes differentiation along the mesodermal path (Niwa et al. 2000; Teo et al. 201 1 ;  Yu et 
al. 201 1) while forced Sox2 expression on the other hand seems to induce neuroectodermal 
cel lu lar state 
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Fig. 2: schematic summary of epigenetic and molecular events during induction of pluripotency in 
somatic cells. 
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specifications (Kopp et al. 2008). The balance in expression of these "pluripotency" factors 
in pluripotent stem cells prevents a preferential differentiation path to be taken and so the 
cells are kept in a 'sternness' state until the equilibrium is disturbed by the dominance of 
one of the factors. 
Midbra i n  dopam inerg ic neurons  
Midbrain DA (mDA) neurons are located in the ventral mesencephalon from where they 
project to multiple brain regions. The dopaminergic system in the human brain contains 
between 400.000 - 600.000 neurons and thereby represents only approx. 1 % of the total 
neurons number in the CNS (in rodents the number lies between 30.000 and 40.000 
DA neurons) (Lindvall & A Bjorklund 1978; S. M. Williams & Goldman-Rakic 1998) 
Historically this mesencephalic group of neurons is designated as AS, A9 and Al O neurons 
and contribute to the substantia nigra (A9) the ventral tegmental area (VTA, AlO) and the 
retrorubral area (AS) (Dahlstrom & Fuxe 1964). DA neurons from these areas form four 
important pathways: 1. The mesocortical pathway, which projects from the VTA to the 
frontal lobe of the pre-frontal cortex. 2. The mesolimbic pathway, which projects from the 
VTA to the nucleus accumbens and the hippocampus. 3. The nigrostriatal pathway with 
its projection from the SN to the striatum (these projections are mainly affected in PD) 
and 4. the tuberoinfundibular pathway that connects the hypothalamus and the pituitary 
gland (Anders Bjorklund & Dunnett 2007). MDA neurons are usually characterized 
by specific markers; often these are genes involved in the DA synthesis or signaling. 
The enzyme tyrosine hydroxylase (TH), for example, is the rate-limiting enzyme of DA 
synthesis, converting tyrosine to the DA precursor L-dihydroxyphenylalanine (L-DOPA). 
Therefore, TH is commonly used to identify mDA neurons. Other characteristic enzymes 
are L-aromatic amino acid decarboxylase (Aadc) and aldehyde dehydrogenase 2 (Ahd2). 
Cell type specific markers also include DA transporters such as vesicular monoamine 
transporter type 2 (Vmat2), which is involved in the packing of DA in presynaptic vesicles, 
and the dopamine transporter (DAT), which is responsible for DA reuptake in the pre­
synapse. The CNS possesses five types of DA receptors (D 1-D5) ,  of which the D2 receptor 
is know for its auto-receptor function, acting as regulator of an inhibitory feedback 
loop regulating DA release. In parallel there are several transcription factors that play 
crucial and specific roles in the generation of mDA neurons and therefore can be used to 
identify this specific subtype of neurons. Early in development a specific neuroanatomical 
patterning and the release of specific signaling factors favor the generation of mDA 
neurons. The isthmus (also called the midbrain-hindbrain border) is the most crucial 
organizing structure for fate specification and determination of DA progenitors. In this 
brain region the secretion of fibroblast growth factor 8 (FGFS) and wingless-type MMTV 
integration site family, member 1 (Wntl)  has a major impact on the formation of mDA 
precursors. The secreted molecules around the isthmus result in a specific patterning 
along the anterior-posterior (AP) axis of the developing embryo. In addition, the dorsal­
ventral organization is accomplished by counteracting molecules secreted from opposite 
sides of the neural tube. Sonic hedgehog (Shh), which is secreted from the floor plate 
-
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( ventral) of the neural tube, is indispensable for the generation of the ventral mid brain. 
Bone morphogenic protein (BMP), which is produced on the opposite, dorsal extreme of 
the neural tube, has inhibiting effects on DA neurons generation. 
Eventually, the orchestrated actions of Shh, FGF8 and Wntl are mainly accountable for 
induction of early DA specific transcription factors (see figure 3). Ventral midbrain DA 
specification starts with the expression of Otx2, Nkx2.2 and Ngn2. The induction of mDA 
neurogenesis is accomplished by proneural genes, such as Mash (Ascll), Msxl and Ngn2, 
followed by the expression of early mDA progenitor markers such as Lmxla/b, Msxl, Enl/2 
and FoxAl/2. Final differentiation of mDA neurons is initialized by expression of Nurrl 
(Nr4a2) and the abovementioned DA synthesizing enzyme Aadc. Nurrl was first identified 
as brain-specific transcription factor with a predominant role in the regulation of gene 
expression in the CNS (Law et al. 1992). Subsequently, its crucial specific involvement in 
mDA neuron differentiation was established (Zetterstrom, Solomin, et al. 1996; Zetterstrom, 
R. Williams, et al. 1996; Zetterstrom et al. 1997; Saucedo-Cardenas et al. 1998). At this 
stage of mDA neuron differentiation, Nurrl appears to be crucial. The start of Nurrl 
expression accompanies the down-regulation of Ngn2, inducing the final differentiation 
towards a postmitotic stage. Knock-out studies have shown that loss of Nurrl in mDA 
progenitors leads to a complete lack of TH expression in the developing mDA neurons 
(Saucedo-Cardenas et al. 1998; Zetterstrom et al. 1997). Interestingly, it appeared that 
the complete loss of Nurrl had direct influence on other mDA specific markers such as 
Vmat2 and DAT (Smits et al. 2003; Wallen et al. 1999) but other factors crucially involved 
immature DA neurons 
mature DA neurons 
Fig. 3: schematic representation of in vivo development of midbrain dopaminergic neurons and 
corresponding marker expression. (see text for details) 
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in mDA specification and differentiation, such as Enl /2, Lmxlb, FoxA2 and Pitx:3 were not 
effected (Saucedo-Cardenas et al. 1998; M P  Smidt et al. 2000; Wallen et al. 1999). Together, 
these studies indicated that Nurrl deficiency did not cause a major disruption during the 
development of mDA neurons, however, the postnatal maintenance of mDA neurons in 
Nurrl -deficient mice was heavily disrupted. 
Another highly crucial transcription factor is Pitx3, which is expressed shortly after 
Nurrl expression can be detected. Pitx3 is a member of a homeodomain-containing 
transcription factor subfamily and is, within the brain, exclusively expressed in 
mesodiencephalic (md) DA neurons. Moreover, in particular in the adult mouse brain 
Pitx3 expression almost completely overlaps with TH expression in the mesodiencephalon 
(S. Zhao et al. 2004; Maxwell et al. 2005; M P  Smidt et al. 1997). Pitx3 and its involvement 
in mdDA development have been extensively studied in a naturally occurring null-mutant 
(Aphakia mice). The absence of Pitx:3 caused a specific loss of mdDA neurons in the SNc, 
whereas mdDA neurons in the VTA remained largely unaffected (Marten P Smidt et al. 
2004; Hwang et al. 2003; Nunes et al. 2003) In a series of more recent studies, Jacobs et al. 
unraveled the complex interaction of Pitx:3 with Nurrl and identified pathways of Pitx:3 
that are subsequently required for mdDA neurons development (Jacobs et al. 2009; Jacobs 
et al. 2007; Jacobs et al. 201 1). Together, these studies depict Pitx3 as a highly specific 
marker for mdDA neurons, which moreover marks functional differences between SNc 
and VTA mDA neurons. 
Due to its specificity Pitx3 could serve as a valuable tool to selectively identify mdDA 
neurons. This has been accomplished by the generation of transgenic mice that carried 
a heterozygous GFP knock-in (KI) modification in the locus of the Pitx:3 gene (S. Zhao 
et al. 2004; Maxwell et al. 2005). These KI animals did not only allow the identification 
of mdDA neurons isolated from the embryonic ventral midbrain but also opened up 
the possibility to purify in vitro differentiated Pitx3-GFP neurons derived from mouse 
embryonic stem cells (ESCs). 
-
Recent studies suggest two interconnected pathways that together orchestrate mDA 
differentiation during mouse development but also during ESC differentiation (see 
figure 4, modified from Kittappa et al. 2007; S. Chung et al. 2009). First, the SHH­
FoxA2 pathway induces a ventral phenotype, which is however not selective for mDA 
progenitors. Second, the Wntl-Lmxla pathway inhibits alternate ventral phenotypes. 
Together they induce the expression of proneural genes, such as Ngn2, whereby early 
floor plate cells will convert to neural precursors (E Andersson, Jensen, et al. 2006; Kele et 
al. 2006). Both signaling pathways drive the expression ofNgn2 by joint action of FoxA2, 
Otx2 and Msxl (Vernay et al . 2005; Ferri et al. 2007; Elisabet Andersson, Tryggvason, et 
al. 2006). Finally both pathways contribute to initialize the expression of mDA specific 
markers such as Vmat, DAT and TH, with Nurrl and Pitx3 as central players (Ang 2006; 
Marten P Smidt & Burbach 2007). 
Given the complexity of dopaminergic differentiation in becomes apparent that these 
processes need to be regulated in a highly sophisticated manner. In recent years regulation 
of gene expression (and therefore also controlled embryonic differentiation) has been more 
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Fig. 4: Interconnected feedback loops connecting and controlling key players of dopaminergic 
differentiation. Shh and Wnt signaling activates intracellular mediator that up-regulated Lmxla and 
FoxA2, two central players of DA neuron development. As a result subsequent key transcription 
factors, such as Enl /2, Nurrl and Pitx3 become active and drive DA differentiation. Additionally 
secretion of Shh and Wnt provides feedback activation. 
and more connected to epigenetic regulation. To date not much is known about neuron­
type specific epigenetic control, however, there is increasing evidence about the paramount 
involvement of epigenetics in neurogenesis. The following section provides a brief overview 
about recent knowledge regarding epigenetic regulation of neural/neuronal differentiation. 
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EPIGENETIC REGULATIONS; FROM STEM CEL LS 
TO NEURONS. 
Ep igenetic ma rks i n  genera l  - a brief overview 
In general, epigenetic regulation refers to modifications of the chromatin structure 
(comprising DNA and histones), which do not change the underlying genetic code. These 
modifying moieties do however have drastic influence on gene expression. The importance 
of epigenetic regulation is most evident during embryonic development and differentiation 
of the multitude of cell types. Transient epigenetic modifications induced by environmental 
stimuli assure the orderly, temporal and sequential transcription and repression of genetic 
programs essential for normal development of the different tissues in an organism. More 
permanent epigenetic modifications assure the stability of differentiation of cells in the 
adult stage, preventing erroneous transcription of inappropriate gene programs of other 
cell types. For proper physiologic function of most cells, dynamic epigenetic modifications 
are essential, enabling cells to respond and adapt in an adequate way to environmental 
changes. Apart from gene transcription regulation ("fine tuning") by noncoding RNAs, the 
two major epigenetic modes of gene transcription regulation are histone modification and 
DNA methylation, often acting in an interconnected way. 
Hi stone modification 
Histones are a family of nuclear proteins that crucially contribute to a compact packaging of 
DNA by forming nucleosomes. Five major types of histones can be distinguished; Hl/HS, 
H2A, H2B, H3 and H4. The last four constitute the so-called core histones, whereas Hl and 
HS have supporting functions as linker histones. Nucleosomes are formed by two H2A-H2B 
dimers and a H3-H4 tetramer, with 147 base pairs of DNA wrapped around it (Luger et al. 
1997; Alva et al. 2007). The global assembly of DNA and core histones is called chromatin 
and its structure allows highly flexible changes between densely packed chromatin 
(heterochromatin) and loosely packed chromatin (euchromatin). Heterochromatin is 
widely associated with gene silencing, whereas euchromatin characterizes active gene 
expression. Regulation of these two stages is accomplished by covalent modifications of 
N-terminal histone tails by addition or elimination of methyl-, acetyl- and phosphorus­
groups. But also SUMOylation, ubiquitination and ADP-ribosylation can contribute either 
to euchromatin or heterochromatin (for review see: Jenuwein & Allis 2001). 
Histone acetylation is generally contributing to active genes/promoters. Acetylation 
occurs on lysine residues and drastically changes the net charge of histones. This change 
from a negative charge to a rather neutral stage leads to less electrostatic attraction 
between DNA and histone and therefore favors loosely packed chromatin. Modification 
by acetylation is catalyzed by two counteractive enzymes. Acetylation is introduced by 
histone acetyl transferases (HATs), whereas deacetylation is accomplished by histone 
deacetylases (HDACs). 
More complex is the effect of histone methylation, as it can facilitate either activation 
or repression of gene transcription. Both types of modifications are established by two 
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different protein complexes. Repressively acting trimethylation of histone 3 lysine 27 
(H3K27me3) is established by the polycomb group protein complex PrC2 (Cao et al. 2002). 
On the contrary, trimethylation of H3K4 (H3K4me3) by so-called trithorax-group (TrxG) 
proteins contributes to active genes (Nagy et al. 2002) (it should be mentioned that also 
other protein complexes have methyltransferases activity - see below). 
DNA methylation 
DNA methylation predominantly occurs at CS of the cytosine pyrimidine ring within CG 
( CpG) dinucleotides, which are mostly methylated but underrepresented in the vertebrate 
genome (A. Bird 2002; Klose & A. P. Bird 2006). Exceptions to this global appearance 
are highly dense CpG-rich regions (so called CpG islands (CGis)) that tend to be widely 
unmethylated. These CpG-rich regions (that is to say their CG content exceeds by far the 
expectation) are associated with approx. 70% of annotated promoters (Saxonov 2006; 
Deaton & A. Bird 2011 ), which include almost all housekeeping genes but also tissue-specific 
genes as well as developmental regulator genes (Larsen et al. 1992; Zhu et al. 2008); see 
figure 5). Interestingly, a large class of CG Is has been discovered that locate rather remote 
(trans) to annotated promoters but apparently still show promoter-regulating functions (R. 
S. Illingworth et al. 2010; Maunakea et al. 2010). DNA methylation of promoter-associated 
CG Is is commonly correlated with stable silencing of a particular gene. 
The integration of the methyl residue to the CpG dinucleotide is accomplished by DNA 
methyltransferases (DNMTs). Two types of DNA methyltransferases can be distinguished. 
DNMT l is considered to be a 'maintenance' methyltransferase that is responsible for 
reestablishment of specific DNA methylation patterns after mitosis. The enzyme uses 
the methylation pattern provided by the parental DNA strand to complete the original 
methylation on both strands (Bestor et al. 1988; Burgers et al. 2002; Robertson 2002). For 
the epigenetic regulation of e.g. neural development or in vitro differentiation of stem cells, 
DNA methylation requires 'de novo' methyl transfer. This process is conducted by two 
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Fig. 5: Architecture of a typical CpG island promoter. The DNA strand contains high amounts of 
CpG dinucleotides around the start codon of a particular gene, but very little elsewhere in the genome. 
These promoter CpGs are widely unmethylated, whereas CpGs upstream of the promoter area or 
intragenic CpGs are often methylated. 
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Regulation of expression via DNA methylation is based on the recruitment of proteins 
that recognize and bind either methylated or unmethylated DNA. These proteins, when 
attracted to the DNA mostly show histone modifying activities. Proteins that bind to 
unmethylated CGis often possess a CXXC domain (e.g. R. Illingworth et al., 2008). Besides 
DNA methyltransferases (DNMTs), proteins or protein complexes like the Setdl complex 
(which contains the DNA-binding protein Cfpl), which is a histone 3 lysine 4 (H3K4) 
methyltransferase complex, bind to unmethylated DNA to initiate H3K4 tri-methylation 
(H3K4me3), a histone modification that is in general associated with active promoters (Lee, 
Voo, & Skalnik, 2001; J.-H. Lee & David G Skalnik 2005) see figure 6). A recent study points 
towards a mechanistic link between unmethylated CpGs, Cfpl and H3K4me3. Illingsworth 
and colleagues (2010) found that CpG density in CGis correlates positively with H3K4me3 
levels. This particular histone modification has been shown to directly interact e.g. with 
the core transcription factor TFIID, which has specific affinity to the H3K4me3 mark 
(Vermeulen et al. 2007; van Ingen et al. 2008). In turn the core transcriptional machinery 
can further recruit H3K4 methyltransferases, indicating that transcription may also 
contribute to H3K4me3 at CGI sites (Ruthenburg et al. 2007). Instead of activation of 
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Fig. 6: Simplified description of DNA methylation-regulated gene activity. An active promoter often 
contains unmethylated CGis. Unmethylated CpG are recognized by CXXC domain proteins, such as 
Cfpl ,  which in turn recruit histone methyltransferases (e.g. Setdl )  that contribute H3K4me3 (purple 
star). Usually transcriptionally active chromatin also contains acetylated histone (yellow diamond). 
Together, these configurations allow transcription factor (TFs) and RNA pol II binding and therefore 
favor active gene expression. On the contrary, inactive promoters can be stabilized by methylated 
CG Is. Here MBD proteins specifically bind methylated DNA and recruit HADCs that catalyze histone 
decateylation. This combined with reduced binding capabilities of TFs results in silenced genes. 
-
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specific promoters, other CpG-binding proteins have been shown to cause silencing of a 
promoter (see figure 6). Typically unmethylated CGis are widely surrounded by otherwise 
heavily methylated DNA stretches. However, there are several well-known examples in 
which CGis become strongly methylated, e.g. during normal development (Mohn et al. 
2008; Payer & J. T. Lee 2008). CGI methylation is commonly associated with silencing of 
the corresponding promoter. It is thought that promoter inactivation is caused by either 
direct inhibition of transcription factor binding to methylated DNA or by methyl-binding 
domain (MBD) proteins that recruit other, histone-modifying proteins, which for example 
can cause deacetylation of histones inhibiting transcription ( see fig. 6 and (Klose & A. P. 
Bird 2006)). Examples for CGI methylation are X-chromosome inactivation and genomic 
imprinting (Payer & J. T. Lee 2008). 
De novo methylation has been reported during the transition from germline to somatic 
cells (Schilling & Rehli 2007; Shen et al. 2007; Weber & Schiibeler 2007) but also during 
in vitro differentiation of embryonic stem cells or induced pluripotent stem cells towards 
committed neural progenitor and subsequently mature neurons (Mohn et al. 2008). CpG 
methylation is not considered to initiate gene silencing but rather to lock in the generated 
inactive state. During random inactivation of one X chromosome in female cells for 
example DNA methylation is observed only after several silencing chromatin modifications 
(for reviews: Okamoto & Heard, 2009; Payer & Lee, 2008). 
Epigenetic regulation is in most cases considered to be rather dynamic ( changing 
expression of genes due to changing environmental conditions) in which it is generally 
thought that histone modifications can be adapted much quicker than CpG methylation 
patterns. This implies that the establishment of a specific regulatory mark (such as CGI 
methylation) caused by cellular responses to a particular environmental state must be 
reversible if the environment changes. 
Ep igenetic reg u l ation  of neu rogenes i s  
Neurogenesis occurs during early development but surprisingly persists into adulthood 
(F H Gage 2000). During embryonic development neurogenesis proceeds gliogenesis, 
indicating that expression of genes in neural precursors needs to be delicately regulated 
in order to organize CNS specific differentiation. It is believed that these regulations are 
widely epigenetically controlled (Feng et al. 2007; Hsieh & Fred H Gage 2005). It has for 
example been shown that demethylation of the promoter of glial fibrillary acidic protein 
(GFAP), a marker for astrocytes, is correlated with GFAP expression during astrogliogenesis 
(Takizawa et al. 2001; Teter et al. 1994). Additionally a study of a conditional knock out 
for DNMTl revealed that deficiency of this 'maintenance' methyltransferase results in 
premature astroglial differentiation (Fan et al. 2005). 
Adult neurogenesis, which is usually defined as the process of generating functional 
neural cell types from neural stem cells, takes place in the subgranular zone (SGZ) of the 
dentate gyrus of the hippocampus and in the subventricular zone (SVZ) of the lateral 
ventricle (for review see Ma et al., 2010). Adult NSCs from the SGZ can give rise to dentate 
granule cells. These newly generated neurons can contribute to learning and memory 
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functions (Kempermann et al. 2004; W Deng et al. 2010). NSCs from the SVZ on the other 
side give rise to glia and neuroblasts (G. Zhao et al. 2007). The later migrate over a long 
distance to the olfactory bulb where they differentiation into interneurons and side-specific 
dopaminergic neurons with a variety of functions in olfaction. 
As during embryonic development, adult neurogenesis is orchestrated and directed 
by epigenetic changes imposed on identical genomes in order to control gene expression 
in a special and temporal fashion. These modulations are the result of a wide variety of 
environmental, physiological and pharmacological stimuli. Epigenetic mechanisms conduct 
the translation of these stimuli ( after signal transduction to the nucleus) in gene expression, 
which can vary due to environment, experience and internal physiological states. As a 
result of specific epigenetic mechanisms (as described above) long-lasting effects can be 
caused in adult NSCs. Although epigenetic effects are thought to be relatively long-lasting, 
an accurately choreographed change in the epigenetic program is crucial for a properly 
executed transition from one cellular stage to another (e.g. from a NSCs to a neuroblast). 
Adult neurogenesis retains the possibility for the CNS to reproduce neurons throughout 
the adult live. To assure this capacity it is important to maintain multipotent NSCs but at 
the same time it must be possible to generate postmitotic neurons. Two epigenetic players 
that are centrally involved in this balancing act are the PcG complex and the TrxG complex. 
There is evidence that Bmil (a PcG group protein) crucially contributes to the maintenance 
of "sternness" in adult NSCs. The PcG complex has histone methylation activity and 
specifically transfers methyl residues to H3K27, a histone modification that is known to 
silence the associated gene activity. SVZ-derived NSCs are depleted in Bmil knockout mice 
and Bmil overexpression increases the number of adult NSCs in the SVZ and maintains 
their potential to generate neurons (Fasano et al. 2007; Fasano et al. 2009). Besides, Bmil 
might be required for the self-renewal capacity in postnatal NSCs (Fasano et al. 2009; He et 
al. 2009). It is speculated that PcG complex-induced methylation of H3K27 silences genes 
that are required for neural differentiation, even over several cell divisions, and therefore 
promotes self-renewal as a form of "cellular memory" (for review see Ma et al., 2010). 
On the other side of the balance ( which in this case represents differentiation of 
NS Cs) are TrxG group proteins, which are known to establish stable and transcriptionally 
active chromatin domains. This is achieved by H3K4 methylation, which, unlike H3K27 
methylation, leads to transcriptionally permissive chromatin conformations (Ringrose 
et al. 2004). One member of this complex is Mlll (mixed-linage leukemia 1), a H3K4 
methyltranferase that is specifically required for neuronal differentiation of adult NSCs (D. 
A. Lim et al. 2009). Mlll is required to destabilize equally contributing H3K4 and H3K27 
methylation in order to induce the expression of Dlx2, which is consequently a direct target 
of MU 1 and crucially involved in neurogenesis. 
Together, these finding indicate that embryonic as well as adult neurogenesis is a strictly 
regulated process that crucially depends on proper epigenetic regulation. Disturbances of 
these processes can lead to massive malfunction and disease (see below). 
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The ro le of ep igenetics i n  neurons 
In comparison with histone modifications, which are thought to be  rather dynamic, DNA 
methylation is considered to be a stable and more robust, expression-regulating DNA 
modification. This makes DNA methylation less likely to be involved in regulation of gene 
expression in mature neurons that have to react flexibly to environmental and activity 
dependent changes. However, there is increasing evidence that DNA methylation turnover 
(that is active change in methylation) plays a crucial role in the normal physiological 
function of neurons. All DNA methyltransferases are highly expressed in the CNS (Feng 
et al. 2005; Goto et al. 1994; MacDonald et al. 2005; Watanabe et al. 2006). Dnmtl, for 
example, which is highly expressed in the developing nervous system, remains at a high 
level in mature neurons. The 'de novo' methyltransferases Dnmt3a and Dnmt3b show 
different expression patterns in the CNS: whereas Dnmt3b is mainly expressed during early 
development and is also present in neural precursors, Dnmt3a is expressed at later stages 
up into adulthood. The latter can be found in adult NSC, and in all maturing neural lineages 
(Feng et al. 2005). As mentioned above, conditional knock out of Dnmtl results in reduced 
neural differentiation in neural precursors, however, in postmitotic neurons neither DNA 
hypomethylation nor increased cell death could be detected (Fan et al. 2001). If loss of 
Dnmtl has no obvious influence on mature neurons it remains intriguing why neurons still 
do express high amounts of that enzyme? There is the notion that maintenance of DNA 
methylation is important after base-excision repair of G:T mismatches that might occur 
during deamination of methylated cytosines (P. Brooks et al. 1996). Such maintaining­
function of epigenetics, and therefore also genetic integrity might be crucial in particular 
for non-dividing cells. Parallel evidence that points towards crucial contribution of DNA 
methylation in normal function of adult neurons can be found in neuropsychiatric disorders 
that are linked to malfunctioning proteins that are involved in methyl-DNA binding. The 
most prominent example is Rett syndrome. In patients (predominantly females) high 
correlations can be found between the disease and mutations in MeCP2, a protein that 
usually binds methylated DNA. Transgenic mouse model studies provide evidence that 
functional MeCP2 is particularly crucial in mature neurons and that mutations in the 
MeCP2 gene cause a Rett syndrome-like phenotype (Chen et al. 2001; Guy et al. 2001). 
Interestingly, overexpression of Dnmtl selectively in GABAergic neurons was found in post­
mortem brain of schizophrenia patients (Veldic 2005) and promoter hypermethylation­
related decrease in GABA receptor expression was found in suicidal or major depression 
disorder brains (Poulter et al. 2008). Maybe even more surprisingly, DNA demethylation 
has also been described to be crucial for healthy neuronal function. There is evidence that 
DNA demethylation-catalyzing enzymes are expressed in mammalian cells (Bhattacharya 
et al. 1999; Barreto et al. 2007). Interestingly Ma and colleagues (2009) identified Gadd45b 
as neural activity-induced immediate early gene in mature hippocampal neurons that 
mediates DNA demethylation. 
This study thus provides evidence that Gadd45b links neuronal circuit activity with 
epigenetic DNA modification and identified DNA demethylation as active process 
involved in regulation of neuronal activity (D. K. Ma et al. 2009). Taken together, DNA 
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methylation seems to play a pivotal role in neuronal differentiation as well as in normal 
neuronal cellular activities; aberrant neuronal DNA methylation activity seems to be 
involved in the development of neuropsychiatric disorders. However detailed information 
about DNA methylation in specific subtypes of neurons are still missing. Considering the 
wide functional variety of neurons it would be surprising if not also subtype specific DNA 
methylation fingerprints could be found in the future. 
O U T LINE O F  T HESIS 
The loss of DA neurons in the SNc seems to be the central event of PD. Extensive studies, 
beginning in the 19th century until now, have provided ample data that help to understand 
and treat major symptoms of PD. However, it is as yet not clear what initially causes PD nor 
is it possible to cure the disease. One approach to address both aspects is the use of stem 
cells, either as potential source for cell replacement therapy or as tool for in vitro disease 
modeling. For both purposes, proper differentiation of stem cells into midbrain DA neurons 
is crucial. The major aim of the studies described in this thesis, therefore, concerns a detailed 
analysis of the efficiency of DA differentiation of different relevant stem cell types in order 
to establish and assure the completeness of differentiation necessary to obtain DA neurons, 
which are phenotypically and functionally comparable to primary midbrain DA neurons. 
In Chapter I we first provide a general overview on Parkinson's disease and subsequently 
give a survey on the most significant extrinsic and intrinsic factors involved in the normal 
embryonic development of mesencephalic dopaminergic neurons. In addition, we provide 
a brief overview of epigenetic regulation of gene expression during neurogenesis and in 
neurons with a particular focus on DNA methylation. Furthermore Chapter II elaborates 
on the latest developments in in vitro DA differentiation of induced pluripotent stem cells 
(iPSCs). We describe the general potential and obstacles of reprogramming technologies and 
indicate a roadmap for patient-specific 'disease in a dish' approaches and cell replacement 
therapies. Eventually we touch upon the exciting possibility to generate patient-specific 
neurons directly from skin fibroblasts. In Chapter III we start to investigate the possibilities 
to use non-mesencephalic NSCs as potential source for in vitro generated DA neurons. 
In principal, this type of NSCs does not have the intrinsic ability to generate DA neurons 
and are most likely the type of patient-derived NSCs that may be used in a prospective PD 
therapy, either isolated endoscopically via a small needle from the adult ventricle wall or 
via differentiation of iPSCs. We show that a complex combination of signaling molecules 
and histone deacetylase inhibitors leads to improved in vitro DA differentiation of non­
mesencephalic NSCs. In Chapter IV we report on the generation of mouse transgenic 
induced pluripotent stem (iPSC) cells that allowed us to purify specific in vitro generated 
cell types, namely neural precursors and midbrain dopaminergic neurons. We extensively 
studied genetic and epigenetic features of the purified iPSC-derived midbrain dopaminergic 
neurons and we collected comprehensive DNA methylation data as well as global gene 
expression data; these data were used to compare primary midbrain DA neurons with the 
iPSC derived DA neurons. A detailed understanding of in vitro differentiation processes 
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and an in-depth characterization of in vitro generated cell types is crucial for future studies 
on human iPSC derived DA neurons. Chapter V comprises a pilot study in which purified 
iPSC derived DA neurons have been functionally tested in an in vivo Parkinson rat model. 
The data so far indicate that purification of iPSC derived DA neurons by FACS results in a 
population of cells that seem to relief symptoms in neurotoxin-induced parkinsonian rats. 
Finally in Chapter VI we generated human iPSCs and performed experiments to optimize 
their DA in vitro differentiation. Several protocols for the generation of DA neurons 
derived from human ESCs have been established. We combined the latest developments 
and insights for this specific in vitro differentiation in order to confirm the efficiency of in 
vitro DA differentiation of human midbrain DA neurons. Such autologous patient-tailored 
dopaminergic neurons might serve as crucial tool for possible future cell based therapies and 
will also be indispensable to study molecular pathologies of PD in a patient-specific fashion. 
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A B STRACT 
Recent developments in in vitro disease modeling and regenerative medicine have placed 
induced pluripotent stem cells (iPSCs) in the center of attention as a unique source to study 
Parkinson's disease. After only five years of intensive research, human iPSCs can be generated 
without viral integration and under xeno-free conditions. This, combined with increasingly 
sophisticated methods to differentiate iPSCs into functional dopaminergic (DA) neurons, 
led us to recapitulate the most important findings concerning the use of iPSC technology 
as a prospective tool to treat symptoms of Parkinson's disease as well as to obtain insight in 
disease related cell pathogenesis. Moreover, we touch upon some of the latest discoveries in 
which patient-derived autologous DA neurons come into even more direct reach thanks to 
a method that allows transdifferentiation of fibroblasts into DA neurons. 
Keywords: induced pluripotent stem cells, Parkinson's disease, dopaminergic neurons, in 
vitro disease modeling, cell based therapy, transdifferentiation 
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THE R I SE OF I ND U CED PLU R I POTENCY 
The discovery of induced pluripotent stem cells quickly developed into one of the most 
competitive and most sophisticated research areas in biology. In 2006, a key study by the 
group of Shinya Yamanaka showed for the first time that somatic cells, such as murine 
embryonic fibroblasts (MEFs), could be reprogrammed to a pluripotent, embryonic stem 
(ES) cell-like state (Takahashi & Yamanaka, 2006). This epigenetic reprogramming event in 
fibroblasts was driven by viral delivery of four transcription factors (hereafter referred to 
as 'Yamanaka factors'), namely Oct4, Sox2, Klf4 and cMyc. It became clear that when these 
genes successfully integrated into the genome of a host cell and expression occurred in an 
optimal stochastic manner, the virus transfected cell changes from a differentiated somatic 
cell into a pluripotent stem cell, which in turn is able to differentiate into every cell type 
of the body. Shortly after this groundbreaking discovery several other groups confirmed 
and reported the generation of iPSCs. Procedural optimization steps have been undertaken 
thereafter for example by using a more suitable selection marker for the reprogrammed 
induced pluripotent stem cells (Oct4 or Nanog(Wernig et al., 2007) instead of FbxlS  (used 
by the Yamanaka group) or even by identifying iPSC colonies merely on their morphology 
instead of the use of genetically modified fibroblasts as starting material (Meissner, Wernig, 
& Jaenisch, 2007). IPSCs generated by this epigenetic reprogramming process have been 
characterized and identified as truly fulfilling the criteria for pluripotency within a very 
short time span. Thus, iPSCs were not only able to differentiate into cell types from all three 
germ layers (mesoderm, endoderm and ectoderm) and to contribute to embryo formation 
after injection in a blastocyst (chimeric mice), they could also contribute to the germ line in 
such a setup. Moreover, they formed teratomas after subcutaneous injection or subcapsular 
implantation in the testis or kidney (Miura et al., 2009; Zhao et al., 2009). Last but not 
least, as one of the most stringent criteria for pluripotent cells, iPSCs have been injected in 
a tetraploid blastocyst, which was subsequently implanted in a surrogate mother mouse, 
where they gave rise to so called 'all-iPS mice', viable mice that exclusively originated from 
the implanted iPSCs, via a process called tetraploid complementation (Kang, Wang, Zhang, 
Kou, & Gao, 2009; Zhao et al., 2009). The next major step in iPSC research was the discovery 
that also human somatic cells could be reprogrammed into iPSCs using a similar approach 
and with similar properties as mouse iPSCs(Park et al., 2008; Takahashi et al., 2007). 
Due to the extremely rapid development in this particular research field, iPSCs became 
highly interesting tools for in vitro disease modeling but also for potential application in 
regenerative medicine. However, the reprogramming procedure itself was bearing a crucial 
and very undesirable component. IPSCs so far were generated by the use of integrating 
viruses that intrinsically modified the genome of the host cells. Especially the integration 
of oncogenes such as cMyc and Kif 4 would not be acceptable for any clinical application 
of iPSC-derived cells or tissues. In order to avoid this hurdle, several methods have been 
tested to circumvent viral integration events. First attempts were directed to reduce the 
number of integrating proviruses e.g. by eliminating Myc transduction (Nakagawa et al., 
2008), but also the generation of iPSCs with non-integrating adenoviruses and temperature 
sensitive Sendai viruses has been tested and proven possible (Ban et al., 2011 ;  Stadtfeld, 
-
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Nagaya, Utikal, Weir, & Hochedlinger, 2008). In a next logical follow up step, the use of 
viruses has been abandoned completely by utilization of direct repeated transfection with 
'Yamanaka factor' containing plasmids ( Oki ta, Nakagawa, Hyenjong, Ichisaka, & Yamanaka, 
2008) or piggyback transposons (Yusa, Rad, Takeda, & Bradley, 2009). Another interesting 
approach is the use of microRNAs (miRs) to drive induction of pluripotency. Anokye-Danso 
et al. (2011) showed that two specific miRs (miR302 and miR367) are sufficient to induce 
pluripotency in mouse and human somatic cells without forced expression of exogenous 
transcription factors (Anokye-Danso et al., 2011). Even more towards a safe clinical use is 
the induction of pluripotency with RNA molecules that code for the four 'Yamanaka factors' 
(Warren et al., 2010). Eventually it has been shown that iPSCs can also be generated by direct 
Oct4-, Sox2-, Klf4- and cMyc- protein delivery to human fibroblasts (D. Kim et al., 2009). 
In general it seems that technical safety issues that previously hampered the use of 
iPSCs for a wide variety of clinical applications are about to be solved. In the scope of this 
review these developments are particularly interesting for the in vitro generation of iPSC 
derived DA neurons (figure 1). 
MOUSE iPSCs AS CRUCIAL MODEL SYSTEM 
Mouse as well as human iPSCs have been shown to be capable to differentiate into varying 
clinically relevant cell types, such as cardiomyocytes(Kuzmenkin et al., 2009; Ren et al., 
2011), hepatocytes (Espejel et al., 2010), hematopoetic progenitors (Hanna et al., 2007), 















Fig. I: Schematic comparison between iPSC technology and trans-differentiation to generate DA 
neurons in vitro. IPSC technology requires a forced expression/induction (either by viral transduction, 
RNA or protein transfection) of Oct4, Klf4, Sox2 and cMyc. Recent DA differentiation protocols 
provide robust yields of neurons highly resembling DA neuron characteristics. Directly converted 
neurons are not derived from a pluripotent intermediate, which minimizes undesired differentiation 
potential and risks for teratoma formation. DA-like neurons generated so far however show only very 
limited resemblance with primary midbrain DA neurons. 
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(Karumbayaram et al., 2009). In particular, iPSC-derived DA neurons appear to be a very 
interesting, clinically relevant cell type (for overview of key studies see table 1). First, they 
might serve as novel easily accessible autologous source for cell replacement. Many studies, 
starting in the 1980s, have already demonstrated that the consequences of the specific loss of 
midbrain DA neurons in the substantianigra pars compacta (SNc), the hallmark of Parkinson's 
disease, can be partly obviated by the intrastriatal implantation of extrinsic (heterologous) 
abortion-derived fetal human DA neurons (Kopyov, Jacques, Lieberman, Duma, & Rogers, 
n.d.; Olanow, Kordower, & Freeman, 1996; Roybon, Hjalt, Christophersen, Li, & Brundin, 
2008). Although this approach itself appeared to be successful, major practical and ethical 
concerns related to the use of this fetal human graft source were unbridgeable and made this 
strategy not feasible for the clinic (Freed et al., 2001; Lopez-Lozano et al., 1997). 
Secondly, iPSC derived DA neurons provide a unique tool to investigate cell pathogenic 
mechanisms in detail (e.g. the role of a-synuclein or LRRK2, etc.), particularly when the 
iPSCs are generated from patients with a hereditary form of Parkinson's disease (Devine 
et al., 2011; Nguyen et al., 2011). Before the iPSC technology entered the playground, DA 
Table 1 . :  Key studies for in vitro generation of DA neurons/iDA neurons from pluripotent stem cells and 
somatic cells (transdifferentiation) ,  respectively. 
Viral Pluripotent 
Species integration stem cel ls Characterization Reference 
mouse Yes iPSCs DA markers, electrophys .  Wernig et  a l . ,  
properties, functional  PNAS, 2008 
integration 
human Yes i PSCs DA markers Soldner et a l . ,  
(C  re-excised) (patient specific) Cel l  Stem Cell 2 009 
human Yes i PSCs DA markers, functional Hargus et a l . ,  
(C re-excised) (patient specific) i ntegration (60HDA rats) PNAS, 20 1 0  
human No ESCs/iPSCs Floor plate based DA Kirks&Sim et a l . ,  
(Sendai vi rus) induction, DA gene Natu re, 201 1 
expression profi le, 
electrophys. properties, 
functional i ntegration 
Viral 
Species i ntegration Transdifferentiation Characterization Reference 
mouse Yes 
mouse Yes 
transd iff. fibroblasts 
iDA neurons 
DA markers (TH selection) 
electrophys .properties, 
DA release, global gene 
expression (TH sorted), 
functional i ntegration 
Ca iazzo et a l . ,  
Nature, 20 1 1 
----------
transd iff. fi broblast 
iDA neurons 
DA markers (Pitx3 
selection), e lectrophys. 
properties, DA release, 
selected gene expression 
(Pitx3 sorted), functional 
integration 
Kim et a l . , 
Ce l l  Stem Cel l ,  2 0 1 1 
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neuron differentiation has been extensively studied for embryonic stem cells (ESCs) and 
neural stem cells (NSCs), either derived from ESCs (Chung et al., 2006, 2011) or primary 
isolated (Roybon et al., 2008; Rossler, Boddeke, & Copray, 2010). In order to improve in vitro 
generation of DA neurons derived from ESCs protocols have been developed that enhance 
DA differentiation. Early approaches involved the use of stromal feeder layers (such as MSS 
or PA6 cells) (H Kawasaki et al., 2000; Hiroshi Kawasaki et al., 2002). Later, in order to 
avoid undefined factors, protocols have been established that employ small molecules and 
recombinant proteins which specifically inhibit BMP signaling pathway ( dual inhibition of 
SMAD signaling) (Chambers et al., 2009). Recent studies provide evidence that derivation 
of floor plate cells (the floor plate is a crucial organizing structure in the developing embryo, 
located along the ventral midline) from pluripotent stem cells, by early supplementation 
with high concentrations of sonic hedgehog and induction of canonical Wnt signaling by 
small molecules, drastically improves the quantity and quality of subsequently generated 
DA neurons (Fasano, Chambers, Lee, Tomishima, & Studer, 2010; Kriks et al., 2011). 
Based on established methods for in vitro differentiation of DA neurons efficient protocols for 
dopaminergic differentiation of iPSCs have been developed. One of the first studies by Wernig et 
al. (2008) showed successful generation of DA neurons derived from mouse iPSCs(Wernig et al., 
2008). These cells showed some specific DA marker expression, such as the transcription factors 
Nurrl, Pitx3 and the enzyme tyrosine hydroxylase (TH). Furthermore, they revealed typical 
neuron-like electrophysiological properties and they functionally integrated in a rat model for 
PD after transplantation. However, the number of DA neurons that could be generated did not 
exceed 4% of the starting iPSC population, indicating that most of the cells that developed with 
that differentiation procedure had non-DA characteristics. While the study provided the proof 
of principle for treating PD symptoms with iPSC derived DA neurons in an animal model, 
various important issues were not or could not be addressed. Firstly, since only a minority of 
grafted iPSC derived cells were DA neurons, it can be questioned what the effect was of the vast 
majority of other cell types in the graft; it is clear that some kind of purification step is required. 
Secondly, in view of the exceptional origin of the DA neurons, characterization of the iPSC 
derived DA neurons and assessment of the completeness and stability of differentiation should 
not only be based on a set of general DA markers and electrophysiological characteristics, 
but should also contain extensive genetic and epigenetic screening. The challenge for a more 
comprehensive study of epigenetic and genetic characteristics of iPSC derived DA neurons 
mainly lies in the necessity to generate a cell population that allows purification based on a 
highly specific midbrain DA marker. Earlier studies reported the generation of ESC lines with 
specific heterozygous GFP knock-in modification in the dopamine transporter (DAT) locus 
and the Pitx3 locus (Hedlund et al., 2008; Zhou, Lee, Guy, & Freed, 2009). Both genes code for 
specific DA markers. Pitx3 is a transcription factor specifically expressed in mDA neurons, that 
interacts with Nurrl and is crucially involved in differentiation and maintenance processes for 
mDA neurons (Jacobs et al., 2009, 2011; Nunes, Tovmasian, Silva, Burke, & Goff, 2003; van den 
Munckhof et al., 2003). DAT is widely expressed in DA neurons and specifically indicates their 
maturation (Nirenberg, Vaughan, Uhl, Kuhar, & Pickel, 1996). However, because of its general 
function in all DA neurons (residing e.g. in the olfactory bulb or the ventral tegmental area) 
DAT cannot be considered as a selective marker for mDA neurons. 
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Our group has used Pitx3-GFP knock-in mice (kindly provided by Prof. M. Smidt, SILS, 
University of Amsterdam) for the generation of iPSC lines. The Pitx3-GFP knock-in feature 
allowed us selective isolation, identification and purification of primary embryonic and 
postnatal mDA neurons as well as of DA neurons that were obtained via differentiation 
of the iPSCs (see fig. 2). This approach enabled us to perform an extensive comparison of 
iPSC-derived DA neurons with primary mDA neurons (including varying developmental 
stages) as far as their genetic and epigenetic profiles are concerned. We particularly focused 
on DNA methylation, since reprogramming of somatic cells towards pluripotent cells 
and subsequent differentiation into DA neurons must entail massive changes in DNA 
methylation patterns in specific genomic loci (Doi et al., 2009; Maherali et al., 2007; Nishino 
et al., 2011; Ohi et al., 2011). This type of characterization, which was based on the ability 
to analyze purified Pitx3-GFP DA neurons, enabled us to determine a close similarity in 
terms of DNA methylation patterns between iPSC-derived DA neurons and primary DA 
neurons and provides novel insight in cell type specific de novo methylation during in 
vitro differentiation (Roessler et al., manuscript in preparation, see chapter 4 of this thesis). 
Before human iPSC-derived DA neurons might serve as tool for future cell replacement 
approaches such detailed in depth-studies will certainly be required in order to assure their 
clinically safe status as well as their bona fide characteristics. It will however remain difficult 
to directly compare human iPSC-derived DA neurons to their primary counterpart. 
HUMAN iPSCs TO STUDY AND TREAT PD 
Clinical application of iPSC-derived DA neurons for treating Parkinson's disease is still a distant 
option. All the aforementioned issues concerning the clinically safe use of iPSCs as well as the 
incomplete characterization of in vitro generated DA neurons form prominent roadblocks that 
remain to be cleared. A recent study provides evidence that human iPSCs completely free of 
Fig.2: Pitx3-GFP iPSC derived mDA neurons show co-expression of transgenic GFP (Pitx3gfp/ +) and 
Map2 (A) as well as tyrosine hydroxylase (TH) (B). Confocal microscopy (B) revealed that most of the 
Pitx3 expressing cells also express TH. However TH positive cells do not always show Pitx3 expression. 
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proviruses ( these hiPSCs were generated by direct protein delivery) are efficiently capable to 
differentiate towards functional DA neurons (Rhee et al., 2011). Such patient-derived iPSCs will 
provide a valuable tool for possible future cell based therapy approaches. 
Soldner et al. (2009) were the first to generate human iPSCs (hiPSCs) cells from patients 
with idiopathic PD (Soldner et al., 2009). Their study showed that indeed reprogramming 
factor-free iPSCs could be generated from PD patients using Cre-recombinase excisable 
viral constructs. Moreover, those patient-specific iPSCs could be differentiated in tyrosine 
hydroxylase (TH)-expressing neurons. In a follow-up study, PD patient iPSC-derived TH 
expressing neurons have been transplanted in a PD rat model ( 6-OHDA), where they 
reduced specific neurotoxin-induced asymmetric motor behavior (Hargus et al., 2010). 
These studies demonstrate the capability of hiPSCs to differentiate into functional neurons 
that improve PD symptoms associated with reduced dopamine signaling in the striatum. 
However, more extensive research needs to be done to further characterize patient-specific 
iPSC derived DA neurons in terms of the completeness and stability of their differentiated 
state. For that, global gene expression studies but also, as mentioned above, in-depth 
studies of epigenetic characteristics such as DNA methylation and histone modifications 
are required before clinical application will come within reach. 
Regarding the use of patient-specific iPSC-derived DA neurons as in-vitro PD model, it 
should be considered that PD is in general a late onset disease, which affects patients after decades 
of latent disease progress. Therefore, it may be quite challenging to model PD in vitro. Slowly 
developing molecular changes such as a-synuclein aggregation in patient derived DA neurons 
might not be detectable in cell culture that at best can be maintained for a few month. Moreover, 
genetic variations intrinsic to patient-specific iPSCs could complicate disease modeling since 
it will be literally impossible to generate experimentally defined conditions. A very interesting 
approach in that respect is a technology known as 'genome editing: employing zinc finger 
nucleases (ZFNs) to site-specifically target a disease relevant gene. Soldner et al. (2011) used 
ZFNs in patient-specific iPSCs to exclusively manipulate a point mutation site in the a-synuclein 
gene known to be key in rare forms of familial PD ( Soldner et al., 2011). Mutations in a-synuclein 
at specific sites ( e.g.: A53T; E46K or A30P) lead to the formation of Lewy bodies, which are 
inclusions present in affected DA neurons (for reviews on a-synuclein and Lewy bodies see e.g. 
45; 46). In this study by Soldner and colleagues (2011) these mutations have been addressed with 
genome editing aiming either at correction of a specific mutation ( e.g. in PD patient specific 
hiPSCs) or vice versa at generation of a mutation ( e.g. in wild-type ES cells) in order to study cell 
pathogenic consequences of such disease relevant modifications. 
Even though, DA neurons generated from human iPSCs do not easily allow purification 
as indicated for transgenic mouse iPSC-derived DA neurons, a thorough characterization is 
extremely crucial. Conceivable approaches also involve genome editing. ZFNs (as described 
above) and transcription activator-like effector nucleases (TALENs) have been used to 
genetically engineer human iPSCs that contain the GFP coding sequence (either 2A-eGFP 
or eGFP) in the locus of the Pitx3 gene (Hockemeyer et al., 2009, 2011). As yet, however no 
study showed the purification of Pitx3-GFP cells derived from ZFNs- or TALENs-modified 
human iPSCs. Succeeding in such a purification step will certainly improve the possibility to 
study specific molecular modifications (e.g. mutations in the a-synuclein- or LRRK2-gene) 
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and their consequences in affected cells. It might also allow to find changes in cells bearing 
disease relevant modifications before phenotypic (pathological) changes are detectable. 
TOWARDS A DIREC T PATIENT SPECI FIC CEL L 
REPLACEMENT STRATEG Y 
Very recent studies report about the direct conversion or transdifferentiation of fibroblasts 
to neurons (see figure 1), avoiding a pluripotent 'in between-stage'. This approach, 
although in a yet premature phase, shows a highly interesting option to generate DA 
neurons, circumventing some of the most critical pitfalls of the iPSC technology. In 2010, 
researchers described the possibility to manipulate mouse fibroblasts by introducing three 
neurodevelopmental factors (Brn2, Ascll and Mythll) in such a way that they directly 
converted into neuronal cells, so called induced neurons, or iNs(Vierbuchen et al., 2010). 
Shortly after that, the same group reported the same achievement for human fibroblasts 
(Pang et al., 2011 ). Both, mouse and human iNs showed expression of neuronal markers such 
as Tujl, Map2, Tau and synapsin and revealed neuron-like electrophysiological properties. 
In a more PD relevant approach two groups showed that the combination of the 
above mentioned iN factors combined with Lmxla and FoxA2 (Pfisterer et al ., 2011) or a 
combination of Lmxla and Nurrl (Caiazzo et al., 2011) in fibroblasts is sufficient to directly 
induce cells with DA neuronal characteristics, therefore called iDA neurons. 
The combination of the three neurodevelopmental factors (BAM) with factors known 
to be crucially involved in the embryonic development of mDA neurons as well as for their 
beneficial effect for DA differentiation of ESCs (Andersson et al., 2006; Cai et al., 2009; 
Chung et al., 2009; Lee et al., 2010; Lin et al., 2009; Nakatani, Kumai, Mizuhara, Minaki, 
& Ono, 2010) seem to specifically boost the transdifferentiation towards DA-like neurons. 
Even though these findings provide a proof of principle for the amazing possibility to 
directly transdifferentiate/ convert somatic cells just by simple forced expression of a specific 
set of transcription factors, also for iDA neurons a very thorough characterization would be 
necessary before one could seriously consider their clinical application. 
For a better understanding of to what extent iDA neurons are similar to primary midbrain 
DA neurons, the use of transgenic Pitx3-GFP mice, as described above for iPSCs, can be an 
adequate tool. Kim et al. (2011) used tail tip fibroblasts from transgenic Pitx3-GFP mice 
for transdifferentiation experiments (J. Kim et al., 2011). iDA neurons were isolated based 
on GFP expression and gene expression was compared to primary midbrain DA neurons 
(equally positive for Pitx3-GFP). Comparison of a selected list of markers for DA neurons 
showed only limited similarities between iDA and primary DA neurons. However, Pitx3-GFP 
sorted iDA neurons showed dopamine release, acquired highly similar electrophysiological 
properties and showed functional integration in 6-OHDA lesioned mice. 
Taken together, the possibility to directly convert somatic cells into neurons might 
provide a valuable tool to study diseases like PD in vitro. Besides, when issues such as the 
conversion efficiency and the not yet optimal genotypic and phenotypic characteristics are 
solved and improved, iDA neurons could provide a cell replacement tool as well. 
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CO N C L U DI N G REMARKS 
The full scope of iPSC-based technology in terms of in vitro disease modeling as well as in 
regenerative medicine becomes more and more apparent. This might in particular be the 
case for approaches to treat Parkinson's disease. We strongly believe that future research in 
this exciting field will provide much more details about disease-causing factors, at cellular 
as well as environmental level. In addition, a clinically safe generation of human iPSCs and 
the subsequent in vitro generation of patient specific DA neurons might provide realistic 
tools to replace lost DA neurons in PD patients. Last but not least the sheer possibility to 
generate specific DA neurons directly from patient fibroblasts opens up a completely new 
angle concerning cellular PD research. 
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A B S T RACT 
Neural stem cells (NSCs), either isolated from fetal or adult human brain or derived from 
induced pluripotent stem cells, are now considered major candidates for in vitro generation 
of transplantable dopaminergic (DA) neurons and modeling of Parkinson's disease. It is 
generally thought that in vitro differentiation of neural stem cells into meso-diencephalic 
dopaminergic neurons, requires recapitulation of dopaminergic differentiation pathway 
normally occurring in the ventral mesencephalon during embryogenesis. This dopaminergic 
pathway is partially activated by a combination of the extracellular induction factors Shh, 
FGF8 and Wntl that trigger specific intracellular transcription cascades. In vitro mimicking 
of these embryonic ventral mesencephalic conditions has been successful for dopaminergic 
differentiation of embryonic stem cells and ventral mesencephalic NSCs. Dopaminergic 
differentiation of non-mesencephalic NSCs (nmNSCs), however, is considered arduous. 
Here we examine whether Shh, FGF8 and Wntl can activate typical dopaminergic 
transcription factors, such as Lmxla, Msxl and Otx2 in nmNSCs. We found that Shh, 
FGF8 and Wntl induced theexpression of Lmxla and Otx2 in nmNSCs resulting in the 
differentiation of up to 39% of the nmNSCs into neurons expressing Pitx3. However, only 
a low number (- 13%) of these cells became more DA-like neurons also expressing tyrosine 
hydroxylase (TH). The HDAC-inhibitor trichostatin A combined with Shh, FGF8 and Wntl 
caused orchestrated induction of Lmxla, Otx2, Msxl plus the early DA transcription factor 
Enl. Now significantly increased numbers of TH (-22%) and Pitx3 (-33%) neurons were 
observed. Most of these cells coexpressed the DA markers DAT and Vmat2. Taken together, 
we demonstrate that nmNSCs indeed can be differentiated towards DA-like neurons, but 
this differentiation is far from complete in comparison to ventral mesencephalic NSCs and 
embryonic stem cells; most likely, the nmNSCs lack the proper "primed" epigenetic state for 
DA differentiation facilitating the induction of DA specific transcription factors. 
Key words: in vitro differentiation, ventralization factors, TH, Pitx3, HDAC inhibitor 
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INTROD U CTION 
In Parkinson's disease (PD) DA neurons selectively and progressively undergo cell death in the 
substantianigra (SN) pars compacta, resulting in the destruction of the nigrostriatal connections 
and subsequently in the depletion of dopamine in the striatum. Due to the specific loss of DA 
neurons, PD is associated with typical clinical symptoms such as rigidity, tremor, akinesia and 
loss of postural reflexes but also psychiatric disorders like depression or anxiety are related to this 
neurodegenerative disease (for review see Kempster et al., 2007 or Lees et al. 2009) 
About 20 years ago, a cell graft approach to treat PD was forwarded which aimed to 
restore the baseline dopaminergic levels in the striatum by the striatal implantation of fetal 
dopaminergic neurons derived from aborted human embryos (Olanow et al. 1996; Lindvall 
and Hagell, 2000; Bjorklund et al. 2003). Despite clear beneficial effects in many patients, 
severe side effects in a number of patients were reported after some years. The occurrence 
of these side effects was ascribed to a number of patient-related factors (like age, stage and 
severity of the disease at the time of implantation) but also to the location and, in particular, 
the obscure, highly variable cellular composition of the graft. Therefore, practical as well 
as ethical reasons made this approach not suitable for clinical applications and other cell 
sources had to be found. 
Neural stem cells, either isolated from fetal (heterologous) or adult (autologous) 
human brain (Westerlund et al., 2005) or derived from pluripotent stem cells, are now 
considered major candidates for the large scale in vitro generation of transplantable 
dopaminergic neurons. It is generally thought that in vitro induction of differentiation of 
neural stem cells into meso-diencephalic dopaminergic neurons, requires recapitulation 
of the dopaminergic differentiation pathway normally occurring in the neural stem cells 
of the ventral mesencephalon during embryogenesis. Dopaminergic differentiation in the 
embryonic ventral mesencephalon is regulated by a combination of extracellular induction 
factors that trigger specific intracellular transcription cascades. On one side, there is 
the secreted factor Wntl (and also other members of the Wnt family) which blocks the 
differentiation of ventral mesencephalic neural stem cells into GABAergic or serotonergic 
neuronal fates by repressing the transcription factor Nkx:2.2 via the upregulation of Otx2. 
On the other side, there is Sonic Hedgehog (Shh) and Fibroblast Growth Factor 8 (FGF8) 
which are considered to be essential for the specific induction of the DA neuronal lineage 
in the embryonic ventral mesencephalon (Ye et al. 1998) via the expression of Lmxla and 
Msxl (for review see Burbach and Smidt 2006). These two early transcription factors, in 
particular Lmxla, have been reported to be necessary and sufficient to induce mesencephalic 
DA differentiation (Andersson et al., 2006). 
Indeed, using the extrinsic induction factors described above, successful in vitro 
induction protocols for dopaminergic differentiation have been developed for neural 
stem cells isolated from the embryonic ventral mesencephalic region (Roybon et al., 
2008; Jonsson et al., 2009). However, induction of dopaminergic differentiation of non­
mesencephalic neural stem cells appears to be difficult, suggesting pre-existing differences 
in the responsiveness to dopaminergic induction signals between mesencephalic and non­
mesencephalic neural stem cells. This is of relevance since the neural stem cells presently 
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considered for the generation of implantable dopaminergic neurons, e.g. those derived from 
induced pluripotent stem (iPS) cells, should be considered non-mesencephalic in origin. 
The low yield of dopaminergic neurons obtained in first differentiation experiments with 
iPS-derived neural stem cells seems to confirm this (Wernig et al., 2008; Solnder et al., 2009). 
In the present study, we examine the potential of above mentioned extrinsic and intrinsic 
key players to induce dopaminergic differentiation in non-mesencephalic neural stem cells. 
Apart from establishing the effects of Shh and FG F8 on the expression levels of Lmx 1 a and 
Msxl ,  we aimed to determine whether the (forced over-) expression of these transcription 
factors can circumvent extrinsic induction mechanisms and can be employed to trigger 
pathways leading to dopaminergic differentiation of non-mesencephalic neural stem cells. 
EX PER I MENTAL  P ROCED U RE 
An ima l s  
For all experiments C57BL/6 mice were housed under standard conditions with free access 
to food and water. All animal experiments were carried out in accordance with the National 
Institute of Health Guide for the Care and Use of Laboratory Animals and regulations of the 
local Experimental Animal Committee. 
Cel l  cu ltu re 
Neural stem cells were isolated from the telencephalon of CS 7BL/ 6 mouse embryos at E 14; in 
here they are further referred to as non-mesencephalic neural stem cells (nmNSCs). Briefly, 
the telencephalon was cut into small pieces at room temperature and after mechanically 
triturating in ice-cold phosphate buffered saline the tissue was incubated with accutase 
(Sigma Aldrich, Zwijndrecht, The Netherlands) for 1 5-20min at 37°C. After repeated 
trituration the cell suspension was passed through a cell strainer (70µm pore size, Falcon, 
Franklin Lakes, NJ) and seeded ( 1 - 1 ,5 million cells) in T25 tissue culture flasks (Nunc, 
Roskilde, Denmark) containing proliferation medium, which consisted of Neurobasal 
medium (Invitrogen, Breda, The Netherlands), supplemented with B27 (2%, Invitrogen), 
recombinant human epidermal growth factor (EGF) (20ng/ml, Invitrogen), basic fibroblast 
growth factor (bFGF) (20ng/ml, Invitrogen), glutamax ( 1  %, Gibco, Invitrogen) , primocin 
( l0Ong/ml, Amaxa, VZA- 1022), and heparin (5µg/ml, Sigma Aldrich) in a humidified 5% 
CO/ 95% air incubator at 37°C (standard culture conditions). Within 3-5 days the cells 
grew as free-floating neurospheres and were dissociated using accutase and passaged at least 
twice a week. To induce differentiation into neural cell types, neurospheres were treated 
with accutase for 5- lOmin and dissociated by trituration. Subsequently these cells were 
plated on poly-D-lysine- and laminin-coated coverslips in 24 well plates at approximately 
20 .000 cells per well in Neurobasal medium supplemented with B27 alone. 
Differentiation 
For the differentiation induction experiments (see figure 1) ,  nmNSCs (passage number 
2-5) were exposed to varying concentrations of Shh (PHC2095, Invitrogen) and FGF8 
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(423-FB-025, R&D Systems) ( l 0nM or lO0nM each, adapted from Andersson et al. 2006) 
and Wntl (50 or 1 00 ng/ml, PHC1804, Invitrogen; adapted from Joksimovic et al., 2009) 
for 72h. After this treatment, the factors were withdrawn from the medium and the cells 
were put in culture for actual differentiation for 5 to 9 days (see figures/legends for exact 
differentiation time for each experiment). In a number of experiments, we examined the 
effect of the histone deacetylase inhibitor trichostatin A (TSA) on transcription factor 
expression before and during differentiation (see figure 1 ) .  To that purpose, ! Ong/ml TSA 
was added to the cells 24h after beginning of the Shh/FGF8/Wntl treatment and remained 
in the medium during the first 24h of differentiation. To analyze the effects of the induction 
factors on differentiation periods, cell samples were collected after different differentiation 
periods for RT-PCR and Western Blot analysis or were fixed for immunostaining. 
Gene tra nsfect ion 
Overexpression of Msxl (pCMV-SPORT6, Openbiosystems) was induced by electroporation 
of nmNSCs with these expression vectors. Gene transfections were performed using an 
electroporation-based transfection protocol (Amaxa GmbH, Cologne, Germany) specifically 
designed for transfection of embryonic mouse NSCs by Amaxa"'. Neurospheres were dissociated, 
1 -3 million cells were transfected with a maximum of lOµg DNA in total. As a control, cells have 
been transfected with a GFP control vector (pmaxGFP, 0,5µg/µl, Amaxa"'). Cells were cultured up 
to 5-9 days under standard culture conditions, fixed and immunostained. 
RT- PCR 
Total RNA was prepared by performing Phenol/Chloroform extraction followed by RNase­
free DNase treatment. Synthesis of cDNA has been primed by using random hexamers. 
The following primers have been used to detect mRNA expression level of Lmxla (FW: 
5'-CTAGGCTCATTCTTGTCGCC-3: BW: 5'-CCTCTGGGTGTTCTGTTGGT-3'), Msxl (FW: 
5' -GAAGATGCTCTGGTGAAGGC-3: BW: 5' - CAGCCTCTAATTCTGCTGGG-3'), Otx2 
(FW: 5' -GCTATGCTGGCTCAACTTCC-3: BW: 5' -GTCCATTTCAGGTTGCTGGT-3'), and 
Enl (FW: 5' -ACGCACCAGGAAGCTAAAGA-3: BW: 5' -CGGAGGATTGCTTTCTCTTG-3'). 
A !cQ!!lrQI B Shh/FGF8/Wnt1 
� I I I= Differentiation I I � I I � Differentiation I I 
24h 48h 72h 5DDC 9DDC 24h 48h 72h 5DDC 9DDC 
C Shh/FGF8/Wnt1 D Shh/FGF8/Wnt1 
� I I la Differentiation I I � I I � I Differentiation I I 
24h 48h 72h 5DDC 9DDC 24h 48h 72h 1 DOC 5DDC 9DDC 
Msx1 tratsfection TSA(10ng/ml) 
Fig.I: Differentiation schemes.(A) Shows the control differentiation condition, no inductive 
factors were applied. (B) Shows the culture condition when Shh, FGF8 and Wntl were applied 
before differentiation was induced. This condition we refer to as "in vitro ventralization". (C)Shows 
ventralization condition combined with transduction of Msxl .  (D) Shows ventralization condition 
combined with histone deacetylase inhibitor Trichostatin A. 
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Western B latting 
SDS-PAGE gel electrophoresis and Western Blot analysis have been performed to detect Lmxla, 
Msxl ,  Otx2 and Patched expression in undifferentiated and differentiated NSCs. Cells were 
collected, centrifuged for 20min at 4 °C and resuspended in Radio Immuno Precipitation Assay 
(RIPA) buffer along with a cocktail of protease inhibitors (Roche, . Resuspensions were mixed 
with Laemmli sample buffer (Laemmli, 1970) and sonicated for 2 times 5 seconds. Samples were 
boiled for 5 min. Proteins were separated for 1 ,5h on a 10% SDS-polyacrylamide gel in a BioRad 
electrophoresis apparatus (Bio Rad, Hercules, CA). Proteins were transferred to nitrocellulose 
membranes using semi-dry transfer buffer (25mM Tris, 150mM Glycin, 10% (v/v) Methanol) 
and 3 mA/cm2 current for 45 min. Nitrocellulose membranes were blocked using Odyssey 
Blocking Buffer (LI-COR, Biosciences) for lh at room temperature. Membranes were probed 
overnight at 4°C using rabbit anti-Lrnxla antibody ( 1 : 1000, ab3 1006, Abeam, Cambridge, 
UK), mouse anti-Msxl antibody ( 1 : 1000, ab73883, Abeam, Cambridge, UK), rabbit anti­
patched ( 1 :500, ab39266, Abeam, Cambridge, UK) and rabbit Otx2 (1 : 1000, ab21990, Abeam, 
Cambridge, UK) and mouse anti-a-Actin (ab6276, Abeam, Cambridge, UK) at 1 : 10.000 dilution. 
The housekeeping gene �-Actin has been used for normalization of different Lmxla expression 
levels. Membranes were washed four times with PBS-T, 10 min each. Primary antibodies were 
detected using fluorescently labeled secondary antibody donkey anti mouse (IRDye® 680, 
LI-COR, Biosciences) and donkey anti rabbit (IRDye® 800CW, LI-COR, Biosciences). Incubation 
with secondary antibodies ( 1 :8.000 in PBS-T) was performed for lh at room temperature in the 
dark. After four times washing in PBS-T, protein signals were detected and analyzed using the 
Odyssey Imager system/software (LI-COR, Biosciences). This software allows to measure pixel 
counts (intensity of the blot signals). After normalization using �-actin measurements, signal 
ratio's were calculated and conditions were compared. If not described differently independent 
experiments were performed threefold (n=3). 
l mmunocytochemistry 
After 5-9 days of differentiation nmNSC were fixted with 4% paraformaldehyde and 
immunostained for the following makers: neuronal markers mouse anti �-III-Tubulin 
( 1 :500, ab775 1 ,  abeam) and mouse anti Map2 ( 1 :500, AB5622, Chemicon) ,  neural stem cell 
marker mouse anti nestin ( 1 :500, MAB 353, Chemicon), DA neuron markers rabbit anti 
tyrosine hydroxylase ( 1 :500, AB1 52, Chemicon) ,  rabbit anti-dopamine transporter ( 1 :500, 
MB369, Chemicon) ,  anti Vmat2 ( 1 :500, (H-90), sc- 1 53 14, Santa Cruz) and rabbit anti Pitx3 
( 1 : 1 000, gift from Prof. Marten Smidt, Rudolf Magnus Institute of Neuroscience, Utrecht) . 
Differentiated nmNSCs were probed for 24h with anti-TH, anti-Pitx3, anti-nestin, and anti­
�-III-tubulin and anti-Map2 at 4°C. Primary antibodies were detected with fluorescently 
labeled secondary antibodies goat anti mouse Cy3 ( 1 :500, Jackson Immuno Research), and 
goat anti rabbit Alexa 488 ( 1 :500, Molecular Probes) for 2-3h at room temperature. 
Microscopic analysis 
Quantitive analysis of differentiated immunostained cells was performed using Zeiss 
(Axioskope 2) Fluorescent Microscope equipped with a Leica DFC300FX camera and a 
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Leica microsystem LAS program. For differential cell type counting, based on cell type 
specific immunostaining, 3 pictures (2 coverslips per condition = 6 observations) per 
coverslip were made at a 20x magnification. Areas were selected randomly or only based 
on Hoechst staining. If nuclei were very dense counting was only taken into account when 
nuclei were distinguishable from each other. Differential cell count analyses were done 
using Image J software. Confocal images were obtained with a Leica AOBS TCS SP2 (Leica, 
Heidelberg, Germany) confocal microscope. 
Stat istica l Ana lys is  
Statistical comparisons were made by ANOVA using post hoc Bonferroni test and LSD test. 
The data were expressed as mean ± standard error of the mean. Differences were considered 
significant if p values were smaller than 0,05. 
RESULTS 
Effects of Shh, FG F8 a n d  Wntl on  dopa m i nerg ic d ifferentiation 
We developed and tested different protocols to examine the effects of the mesencephalic DA 
induction factors Shh, FGF8 and Wntl on the non-mesencephalic NSCs (nmNSCs) (see figure 
1). In view of their ventralization effects, including ventral midbrain DA differentiation (for 
review see Smidt and Burbach 2007), during early brain development, Shh, FGF8 and Wntl 
are also designated as ventralization factors (adapted from Friling et al., 2009) and this term 
is used throughout the paper. In various experiments, we have exposed the cells to either a 
combination of low concentrations of these factors, i.e. 1 0nM Shh, 1 0nM FGF8 combined with 
50ng/ml Wntl or high concentrations, i.e. lO0nM Shh, l00nM FGF8 combined with lOOng/ 
ml Wntl .An obvious prerequisite for nmNSCs to be able to respond to the ventralization 
factors Shh, FGF8 and Wntl is the expression of the specific receptors for these induction 
factors. As a first step, we examined the expression of the Shh receptor Patched in nmNSCs 
(the presence of FGF8- and Wntl receptors in NSCs throughout the E14 mouse brain have 
been extensively documented before, see e.g. in Saarimaki-Vire et al., 2007 and Michaelidis 
and Lie, 2008). Clearly, we found Shh receptor expression in nmNSCs (figure 2A); the level of 
Patched expression in the cultured nmNSCs seems not to be modified by the combination of 
the inductive ventralization factors, when cultured under ventralization conditions for 3 days. 
Next we examined whether these receptors were functional and whether activation by 
the ventralization factors could induce the expression of the early DA transcription factors 
Lmxla, Msxl, Otx2 and Enl in the (undifferentiated) nmNSCs. To that purpose we exposed 
nmNSCs to low and high concentrations of the ventralization factors (figure 2B and C). 
We found increasing levels of Lmxla expression dependent on the amount of ventralization 
factors we added, at mRNA level (figure 2B) as well as at protein level (figure 2C). Analysis of 
the effects of Shh and FGF8 on Lmxla mRNA levels without the addition of Wnt also revealed 
a dose-dependent boost of Lmxla expression but these effects did not reach statistical 
significance (figure 2D). Concerning Msxl, no expression was found in undifferentiated 
nmNSCs either with or without ventralization factor exposure. Otx2, on the other hand, 
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appeared to be clearly expressed in undifferentiated nmNSCs and its expression was 
enhanced after exposure to low concentrations of the ventralization factors. Otx2 expression 
has been shown to be induced merely by Wntl (and not by Shh/FGF8) (Prakash et al., 2005). 
Here it seemed that only S0ng/ml Wntl  (and not lO0ng/ml Wntl )  was able to induce an 
increase in Otx2 expression in undifferentiated nmNSCs (figure 2B and C) . Enl ,  an early 
DA marker was not found in these undifferentiated nmNSCs (figure 2B) . 
In addition, we examined the mRNA expression ofMsxl ,  Otx2 and Enl in nmNSCs after 
8-9 days of differentiation (figure 2E) . Surprisingly, we found low levels of Msxl expression 
when the cells differentiated after exposure to low concentrations of ventralization factors. 
Interestingly, the levels of Otx2 and Enl mRNA expression in differentiated nmNSCs 
were much lower when they were exposed to the ventralization factors in comparison to 
differentiation under control conditions, i.e. in the absence of these factors. 
Next, after having established that nmNSCs expressed the proper receptors for the 
mesencephalic DA induction factors and that these factors could induce the expression of 
Lmxla and Otx2, we examined whether the ventralization factors could actually induce the 
differentiation of these nmNSCs into a DA phenotype. DA neurons were identified by the 
expression of the specific mesencephalic DA marker Pitx3 ( e.g. Smidt et al., 1997) and tyrosine 
hydroxylase (TH) the rate-limiting enzyme for dopamine production. First, we compared the 
number of Pitx3-expressing Map2-positive neurons derived from nmNSCs under control 
conditions with the numbers of Pitx3-expressing neurons that differentiated after exposure to 
low or high concentrations of the ventralization factors Shh/FGF8/Wntl (figure 3A-C). We found 
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Fig.2: Expression analysis of crucial receptors and DA transcription factors in NSCs.(A) 
Western Blot analysis shows that the Shh receptor Patched is expressed in nmNSCs. (B) RT-PCR of 
undifferentiated nmNSCs: the arrow indicates the weak expression of Lmxla, however it increases due 
to application of ventralization factors. (C) Western Blot showing the related protein expression in 
undifferentiated NSCs. (D) The correlation between Shh/FGF8 concentration and endogenous Lmxla 
protein levels has been analyzed in more detail: generally, the Lmxla expression increases with higher 
concentrations of the ventralization factors. (E) RT-PCR analysis shows mRNA levels in nmNSCs after 
5-6 days of differentiation treated with or without (ctrl) the indicated ventralization factors 
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a significant concentration-dependent increase in the number of Pitx:3-positive cells: in control 
conditions, differentiation of nmNSCs resulted in only 20% ± 6% Pitx:3 positive neurons, whereas 
differentiation after induction with low or high concentrations of Shh/FGF8/Wntl increased the 
number of Pitx:3-positive neurons to 28% (±4,8%) and 39% (±1 %) respectively (n=3, p < 0,01). 
In the next step, we examined the expression of TH in these differentiated neurons. Cells were 
costained for �-III-Tubulin and TH (figure 3 D-F). Quantification did not reveal a significant 
change in the numbers of TH+ neurons between the conditions tested (figure 3G); we only 
observed a slight increase when ventralization factors were added at low concentrations to the 
cultures. In all conditions, the number of TH-expressing neurons was a fraction of the number of 
Pitx:3 expressing neurons. It should be noted that TH-positive neurons differentiated in clusters, 
suggesting the need for a specific optimal micro-environment. Additionally, we analyzed the 
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Fig.3: Differentiation of nmNSCs under ventralization conditions. Cells were differentiated for 
8-9d and stained for neuronal marker Map2 and the DA neuron marker Pitx3 (A-C). We found an 
increase of Pitx3 positive cells with raising Shh, FGF8 and Wntl concentrations. (D-F) Confocal 
images of differentiated nmNSCs. Cells were costained for TH, �-III-tubulin and Hoechst. (G) 
Quantitative analysis revealed a significant increase of Pitx3 expressing neurons in the "high" factor 
condition; no change was observed in the number of TH-expressing cells (*** P < 0,001 ,  OnewayAnova, 
PosthocBonferroni). (H) Application of ventralization factors did not cause an increased number of 
(Map2-positive) neurons per se. 
-
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effects of the ventralization factors on pan-neuronal differentiation. We found no change in the 
total amount of cells that differentiated into neurons in general, when low or high concentrations 
of the ventralization factors were applied (figure 3H). 
In summary, a combination of the ventralization factors Shh, FGF8 and Wntl could 
indeed induce the expression of the DA transcription factors Lmxla and Otx2 in nmNSCs 
and could stimulate in a dose-dependent way their differentiation into Pitx3-positive neurons. 
However, the combined application/induction of these extrinsic and intrinsic factors appears 
to be unable to induce the subsequent differentiation of all of these Pitx3 neurons into stable, 
mature TH-positive DA neurons. Besides DA induction via the transcription factors Lmxla 
and Otx2, other transcription factors, in particular Msxl, may be essential to establish the 
differentiation of all Pitx.3 positive DA precursors into mature DA neurons. 
Effects of forced Msxl exp ress ion on  dopa m i n erg ic d iffere ntiat ion 
Since Msxl expression appeared not to be induced in the nmNSCs by the ventralization 
factors Shh, FGF8 and Wntl (see figure 2B), we forced an increase in the level of Msxl 
expression in nmNSCs by gene transfection in order to examine the potential role of Msxl 
in DA differentiation in our nmNSCs. We first examined the endogenous expression levels 
of Msxl in undifferentiated nmNSCs; despite the presence of Lmxla, which is known to 
induce Msxl, we found only a very low expression of Msxl in naYve nmNSCs (figure. 4C). 
We used Amaxa* gene transfection to force Msxl expression in the nmNSCs (figure 4C) and 
subsequently applied our DA differentiation protocol with the ventralization factors. The gene 
transfection procedure and/or the induced high intracellular Msxl levels, however, limited 
the in vitro viability of the cells and so they could only be differentiated for a period of up 
to 6 days. Apparently, this culture period was too short for complete differentiation as could 
be deduced from the number of undifferentiated nestin-positive nmNSCs still present at 6 
days of differentiation and the number of immature bipolar TH cells that still co-expressed 
nestin (fig. 4A and B, white arrows). In all our experiments, in which cells were allowed/ 
able to differentiate up to 9 days, no nestin expression could be detected anymore ( data 
not shown) and all TH-positive cells showed a morphologically mature typical DA neuron 
phenotype. Cell counting of all TH-positive cells (immature and mature morphology) done 
at 6 days of differentiation did not reveal an additional effect of forced Msxl expression on 
DA differentiation in comparison to the ventralization factors alone (figure 4D and E). 
So, induction of the expression of the dopaminergic transcription factors Lmxla, Otx2 
and Msxl by the ventralization factors or via gene transfection appeared to be insufficient 
to accomplish complete differentiation of nmNSCs into fully mature, TH-positive DA 
neurons. Besides the fact that levels of each of these factors may have been suboptimal, 
other essential transcription factors may not have been present. 
Effects of ventra l ization  factors co mb i ned with trichostati n A on  
dopami nerg ic  differentiat ion 
To accomplish a more optimal expression of dopaminergic transcription factors, we used 
the HDAC-inhibitor trichostatin A (TSA). The expression of most transcription factors 
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Fig.4:Effects ofMsxl gene transduction combined with ventralization factors on nmNSCs. Cells 
were differentiated for 5-6days. (A) Immunohistochemical stainingshows the various cell types in 
control cultures to which no inductive factors were applied: only few TH positive cells were found that 
had a mature DA neuron morphology (white arrows). (B) In cultures with ventralization conditions 
combined with Msxl transduction two types of TH-positive cells can be demonstrated with 
immunocytochemistry: one type similar to the cells found under control conditions (white arrows), 
the other type co-expressing nestin and TH (white arrowheads), suggesting immature DA neurons. 
(C)Western blots showing the levels of Msxl protein after 24h and 48h compared to control cells. (D) 
Quantification of nestin- and TH-expressing cells with or without Msxl transfection (E) Cell counts 
comparing the appearance of TH-positive cells after differentiation in the presence of ventralization 
factors alone and combined with Msxl-OE. 
involved in differentiation is under epigenetic control: the activation or silencing of their 
genes is regulated via histone modification, in particular histone acetylation/deacetylation. 
By blocking histone deacetylase (HDAC) activity with the use of the HDAC-inhibitor 
TSA, we aimed to facilitate the expression of DA transcription factors and to examine the 
consequences of this treatment for the DA differentiation of the nmNSCs. 
Initially we analyzed the effect of lOng/ml TSA on Lmxla, Msxl ,  Otx2 and Enl 
expression in undifferentiated nmNSCs. In comparison to basic levels of expression in 
undifferentiated nmNSCs (see figure 2), TSA treatment indeed resulted in an increase in 
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the expression of Otx2, Enl and Lmxla, but not Msxl .  Combining TSA with low doses of 
the ventralization cocktail Shh/FGF8/Wntl additionally increased Enl (figure SA), Lmxla 
(figure SC), and Otx2 (figure SA and B) expression. Whereas, the expression of Msxl could 
not be stimulated by TSA or the ventralization factors separately, a combination of both 
resulted in an increase in the Msxl mRNA level (figure SA). 
The next step was to examine whether the ventralization factors, reinforced by 
TSA, were able to increases DA transcription factor expression and could facilitate DA 
differentiation of nmNSCs and, in particular, could stimulate the maturation towards DA 
neurons. Our results show that TSA treatment without the ventralization factors was unable 
to increase differentiation of Pitx3 positive neurons (figure 6A-K). This suggests that the 
increase of Lmxla, Otx2 and Enl induced by TSA alone (see figure 5) was not sufficient 
to induce DA differentiation. However, the combination of TSA with the ventralization 
factor cocktail resulted in significantly higher numbers of Pitx3-expressing neurons 
differentiated from nmNSCs (figure 6A-C, and J). Contradictory to what we found when we 
applied the ventralization factors without TSA we found significantly increased numbers 
of TH positive neurons when TSA was included (figure 6 D-F). Quantification (figure 6J) 
revealed that TSA only did not show a boosting effect on TH expression (8±1 %), however, 
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Fig.5: Effect of trichostatin A on expression of crucial DA transcription factors. (A) RT-PCR 
analysis shows mRNA levels of Msxl ,  Otx2 and Enl after TSA (10 ng/ml) was added to undifferentiated 
nmNSCs. (B) Western Blotting reveals the protein expression levels of endogenous Otx2 with or 
without TSA (10 ng/ml). (C) Western blot quantification of three independent experiments showing 
the change in Lmxla expression in undifferentiated nmNSCs exposed to TSA and the ventralization 
factors; control level of expression (normalized to 13-actin) in untreated cells is set as 1 .  (n = 3; * P < 
0,05; ** P < 0,01; OnewayAnova, PosthocBonferroni). 
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Fig.6:Differentiation of neural stem cells under ventralization conditions combined with TSA 
application.(A-C) Cells were differentiated for 8-9d and immunostained for Map2 and Pitx3. We found 
an increase of Pitx3 positive cells in the lOnM + TSA condition and in the lOOnM + TSA condition. (D-F) 
Confocal images show differentiated cells (8-9days) that were immunostained for 13-III-Tubulin and TH. 
(G-1) Cells were differentiated for 8-9d and immunostained for 13-III-Tubulin and Dat. (J) Quantification 
of differentiated nmNSCs expressing Pitx3, TH and Dat. When ventralization factors were combined 
with TSA, significantly increased DA marker expression was found (n=3; * P < 0,05; ** P< 0,01; *** P < 
0,001, OnewayAnova, PosthocBonferroni). (K) The total number of neurons (Map2-positive cells) where 
quantified (n=3, §§ < 0,01 ,  OnewayAnova, Posthoc LSD; error bars represent SEM) 
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if TSA was combined with ventralization factors (low and high) we found significantly 
increased numbers of TH positive neurons (22±6% and 17±4% respectively). To further 
characterize a proper DA marker expression pattern we included the specific DA markers 
dopamine transporter (DAT) and vesicular monanine transporter 2 (Vmat2). Clearly we 
found increased numbers of DAT positive neurons (22±5% and 15±3%, respectively) if 
the ventralization factors where combined with TSA (figure 6G-I and J). The increasing 
amount of TH and DAT positive cells correlated clearly with the increased number of Pitx3 
expressing neurons. Furthermore, co-labeling and quantification of DAT positive cells with 
TH and Vmat2 revealed that most of the cells that underwent in vitro differentiation do 
express a combination of these DA specific markers (figure 7). 
Additionally we analyzed the effects of the ventralization factors combined with TSA 
on pan-neuronal differentiation. We found increasing numbers of neurons when TSA was 
added to the ventralization factors (figure 6K). The strongest increase can be seen when TSA 
was combined with low concentrations of ventralization factors. However, no significant 
difference was found between the TSA only condition and the TSA plus factors conditions. 
Based on that and the result in figure 3H we conclude that pan-neuronal induction was 
not caused by the ventralization factors. TSA on the other hand caused induction of pan­
neuronal differentiation. This is in accordance with other studies were HDAC inhibitors have 
been shown to promote neuronal induction (Hsieh et al., 2004; Siebzehnrubel et al., 2007). 
In summary, combining the cocktail of ventralization factors (in particular in low 
doses) with an additional increase in the dopaminergic transcription factors Lmxla, 
Otx2, Msxl and Enl elicited by TSA, did stimulate the differentiation of nmNSCs into a 
dopaminergic neuron-like cell type as envisaged by the significant increase in the number 
of cells expressing Pitx3, DAT and TH. However, the addition of TSA to the ventralization 
factors was still not able to assure full differentiation of all of the Pitx3 positive cells into 
more mature DAT and TH-expressing DA neurons. 
D I S C U S S I O N  
In our study, we aimed to differentiate non-mesencephalic neural stem cells (nmNSCs) 
towards DA neurons, employing extrinsic and intrinsic factors proven to be essential 
for the generation of dopaminergic neurons in the embryonic ventral mesencephalon 
(e.g. Burbach and Smidt 2006 or Abeliovich and Hammond 2007). We demonstrated 
that the extrinsic DA induction factors Shh, FGF8 and Wntl active in the embryonic 
ventral mesencephalon could induce the in vitro differentiation of approximately 40% 
of the nmNSCs towards dopaminergic precursors identified by Pitx3 expression, though 
the number of cells coexpressing TH was low. Combining the ventralization factors with 
chromatine modulation by the HDAC inhibitor TSA, resulted in a significant increase in 
Pitx3- and TH-expressing neurons, which moreover coexpressed DAT and Vmat2. 
Various studies have shown that the in vitro generation of DA neurons from neural 
stem cells emanating from the ventral midbrain (mbNSCs) (e.g. Kim et al., 2003; Kim et al., 
2003) yields high percentages of properly differentiated DA neurons when a combination of 
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Fig.7:Differentiated nmNSCs co-express DA markers. Cells were cultured under ventralization 
conditions combined with TSA. Cells were differentiated for 8-9d and co-stained either for Dat and 
TH or Dat and Vmat2. Under this differentiation conditions most of the DAT positive cell are positive 
for TH or Vmat2 as well. 
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the so-called ventralization factors Shh, FGF8 and Wntl is used. However, the generation 
of DA neurons from embryonic or adult nmNSCs that are not prone to become midbrain 
DA neurons (e.g. patient-derived autologous NSCs or patient specific iPS cells) seems to be 
difficult, inefficient and incomplete. 
The nmNSCs used in our study expressed the proper receptors for the DA inducing 
ventralization factors. This is in line with various studies in which it has been shown that 
embryonic and adult neural stem cells express a wide range of receptors for all kinds of 
growth, trophic and induction factors (see e.g. in Saarimaki-Vire et al., 2007 and Michaelidis 
and Lie, 2008). Activation of the ventralization factor receptors induced a dose-dependent 
expression of Lmxla and Otx2 and this expression correlated with the generation of 
neurons expressing the midbrain DA neuron marker Pitx3. Lmxla has been described as a 
crucial factor for DA differentiation (Andersson et al. 2006). It has been shown that Shh is 
able to induce Lmxla (and Msxl) expression in chick neural plate explants isolated from 
the putative midbrain, but not in forebrain or hindbrain (Andersson et al. 2006). However, 
in mouse, Lmxl a has also been shown to be expressed in other brain regions early during 
development (E8.5 to EI0.5), such as the hippocampus, the cerebellum and the dorsal spinal 
cord (Failli et al., 2002). Also in our telencephalic NSCs, we detected, albeit low, Lmxla 
expression before exposure to Shh. Nonetheless, we found that raising concentrations 
of Shh (in combination with FGF8 and Wntl) increased the protein level of Lmxla. In 
accordance with in vivo studies (Failli et al., 2002; Anderson et al., 2006), once the in vitro 
differentiation of nmNSCs had started, the expression of Lmxla was no longer detectable. 
In contrast to the chick neural plate (Anderson et al. 2006), in nmNSCs Lmxl a seemed to be 
unable to induce the expression of Msx. Lmxla and Msxl are thought to play functionally 
complementary roles in DA differentiation: whereas (sufficient levels of) Lmxla forces 
midbrain NSCs into a dopaminergic cell lineage, Msxl blocks other potential cell fates (via 
inhibition of Nkx6.l) and stimulates neuronal differentiation (via Ngn2) (Guillemot et al., 
2005; Kele et al., 2006; Andersson et al., 2006). We envisioned that the absence of Msxl 
in the nmNSCs after ventralization factor exposure may have been responsible for their 
insufficient dopaminergic differentiation. However, forced overexpression of Msxl via gene 
transfection in combination with exposure to the ventralization factors did not improve the 
DA differentiation pattern.Besides Lmxla and Msxl,  Otx2 has been considered an intrinsic 
DA determinant. Otx2 is crucial for specification, regionalization and differentiation of 
forebrain and midbrain (Acampora and Simeone, 1999; Puelles et al. 2004; Omodei et al, 
2008). The increase in expression of Otx2 is mainly induced by Wntl (Prakash et al., 2005) 
and our in vitro experiments showed that it is most effective at comparably low dose (50ng/ 
ml). It has been shown that the canonical Wnt/beta-catenin signaling pathway interconnects 
with Shh signaling in spinal cord neuroepethilium (Alvarez-Medina et al., 2008; Lei et al., 
2003) and that Wnt antagonizes Shh signaling during neurogenesis in the midbrain floor 
plate to regulate Shh mediated effects (Joksimovic et al., 2009). These studies indicate that 
there is a complex orchestration within these two signal pathways, which makes it very 
difficult to mimic those conditions in an in vitro differentiation approach. 
It is difficult to establish what the exact contribution and role of each of the two 
dopaminergic transcription factors (Lmxl a and Otx2) is during in vitro dopaminergic 
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differentiation of nmNSCs. It is clear that they are able to provoke 39% of the nmNSCs 
to differentiate into Pitx3 positive DA progenitors. However, only a fraction of these 
dopaminergic precursors coexpressed TH, Dat and Vmat2 and apparently developed beyond 
the Pitx3 stage. It has been suggested that Pitx3 is required for the terminal differentiation 
of DA neurons of the substantianigra and that it regulates TH expression (Maxwell et al., 
2005); it is an important factor for DA neuron survival and maintenance (Smidt et al., 
2004) and crucially regulates Nurrl target genes, such as Dat, Vmat2 and D2R (Jacobs et al., 
2009).Concerning Lmxla our findings suggest that it (eventually in combination with Msxl 
and Otx2) can only lead to incompletely differentiated dopaminergic precursors lacking 
TH expression. This is in line with findings of Roybon et al. (2008) where retrovirally 
overexpressed Lmxla (also in combination with Msxl or Pitx3) in rat mesencephalic NSCs 
was unable to induce TH expression. 
We considered the possibility that Shh/FGF8/Wntl in our nmNSCs may not have been 
able to fully activate the expression of intrinsic DA determinant genes and other essential 
genes. By inducing histone hyperacetylation by using the HDAC inhibitor TSA we aimed 
to increase the accessibility of these genes for transcription, activated by the extrinsic 
triggers. We speculated that this treatment may lead to an upregulation of other essential 
genes. Various studies have shown that treating NSCs with histone deacetylase inhibitors 
promotes the expression of a wide variety of proneuronal genes and stimulates neuronal 
differentiation per se (Hsieh et al., 2004; Balasubramaniyan et al., 2006; Siebzehnrubel et 
al., 2007; Yu et al., 2009). Furthermore, HDAC inhibitors have been shown to promote 
DA differentiation even in absence of Pitx3 (Jacobs et al., 2009). Indeed, TSA treatment 
of the nmNSCs in combination with low doses of the 3 ventralization factors resulted 
in a significant increase of Lmxla, Msxl, Otx2 and Enl. As a consequence, the number 
of NSCs that differentiated into Pitx3- and TH-positive neurons increased up to 33 and 
22 % respectively. However, in a remaining fraction of the Pitx3 expressing neurons, TH 
expression could not be induced, suggesting that additional extrinsic ( e.g. BDNF, combined 
with ascorbic acid and low oxygen (Maciaczyk et al., 2008)) and intrinsic factors (e.g. Nurrl, 
Ngn2 (Kim et al., 2003; Andersson et al., 2007 and Foxa2 (Kittappa et al., 2007; for review 
see: Arenas 2008)) are required. Also the microenvironment of differentiating cells in vitro 
may have played a decisive role. We noted that DA differentiation occurred only in clusters. 
This may point to insufficient dissociation of neurospheres, but more likely seem to indicate 
that an optimal (conditioned) astroglial microenvironment is a pre-requisite. Various 
studies have suggested the importance of such feeder-like cells (and factors secreted by 
them) for in vitro differentiation of DA neurons (Iacovitti et al., 2007; Roybon et al., 2008). 
In conclusion our study indicates that midbrain DA differentiation is inducible in 
nmNSC. We showed that the early specific DA transcription factors Lmxla and Otx2 can be 
endogenously increased by application of the extrinsic factors Shh, FGF8 and Wntl. HDAC 
inhibitor treatment combined with the ventralization factors induced additionally DA specific 
endogenous Msxl and Enl. The combined treatment in our differentiation protocol enabled 
us to upregulate four crucial early DA transcription factors at the same time. Subsequently 
this provoked significantly higher numbers of neurons with DA-like characteristics. 
However, stable induction of DA differentiation in these cells seems to be strictly regulated 
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by a complex orchestration of inductive factors and DA specific transcription factors. In 
order to obtain transplantable amounts of DA neurons from non-mesencephalic neural 
stem cells (e.g. adult NSCs or patient specific iPS cells) further research is needed to better 
understand and manipulate the regulatory events of DA differentiationpathways. 
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A B ST RACT 
Induced pluripotent stem cells (iPSCs) hold great promise for in vitro disease modeling and 
cell replacement therapy for Parkinson's disease (PD). Both applications crucially require an 
in-depth profiling of the disease-relevant, iPSC-derived cell type. Midbrain dopaminergic 
(mDA) neurons derived from pluripotent stem cells are of substantial interest because of 
their instrumental value for PD therapy. IPSC-derived mDA neuron-like cells have been 
generated, however, detailed genetic and epigenetic characterization of strictly purified in 
vitro generated DA neurons has so far lagged behind. 
We generated mouse Pitx3gfpt+ iPSC-derived DA neurons that, after fluorescent activated 
cell sorting (FACS) allowed comprehensive comparison to mesodiencephalic dopaminergic 
(mdDA) neurons isolated from the ventral midbrain. We performed detailed analysis 
of global gene expression and genome-scale DNA methylation of CpG islands (CGis) 
by reduced representation bisulfite sequencing. Indeed, the reprogramming pathway 
from fibroblasts to iPSCs left parental cell footprints for both gene expression and DNA 
methylation. However, most gene expression patterns of iPSC-derived DA neurons closely 
resembled that of primary mdDA neurons with the strongest correlations for mdDA 
specific genes. Also, for DNA methylation patterns, high similarities were found for the 
vast majority of CGis when comparing primary mdDA neurons with iPSC-derived DA 
neurons. Additionally, we found de novo DNA methylation during in vitro differentiation 
for hundreds of genes specifically in lineage-committed neural precursors that persisted in 
iPSC-derived DA neurons. 
Our study provides novel detailed characteristics of iPSC-derived DA neurons in 
comparison to the primary cell type. These findings add important information to our 
knowledge about these biomedically highly valuable, in vitro generated neurons. 
Key words: induced pluripotent stem cells, purified dopaminergic neurons, gene expression 
profiling, global DNA methylation analysis 
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INTRODU C TION 
The field of regenerative medicine has experienced a drastic boost after the groundbreaking 
discovery of iPSCs (Takahashi & Yamanaka, 2006). Numerous publications have shown that 
mouse as well as human iPSCs can be differentiated into various, clinically relevant cell types, 
such as cardiomyocytes (Kuzmenkin et al., 2009; Ren et al., 2011), hepatocytes (Espejel et 
al., 2010), hematopoetic progenitors (Hanna et al., 2007), oligodendrocytes (Czepiel et al., 
2011) and specific subtypes of neurons (Karumbayaram et al., 2009; Wernig et al., 2008). 
Such in vitro generated iPSC-derived cell types have a great potential in terms of disease 
modeling and cell replacement strategies. In particular, the generation of autologous iPSC­
derived midbrain dopaminergic neurons might provide an extremely interesting tool to 
study and treat Parkinson's disease (PD) (Roessler, Boddeke, & Copray, 2012). However, 
future clinical application of iPSC-derived DA neurons can only be considered realistic if 
the desired cell population is strictly purified and carefully characterized. 
Several groups have reported the generation of DA neurons form mouse and human 
iPSCs (Hargus et al., 2010; Swistowski et al., 2010; Wernig et al., 2008). In these studies iPSC­
derived neurons showed expression of crucial DA markers, and displayed typical neuronal 
electrophysiological properties. Furthermore, these iPSC-derived dopamine neurons could 
functionally integrate into a rat PD model upon transplantation. In principle these results 
indicated that the dopaminergic neuronal subpopulation could be derived from iPSCs 
and showed important characteristics typical for midbrain DA neurons. However, to our 
knowledge no genome-wide studies comparing genetic and epigenetic features of iPSC­
derived DA neurons and primary mdDA neurons are currently available. 
Therefore, we generated iPSC lines from Pitx3srrt+ knock-in mouse embryonic fibroblasts 
(MEFs). Pitx3 is a highly specific mesodiencephalic dopaminergic (mdDA) neuron marker 
which is required for dopaminergic neuron differentiation in the substantia nigra (Jacobs 
et al., 2009; Smidt et al., 2004). The specific Pitx3-associated GFP expression allowed us to 
strictly identify and purify DA neurons, either iPSC-derived or isolated from the ventral 
midbrain of mouse embryos or pubs at varying developmental stages. In the present study, 
we subjected all these FACS-purified DA neurons to genome wide gene expression analysis 
comparing iPSC-derived DA neurons and primary isolated mdDA neurons. Overall we 
found a high resemblance in gene expression patterns in iPSC-derived DA neurons and 
primary neurons. However, retained gene expression footprints of fibroblasts ( cell type of 
origin) and pluripotent cells were also found. 
Inducing pluripotency in somatic cells is considered an epigenetic process that entails a 
large series of crucial changes in DNA methylation patterns (Bock et al., 2011; Maherali et 
al., 2007; Nishino et al., 2011; Ohi et al., 2011). Furthermore, iPSC differentiation depends 
on properly established de novo DNA methylation (Lee et al., 2010; Watanabe, Uchiyama, 
& Hanaoka, 2006). Therefore, it is not only crucial to characterize gene expression but also 
to compare the methylome of iPSC-derived DA neurons with their primary counterparts. 
In order to obtain a genome-scale view on DNA methylation patterns of iPSC-DA neurons 
versus primary mdDA neurons with high resolution, we performed reduced representation 
bisulfite sequencing (RRBS) (Meissner et al., 2005; S. a Smallwood, Tomizawa, et al., 2011) 
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on genomic DNA samples isolated from the FACS-purified iPSC-DA neurons and 
El4 mdDA neurons. For a selected set of DA specific markers we found strikingly high 
resemblance between iPSC- generated and mdDA neurons. Importantly, in many cases 
DNA methylation patterns within putative promoter areas correlated with gene expression 
profiles, supporting evidence that methylation of CpGs within a specific transcription start 
side contributes to gene silencing (Klose & Bird, 2006). Additionally, we analyzed de novo 
methylation during in vitro differentiation by comparing global methylation patterns in 
undifferentiated iPSCs, iPSC-derived neural precursors and iPSC-derived DA neurons. 
Together, in this study we provide novel detailed information about genetic and 
epigenetic features of iPSC-derived DA neurons. In-depth analysis of DNA methylation 
revealed very subtle differences between primary mdDA neurons and iPSC-generated DA 
neurons that might have profound effects on gene expression profiles and therefore on the 
functionality of these iPSC-derived cells. Moreover, a better understanding of an underlying 
epigenetic code might allow a more sophisticated identification of mature mdDA neurons 
derived from pluripotent stem cells. 
RES U LTS 
I PSC derived,  pu rified Pitx39fp/+ n e u rons  express cruc ia l  DA ma rkers 
IPSC lines were generated from fibroblasts of Pitx3grpt+ mice (see supplemental fig.l for 
characterization of 2 independent iPSC clones). In addition, we generated iPSCs from 
fibroblasts of transgenic nestin-GFP mice (Yamaguchi, Saito, Suzuki, & Mori, 2000) 
(characterization data not shown). We intended to use these transgenic nestin-GFP iPSCs to 
determine whether some DA neuronal markers might already be expressed in iPSC-derived 
neural precursor cells, intermediates during the differentiation from iPSCs to DA neurons. To 
that purpose, nestin-GFP transgenic iPSCs were differentiated into neural precursors (NPs, 
supplemental fig.2A-E). IPSC-derived neural precursors showed co-expression of nestin-GFP, 
Pax6 and Sox2 and, moreover, appeared as neural rosettes, a morphological structure that had 
been identified before during the differentiation of ES cells into neural stem cells (Elkabetz 
et al., 2008). After 12 days of differentiation of the nestin-GFP iPSCs, 40-60% of the total cell 
population showed strong (nestin-) GFP expression, which allowed the separation of two 
populations (GFP+ vs. GFP-) with fluorescent activated cell sorting (supplementary fig.2F). 
RT-PCR experiments confirmed the expression of the NP markers in the GFP+ fraction but 
also revealed the expression of neuronal markers (supplementary fig. 2G). Interestingly, at 
that stage of differentiation, nestin-GFP sorted cells also expressed the two DA markers Nurrl 
and tyrosine hydroxylase (TH). Continuing differentiation of purified nestin-GFP-positive 
NPs resulted in more mature neurons expressing Map2; also expression of TH was retained 
and/or newly established in these cells (supplementary fig.2H and I). 
Next, we differentiated Pitx3gfpt+ iPSCs towards mdDA neurons. In order to induce 
DA-specific differentiation, we combined a stromal feeder based differentiation protocol 
(Kawasaki et al., 2000) with dual inhibition of SMAD signaling (Chambers et al., 2009). 
After 4 weeks of differentiation, Pitx3gfpt+ iPSC-derived cells showed robust expression of 
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GFP. lmmunocytochemical analysis revealed co-localization of GFP with the neural marker 
Map2 (fig.IA) as well as with TH (fig. lB) the rate-limiting enzyme for dopamine production 
in catecholaminergic neurons. Additional to their morphological DA characteristics, iPSC­
derived DA neurons secreted dopamine (fig. 1 C). Nonetheless, the iPSC-derived population 
still contained a large number of different cell types that were not dopaminergic. Therefore, we 
utilized FACS to purify the Pitx3-GFP-positive population (fig. ID). FACS analysis revealed that 
1-4% of the total cell population was GFP-positive. In order to further characterize the FACS 
purified cell population, we selected markers for neural precursors (nestin, Pax:6), neuronal 
markers (Map2, �-III Tubulin) and dopaminergic markers (Nurrl ,  Pitx3, TH and DAT) and 
compared the (Pitx3) GFP-negative fraction with the GFP expressing cells (fig.ID) The GFP­
negative population showed expression of neural precursor makers as well as neuronal markers, 
indicating that a specific subpopulation of neurons was present in this fraction. Surprisingly, 
the GFP-negative cell population also contained the dopaminergic markers Nurrl and TH 
(note that this expression pattern was also found in sorted NPs), whereas no Pitx3 or DAT 
expression was detected (fig. ID). This indicates that the GFP-negative population presumably 
did contain only still immature (Pitx3-negative) DA neurons after sorting. The GFP-positive 
fraction clearly showed expression of all selected markers, for immature and mature mdDA 
Pitx3gfp/+ iPSCs 
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Fig. I :  Generation and purification of Pitx3srpi+ iPSC-derived mdDA neurons. (A) Confocal image 
of co-labeled Map2 - and GFP- positive cells. (B) Confocal image of co-labeled TH- and GFP- positive 
cells. ( C) Quantitative dopamine measurement comparing undifferentiated and differentiated PitxJsfpl+ 
iPSCs. (D) FACS profile comparing undifferentiated and differentiated Pitx3gfp/+ iPSCs. (E) RT-PCR 
shows differences for a selection of specific markers for neural precursors, neurons and DA neurons. 
-
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neurons. We used these purified Pitx3gfp/+ mdDA neurons for further, more detailed analysis 
and compared them with purified Pitx3gfpt+ primary mdDA neurons in terms of global gene 
expression profiles and genome scale DNA methylation patterns. 
Compa rative genome profi l i n g :  pri ma ry md DA neu rons  vs . i PSC­
derived DA neurons 
In  a comprehensive gene expression profiling approach we  isolated mRNA from Pitx3gfpt+ 
iPSC-derived sorted DA neurons and primary Pitx3gfpt+ sorted neurons from embryonic 
day 12,5; 13,5; 14,5; 15,5 and p0 (see fig. 2A for schematic experimental setup). For the 
FACS purification of the primary mdDA neurons, cell suspensions from the Pitx3gfpt+ mouse 
embryonic midbrain were used; Pitx3gfp/+ mouse embryonic telencephalic tissue containing 
no GFP-positive cells served as negative control (fig. 2B). Midbrain cell suspensions usually 
contained approx. 2% of Pitx3-GFP-positive cells. Upon specific DA in vitro differentiation 
iPSC-derived cell suspensions contained a comparable GFP-expressing population. 
Gene expression analysis of the GFP-purified populations using a whole mouse genome 
microarray set up showed high similarities between iPSC-derived Pitx3-positive neurons 
and embryonic mdDA neurons (fig. 2C). In particular for a specific set of midbrain DA 
markers, such as Otx2, Foxa2, Lmxla/b and Pitx3, equally regulated gene expression 
levels were found. Moreover, specific down-regulation for another set of transcripts (such 
as Taf13, Nrip3 and Sox9) was observed in both cell types. Overall this cluster analysis 
of DA specific genes revealed that iPSC derived, Pitx3-positive DA neurons resemble the 
transcript profile of embryonic mdDA neurons rather than that of more maturated mdDA 
neurons. We additionally analyzed expression profiles for genes encoding ion channels and 
axonal guidance factors (supplemental fig.3). Interestingly, strong compliance for these 
neuronal characteristics was observed. 
Since iPSC-derived DA neurons are generated in vitro, it is crucial to assess deviations 
in gene expression profiles before considering their suitability for disease modeling and 
cell-based PD therapies. Therefore, we further analyzed the differences in transcript levels 
for pluripotency genes (fig. 2D) and fibroblast related genes (fig. 2E). Even though, cluster 
analysis for pluripotency markers revealed the same clustering as found for DA specific 
markers, clearly up regulated expression levels of e.g. Nanog, Oct4, Zfp42 and NrObl (also 
known as Daxl) were found comparing iPSC-derived Pitx3-positive neurons with mdDA 
neurons. Interestingly however, Sox2 expression appeared to be equally low in iPSC-derived 
DA neurons and embryonic mdDA neurons. Other deviations in gene expression profiles 
for fibroblast related genes were even more apparent. Thus our cluster analysis clearly 
separated iPSC-derived Pitx3 neurons from mdDA neurons. Fibroblast markers such as 
desmin, Cd151, vimentin, Collal ,  S100a4 and Serpinhl were expressed at much higher 
levels in iPSC-derived Pitx3 neurons than in mdDA neurons. 
Together, comparative genome profiling of mdDA neurons from several developmental 
stages and iPSC-derived DA neurons revealed very strong expression correlation for specific 
DA relevant markers, ion channels and axonal guidance factors. In this respect, iPSC-derived 
DA neurons show closest resemblance to late embryonic mdDA neurons. Noteworthy, 
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Fig.2: Gene expression profiling: mesodiencephalic Pitx3+ neurons versus iPSC-derived Pitx3+ 
neurons (A) Schematic experimental setup. (B) FACS profile of telencephalon and midbrain of 
Pitx3sfpl+ mice compared to iPSC-derived Pitx3sfpl+ neurons. ( C) Expression levels of selected specific 
DA genes, comparing 5 developmental midbrain stages with iPSC derived Pitx3+ neurons. (D) 
Expression levels of selected pluripotency genes. (E) Expression levels of selected fibroblast related 
genes. * in (C) and (E) indicates the selection of genes that have been analyzed in detail for their DNA 
methylation status in fig.3. 
some footprints of fibroblasts (the primary cell type of origin for iPSC induction) and of 
pluripotent stem cells were still present after DA-specific differentiation in vitro. 
Comparative methylome profi l i ng :  md DA neurons vs. i PSC-derived 
DA neu rons  
Correlating gene expression and DNA methvlation 
In addition to gene expression analysis, we set out to compare DNA methylation profiles of 
iPSC-DA neurons and primary mdDA neurons using the Pitx3grpt+ sorted cell populations 
-
GENETIC AND EPIGENETIC FEATURES OF IN VITRO GENERATED DA NEURONS 89 
as described above. DNA methylation is a major player in epigenetic regulation of gene 
expression and strong methylation of promoters is generally associated with gene silencing 
(Klose & Bird, 2006). Reduced representation bisulfite sequencing (RRBS) allowed us to 
analyze specific CpG methylation at nucleotide resolution on a genome scale (Meissner et 
al., 2005; S. A. Smallwood, Tomizawa, et al., 2011). RRBS provides coverage predominantly 
for CpG-rich regions, called CpG islands (CGis). CGis are often associated to promoter 
areas surrounding the transcription start side (TSS) (Deaton & Bird, 2011). 
First we analyzed the methylation status of genes we previously found in the genome wide 
expression analysis. We selected three genes, two of which were found in the DA-specific 
gene list and the third was a member of the fibroblast related genes ( expression levels of these 
genes are shown in figure 2C and E, labeled with an asterisk). Nr2a4 (also known as Nurrl )  
was one of the strongly expressed DA specific genes that showed equal levels in all Pitx3gfp/+ 
purified cells. Detailed analysis of the Nurr l gene revealed four CG Is within the gene body, 
with one co-localizing with exon 1 (fig. 3A). CpGs within this particular CGI appeared 
to be widely unmethylated and an overall equal methylation pattern could be observed 
in both mdDA neurons and iPSC-derived DA neurons. Stronger methylation within the 
gene body did not seem to influence the high gene expression levels. Sox9 on the other 
hand was silenced in most Pitx3gfpt+ sorted cells (see fig. 2C). Overall a high similarity was 
found for the general methylation patters for the Sox9 gene in mdDA neurons and iPSC-DA 
neurons. Although, many of the sequenced CpGs showed low methylation, a particularly 
high methylated CpG region was observed upstream of the first exon (fig. 3B). It has been 
reported that rather small stretches within CGis can be responsible for regulation of gene 
expression by DNA methylation (Weaver et al., 2004). This nearly 100% methylated region 
upstream of Sox9 seems to correlate with its silenced expression in purified DA neurons. 
An important finding of this study is that retrovirally generated iPSCs retain a footprint 
(or memory) of their cells of origin (in this case mouse embryonic fibroblasts)(see fig.2E). 
We found underlying epigenetic correlation for gene expression and DNA methylation 
that distinguish mdDA neurons from iPSC-DA neurons. Desmin, a fibroblast marker, was 
comparably low expressed in primary isolated mdDA neurons but still highly expressed in 
iPSC-derived DA neurons. We identified only one CGI in the Des gene, which is associated 
with its first exon (fig. 3C). This CGI appeared to be highly methylated in mdDA neurons, 
indicating that DNA methylation in its promoter accounts for gene silencing. Supporting 
this notion, the same CGI in iPSC-DA neurons was widely unmethylated, which might 
contribute to comparably up-regulated expression of desmin in iPSC-derived DA neurons. 
DA specific DNA methylation pattern during in vitro differentiation 
We selected a set of DA-specific markers and analyzed their methylation patterns in iPSCs, 
nestin-GFP sorted iPSC-derived neural precursors (NP(iPSC), see above) and the above 
described Pitx3gfp/+ sorted/purified iPSC-derived DA neurons (DA(iPSC)). Additionally, 
we included primary, Pitx3grpt+ sorted mdDA neurons (E14) in our comparison as in vivo 
reference. The selected genes were divided in specific sub-groups for DA progenitors (Msxl, 
Lmxla/b and FoxA2, suppl. fig.4C), pre-mature DA neurons (Pitx3 and Nr4a2, suppl. fig.4D) 
and markers for fully differentiated mature DA neurons (Drd2, Ret, Slc18a2 and Slc6a3, suppl. 
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fig.4E). On average we found rather low methylation of the selected CGis. However, lineage­
specific differences were observed in a base-pair resolution view for Pitx3 and Slc6a3 (DAT) 
(fig.4A and B). In iPSCs, DNA methylation appeared to be low, as also can be seen on a global 
genome-scale below (see. fig.6). A close-up view into the transcription start side of Pitx.3 and 
DAT revealed the highest methylation in iPSC-derived NPs. As shown by RT-PCR, these 
DA specific markers were not expressed in purified NPs (suppl. fig.2G). DNA methylation 
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Fig.3: DNA methylation profiles correlate with gene expression for a set of genes.(A) Representation 
of the Nurrl gene together with associated CG Is. Methylation patterns of primary and iPSC-derived 
DA neurons are equal. Low overall methylation of exon I -associated CGI correlates with induced gene 
expression (see fig.2C). (B) Representation of the Sox9 gene together with associated CGis. Methylation 
patterns of primary mdDA and iPSC-derived DA neurons are equal. High CpG methylation within 
the promoter-associated CGI might contribute to gene silencing (see fig.2C). (C) Methylation patterns 
around the desmin promoter distinguish iPSC-derived DA neurons from primary mdDA neurons. 
Differentially methylated CGI corresponds with differential gene expression (see fig.2E). 
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Fig.4: High resolution DNA methylation patterns of Pitx3 and DAT promoter. Detailed 
representation of exon 1 and its associated CGI for Pitx3 (A) and Slc6a3(DAT) (B). 
of the putative Pitx3 promoter showed high similarity when comparing mdDA neurons and 
iPSC-derived DA neurons (fig.4A); moreover, low methylation in this gene region correlated 
with active gene expression (see fig. 2D and 3C, although low in the array data set when 
compared to the common reference (unsorted adult ventral midbrain cells)). Analysis of 
the methylation of the putative DAT promoter, however, revealed differences between iPSC­
derived and primary mdDA neurons. Although DAT is expressed in iPSC-DA neurons (see 
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fig.IE) gene expression array results indicated a relatively low expression level compared to 
primary embryonic mdDA neurons (suppl.3A). These subtle differences in promoter activity 
may be indicative for an incomplete maturation of iPSC-derived DA neurons. 
Detailed gene body analysis for a set of DA specific marker genes confirmed the widely 
found resemblance of DNA methylation in iPSC-derived DA neurons and mdDA neurons 
but also here small variations can be found (suppl. fig.5). 
Global ONA methylation patterns of iPSC -derived DA neurons resemble those of mdDA neurons 
More than thousand CGis were sequenced and compared. Global methylation patterns 
of iPSC-derived DA neurons showed a high correlation with those of primary mdDA 
neurons (fig.SB), whereas undifferentiated iPSCs and DA-differentiated iPSCs showed 
much less correlation (fig.SA). Selection of more then 300 CG Is associated to transcription 
start sides revealed the same overall pattern (fig.SC and D). Genome wide comparison of 
CpG methylation revealed that DA-specific in vitro differentiation causes massive de novo 
methylation, for both, globally distributed GCis as well as for promoter associated CGis 
(fig.SE and F). Globally, strong CpG methylation occurred in approx. 50-60% of all analyzed 
CG Is upon differentiation, however, the percental contribution of heavily methylated CG Is 
associated with promoters was much lower (10-15%). Interestingly, statistical analysis 
showed that the overall proportion of DNA methylation in all four cell types was significantly 
different in the global analysis (fig.6E). Equal proportional differences were found when 
iPSCs, iPSC-derived NPs and iPSC-derived DA neurons were compared. Crucially, this 
overall difference disappears when iPSC-derived DA neurons where compared to primary 
mdDA neurons (fig.SF&G and suppl. fig.6). 
For both groups (global or promoter-associated), most of the heavily methylated gene 
specific CG Is were shared among differentiated cells (fig.6G and H). 
De novo methylation during in vitro differentiation was observed in 150 global CGis 
and in 19 CGis associated with transcription start sides (fig.6A and B). Besides, only 36  
CGis (globally) maintained a high ( <75%) methylation during in  vitro differentiation 
(fig.6D). Noteworthy, no CGI was found that showed loss of methylation upon iPSC 
differentiation towards DA neurons. 
De novo methylation occurred in three different sequential steps. Fig.7C indicates 
the specific sequence of the methylation steps and the corresponding frequency. Most 
CGI became methylated during transition from pluripotent to multipotent stem ( =neural 
precursor) cells (-97%), a linear increase in DNA methylation during DA-specific in vitro 
differentiation was observed for 2% of all analyzed CGis and lineage specific de novo 
methylation during differentiation of a multipotent neural precursor to a specific neuron 
was observed only very rarely (0,7%). 
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Fig.5: Genome wide DNA methylation correlation. (A) Global correlation of CpG methylation 
comparing iPSCs with iPSC-derived DA neurons. (B) Global correlation of CpG methylation 
comparing primary mesodiencephalic DA neurons with iPSC-derived DA neurons. (C) Promoter 
specific correlation of CpG methylation comparing iPSCs with iPSC-derived DA neurons. (B) 
Promoter specific correlation of CpG methylation comparing mesodiencephalic DA neurons with 
iPSC-derived DA neurons. TSS - transcription start side (E and F) Global distribution of DNA 
methylation states in iPSCs, iPSC-derived NPs, iPSC-derived DA neurons and mesodiencephalic DA 
neurons for all sequenced CpGs (E) and for annotated TSS (F). **"' represent a p-value smaller then 
0,05 (linear regression model) (G) matrix represents all calculated p-values. (H and I) Most heavily 
(80-100%) methylated gene-associated CGis are shared in differentiated cell types. 
DISCUSSION 
With this study we provide the first in-depth profiling of iPSC-derived purified DA neurons 
by analyzing global gene expression and DNA methylation. We used well established DA 
specific in vitro differentiation protocols (Chambers et al., 2009; Kawasaki et al. , 2000) to 
generate Pitx3grpt+ positive DA neurons and compared them to Pitx3gfpt+ positive mdDA 
neurons isolated directly from the ventral midbrain. We have shown that Pitx3-GFP sorted 
iPSC-derived cells display many characteristics of primary mdDA neurons. A large set 
of DA specific markers are strikingly equally expressed (fig.2C and suppl. fig.3) and the 
specific expression levels point towards the generation of pre-mature mdDA neurons (e.g. 
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Fig.6: De novo methylation during in vitro differentiation. (A) Genome wide more than 1 50 GCis 
have been found to be de novo methylated during DA-specific in vitro differentiation. Black dotted 
line show average of the sequential methylation process. (B) 19 CG Is associated to transcription start 
sides (TSS) de novo methylated. (C) Sequential de novo methylation occurs predominantly during 
the transition from pluripotent cells to lineage-committed precursors. (D) No loss of methylation has 
been observed during in vitro differentiation in heavily methylated CG Is in iPSCs. 
comparably low Pitx3 and DAT expression in iPSC-derived DA neurons). Importantly, 
iPSC-derived DA neurons seem to retain some gene expression characteristics of fibroblasts 
and pluripotent stem cells. Besides, we found DNA methylation signatures that are 
characteristic for the somatic cells of origin (fig.2E and specifically for the desmin promoter 
fig.3C). These findings correlate with earlier studies, in which it was shown that iPSCs keep 
an 'epigenetic memory' and are therefore prone to differentiate along their somatic parental 
lineage (Bar-Nur, Russ, Efrat, & Benvenisty, 2011; Kim et al., 2010). It is clear that the iPSC 
lines generated in our study could sufficiently be differentiated to neural precursors and DA 
neurons, but still show signs of such epigenetic memory. 
Analyses of CpG dinucleotide methylation states with a base-pair resolution and subsequent 
quantitative assessment allowed identification of very specific and very subtle characteristics 
-
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for a number of DA specific genes, such as Nurrl (Nr4a2), Pitx3 and DAT (Slc6a3). We found 
that methylation patterns of Pitx3 and Nurrl showed the highest similarities in mdDA and 
iPSC-derived DA neurons. For DAT however, a marker for fully matured DA neurons, we 
found differences in DNA methylation specifically in a putative promoter region. For many 
of the DA-specific genes, the observed DNA methylation status, particularly in promoter 
areas, also seemed to correlate with gene expression, as strong methylation of promoters is 
considered to strengthen gene silencing whereas unmethylated promoters have the tendency 
to be active (Klose & Bird, 2006). Noteworthy, statistical analysis revealed a strong similarity 
regarding DNA methylation proportions between iPSC-derived DA neurons and primary 
mdDA neurons, particularly within annotated transcription start sites. 
Earlier studies reported that pluripotent stem cells contain mostly methylation-free 
promoters (but also intergenic CGis and orphan CGis (Illingworth et al., 2010)) and de 
novo methylation is predominantly found upon loss of pluripotency (Fouse et al., 2008; 
Mohn et al., 2008), indicating that transcriptional repression in pluripotent stem cells 
must be predominantly established via other mechanisms. During DA neuron specific 
differentiation, in particular in the step from iPSCs to the multipotent neural precursors 
(NPs), we also found this general pattern of de novo methylation: major CpG methylation 
was observed in Nestin-GFP expressing NPs, regardless whether it was promoter 
associated or not (fig. 6A and B). Although, we found an increase in methylation for several 
pluripotency markers upon differentiation (suppl. fig.4A), average CGI methylation for 
these markers did not show very drastic elevation. However, actual gene silencing can be 
accomplished by very few methylated CpGs in a particular promoter (Weaver et al., 2004). 
Analysis of methylation showed that iPSCs possess almost no highly methylated CGis 
(globally or within promoter areas). It is thought that such DNA methylation landscape 
is a pluripotent cell-intrinsic trait in order to maintain highly dynamic differentiation 
capacity. This capacity is drastically reduced in lineage-committed multipotent NPs (Mohn 
et al., 2008). Only very few CGis showed de novo methylation during the transition from 
committed NPs to DA neurons and even more surprisingly no loss of methylation was 
observed during in vitro DA differentiation (this to say that highly methylated CGis found 
in our analysis did not loss of methylation during in vitro differentiation - see fig.6D). 
Previous evidence for demethylation during loss of pluripotency (Mohn et al., 2008) might 
have been overlooked in our analysis due to the reduced representation of CpG sequencing. 
However, the lack of more pronounced demethylation upon in vitro differentiation suggests 
that lineage-specific gene activation of NP- and DA-specific genes is either not controlled by 
DNA methylation in corresponding promoter areas or it is regulated via different epigenetic 
mechanisms, such as histone modification, which have not been analyzed in this study. It 
has been reported that gene expression during transition from multipotent progenitors e.g. 
to pyramidal neurons is predominantly regulated by Polycomb-mediated modifications of 
histones rather than by cell type specific DNA methylation changes (Mohn et al., 2008). 
Recently it was demonstrated that a number of crucial DA-specific transcription factors 
(Lmxla, Lmxlb, Msxl ,  Foxa2, Otx2, Pitx3) were the target genes of the repressive Ezh2/ 
PRC2 complex in neural precursors (Sher, Boddeke, Olah, & Copray, 2012). 
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In summary, our study provides a unique data set with detailed characteristics of iPSC­
derived DA neurons. Further investigation is needed to assess whether genes that we found 
to be de novo methylated during specific in vitro DA differentiation are crucially involved 
in this selective differentiation process. Moreover it might be interesting to compare the 
functional efficacy of iPSC-derived Pitx3gfpt+ neurons with that of primary isolated Pitx3grpt+ 
neurons in animal PD models in order to determine whether the subtle differences in genetic 
and epigenetic features we observed have consequences in that. It would be interesting to 
analyze whether these remaining genetic and epigenetic footprints can still be found in DA 
neurons derived from iPSCs free of viral integration (Okita et al., 20 1 1 ;  Okita, Nakagawa, 
Hyenjong, Ichisaka, & Yamanaka, 2008). 
A comparable analysis to our present one in mouse should be performed on purified 
human iPSC-derived DA neurons before these cells can be considered for safe clinical 
applications. The lack of a reliable specific surface marker for midbrain DA neurons appears 
to be a major obstacle for that. 
MET HODS 
iPS cell generation and propagation 
Mouse embryonic fibroblasts were isolated from El4 embryos of Pitx3gfpt+ and nestin-GFP 
mice. The fibroblasts were cultured until passage 5-8 and then retro-virally transfected with 
the four Yamanaka reprogramming factors. Separate vectors containing either Oct4, Klf4, 
Sox2 or cMyc (Takahashi & Yamanaka, 2006) were used for pluripotency induction. The 
retro-viruses were obtained from Phoenix Eco packaging cells that prior were transfected 
with the reprogramming factors (for vector information: Addgene, Cambridge, www. 
addgene.org) . A detailed induction protocol has been described earlier (Czepiel et al., 
201 1 ) .  IPSC clones were characterized by immunocytochemistry, reverse transcriptase 
PCR, Western blot and bisulfite sequencing for the promoter regions of Nanog and Oct4. 
Differentiation of Pitx39fp/+ knock-in iPSCs towards dopaminergic neurons 
In order to obtain optimal in vitro DA differentiation, we combined a stromal feeder-based 
protocol (Kawasaki et al., 2000) with a dual BMP and TGF� inhibition (Chambers et al., 
2009) .  Briefly, iPSC colonies prior cultured on 0, 1 % gelatine were manually picked and 
seeded on MS5 stromal cells in serum replacement medium, containing DMEM-F l 2, 1 5% 
knock-out serum, glutamate and �-mercaptoethanol. The cells were allowed to settle for 
24h; after that, Noggin {300ng/ml) and the TGF� inhibitor SB43 1 541 ( I OµM) were added 
for 4-5 days. Medium was gradually changed to N2 containing Shh {200ng/ml) . After neural 
induction, neuronal patterning and DA differentiation were induced using a combination 
of BDNF, ascorbic acid, Shh and FGF8 in N2 medium. Maturation was initiated by 
withdrawing Shh and FGF8 in the presence of BDNF, GDNF, ascorbic acid and cyclic-AMP 
as described by Perrier et al., 2004. 
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l m mu nocytochem istry 
IPSC colonies as well as differentiated cells were fixed in 4% paraformaldehyde for 10-20 
min. Cells were blocked with 5% normal goat serum, 2% fetal calf serum in 0,1 % Triton 
X in PBS. To characterize iPSC colonies, primary antibodies for Nanog, Oct4, Klf4, Sox2, 
UTFl and alkaline phosphatase have been used. To characterize the iPSC-derived neurons, 
primary antibodies for Map2, TH and GFP were used. To visualize the primary antibodies, 
fluorescently labeled secondary anti-mouse and anti-rabbit antibodies were applied. 
Nuclear staining was performed using Hoechst dye. 
Reverse tra nscri ptase PCR 
Briefly, RNA was isolated using the RNA-easy kit (Qiagen) To characterize the endogenous 
expression of pluripotency markers in the Pitx3GFPt+ iPSC clones 3 and 5, the following 
primer pairs were used: Nanog, Oct, Sox, and cMyc. Expression levels were compared 
between two iPSC clones, the ES cell line IBlO and mouse embryonic fibroblasts (C57BL/6). 
To characterize the sorted Pitx3-GFP positive cells and to compare them to the GFP­
negative population, primers for nestin, Pax6, beta-111-tubulin, Map2, Nurr l,  Pitx3, TH 
and DAT were used (for primer sequences see Barberi et  al., 2003) 
Western B lot 
SDS-PAGE gel electrophoresis and Western Blot analysis were performed to detect Nanog, 
Oct3/4, Sox2 and UTFl. Cells were collected, centrifuged for 20 min at 4°C and resuspended 
in Radio Immuno Precipitation Assay (RIPA) buffer along with a cocktail of protease 
inhibitors (Roche). Resuspensions were mixed with Laemmli sample buffer (Laemmli, 
1970) and sonicated for 2 times 5 seconds. Samples were boiled for 5 min. Proteins were 
separated for 1,5h on a 10% SDS-polyacrylamide gel in a BioRad electrophoresis apparatus 
(BioRad, Hercules, CA). Proteins were transferred to nitrocellulose membranes using 
semi-dry transfer buffer (25mM Tris, 150mM Glycin, 10% (v/v) Methanol) and 3 mA/cm2 
current for 45 min. Nitrocellulose membranes were blocked using Odyssey Blocking Buffer 
(LI-COR, Biosciences) for lh at room temperature. Membranes were probed overnight 
at 4°C using rabbit anti-Nanog antibody (1:1000, ab80892, Abeam, Cambridge, UK), 
mouse Oct3/4 antibody (1:500, sc-5279, Santa Cruz)), rabbit anti-Sox2 (1:4000, ab15830, 
Abeam, Cambridge, UK), rabbit UTFl (1:2000,) and mouse anti-�-Actin (ab6276, Abeam, 
Cambridge, UK) at 1:10.000 dilution. The housekeeping gene �-Actin has been used as 
loading control. Membranes were washed four times with PBS-T, 10 min each. Primary 
antibodies were detected using fluorescently labeled secondary antibody: donkey anti­
mouse (IRDye® 680, LI-COR, Biosciences) and donkey anti-rabbit (IRDye® 800CW, LI-COR, 
Biosciences). Incubation with secondary antibodies (1:8.000 in PBS-T) was performed for 
lh at room temperature in the dark. After four times washing in PBS-T, protein signals were 
detected and analyzed using the Odyssey Imager system/software (LI-COR, Biosciences). 
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Quantitative dopam i ne determ inat ion by LC-MS/MS 
Dopamine was essentially determined as described earlier (van de Merbel et al., 2011). 
Instead of plasma we analyzed 100µ1 of supernatant or cell homogenate from terminally DA 
differentiated iPSCs or undifferentiated iPSCs for the derivatization step. 
FACS 
Undifferentiated as well as differentiated cells (iPSC colonies, nestin-GFP cells and 
Pitx3gfpt+ cells) were dissociated using a Papain dissociation Kit (Worthington Biochemical 
Corporation). Dissociated cells were collected in colorless DMEM (Gibco) and sorted on 
a MoFlo-XDP or MoFlo-Astrios sorter. All cell types were sorted with a lO0µm nozzle at a 
pressure of 15-17 psi. 
Microarray a n a lys is  
Total RNA was isolated from embryonic ventral midbrain tissue using Trizol (Invitrogen) 
and purified using RNA-easy columns (Qiagen) according to the manufacturer's protocol. 
All RNA samples were assayed to ensure the highest quality RNA using a NanoDrop 
ND3300 (NanoDrop Technologies) fluorospectrometer and compared to a set of RNA 
standards. Microarray analysis was performed in triplicates and for each experimental 
sample a dye swap was performed to correct for dye effects. Each experimental sample 
consisted of pooled RNA derived from three embryonic ventral midbrains (VMs), which 
was hybridized to a reference pool consisting of RNA derived from dissected adult VMs. 
Samples from iPS cell-derived Pitx3-GFP cells were generated by pooling two wells from a 
6 well plate. 3 such samples were pooled and hybridized on the array. Agilent whole mouse 
genome microarray (Agilent, G4122F) sets were used for all hybridization. The array set 
is comprised of 60-mer oligonucleotide probes representing over 41.000 mouse genes and 
transcripts. Hybridized slides were scanned on an Agilent scanner (G2565AA) at 100% 
laser power, 30% PMT. After data extraction using ImaGene 8.0 (BioDiscovery), print-tip 
Loess normalization was performed on mean spot intensities. Data were analyzed using 
ANOVA (R version 2.2.1/MAANOVA version 0.98-7; http://www.r-project.org/). P-values 
were determined by a permutation F2 test, in which residuals were shuffled 5000 times 
globally. Genes with P<0.01 after family-wise error correction (or Benjamini-Hochberg 
correction) were considered significantly different. 
Di rect b isu lnte seq uenc ing 
Genomic DNA was purified by proteinase K digestion followed by phenol-chloroform 
extraction. Sodium bisulfite conversion was carried out with the Zymo EZ DNA methylation 
Kit. PCRs were performed for Oct4 (FW:5' -GTGTAGTGTTAATAGGTTTT-GTGG-
3';BW: 5' TATTTTTTAATTTTAA-TTTTTA3'), Nanog (FW: 5 'GGATTTTGTAGG­
TGGGATTAAT 3'; BW: 5' TAAACAACAACCAAAAAACTCAA 3'). Sequence analysis of 
converted fragments was done using Quma Quantification tool for methylation analysis 
( quma.cdb.riken.jp). 
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Reduced representation bisulfite sequencing 
RRBS was performed as described earlier (S. a Smallwood, Tomizawa, et al., 2011). Briefly, 
genomic DNA was purified using QIAamp Micro kit (Qiagen) followed by Mspl digestion 
(Fermantas), end-repair/A-tailing and SmC-adoptor ligation (T4 Ligase, Fermentas) 
performed within the same tube. Heat inactivation was used after each enzymatic step 
and components where adjusted for the following step. Bisulfite convertion was performed 
(Imprint DNA modification) and converted DNA was amplified (6 cycles) using uracil 
stalling free polymerase (Pfu Turbo Cx, Stratagene) followed by size selection (150-450bp, 
Qiagen) and a second round of amplification ( 10-13 cycles, Platinium, Pfx polymerase, 
Invitrogen). Libraries were purified (SPRI beads, Agencourt) and sequenced on Illumina 
Genome Analyzer Ilx. Sequence alignment and methylation calls were performed using 
Bismark (Krueger & Andrews, 2011). Gene specific visualization of methylation sites 
and global genome methylation reports have been generated with SeqMonk. Graphical 
representations of DNA methylations were generated with Microsoft Excel. 
Statistical analysis (RRBS) 
Differences between cell types and proportion of methylated DNA were investigated through 
a generalized linear model. Since the proportion of methylated DNA should be bounded 
between zero and one, and given that the distribution of the proportions observed were 
skewed, we applied a logit transformation to the proportion values b (logit(b)=log(b/(1-b)). 
The logit-transformed proportion values served as the dependent variable and the different 
cell types as the independent variables in the generalized linear model. The proportion 
values across groups, however, are correlated, as they originate from the same gene loci 
across cell types. To incorporate this correlation, we included a locus-specific, random­
effect term. This term captures the unobserved effect that a particular locus can have on 
the proportion of methylated DNA. Hence, any differences between cell types can now be 
considered as conditional to the gene loci. Inclusion of this random term in the model is 
known to improve model accuracy (Pinheiro & Bates, 2000). All statistical analyses were 
performed using the statistical software R (v.2.14.1) 
ACKNOWLED GEMENTS : 
We thank N. Brouwer, E. Wesseling and M. Meijer for excellent technical support. We 
acknowledge the valuable help from the FACS facility team of the UMC Groningen. The 
work was supported by the Hazewinkel-Beringer foundation and the Jan Kornelius de Cock 
Stichting. Confocal imaging has been performed at the UMCG Microscopy and Imaging 
Center (UMIC), which is sponsored by NWO grants 40-00506-98-9021 and 175010-2009-
23. This work was supported by a VICI-grant (no. 865.09.002) to M.P.S. 
100 CHAPTER 4 
REFERENCES 
Bar-Nur, 0., Russ, H. A., Efrat, S., & Benvenisty, N. (201 1 ). Epigenetic memory and preferential lineage­
specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta 
cells. Cell stem cell, 9( 1 ), 1 7-23. doi: 1 0. 10 16/j.stem.201 1.06.007 
Barberi, T., Klivenyi, P., Calingasan, N. Y., Lee, H., Kawamata, H., Loonam, K., Perrier, A. L., et al. 
(2003). Neural subtype specification of fertilization and nuclear transfer embryonic stem cells 
and application in parkinsonian mice. Nature biotechnology, 21(10), 1 200-7. doi: 1 0. 1038/nbt870 
Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z. D., Ziller, M., et al. (201 1 ) . 
Reference Maps of human ES and iPS cell variation enable high-throughput characterization of 
pluripotent cell lines. Cell, 144(3), 439-52. doi: 1 0. 1 0 16/j.cell.201 0. 12.032 
Chambers, S. M., Fasano, C. a, Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009). 
Highly efficient neural conversion of human ES and iPS cells by dual inhibition ofSMAD signaling. 
Nature biotechnology, 27(3), 275-80. doi: 1 0. 1038/nbt. 1 529 
Czepiel, M., Balasubramaniyan, V., Schaafsma, W., Stancic, M., Mikkers, H., Huisman, C., Boddeke, E., 
et al. (201 1 ). Differentiation of induced pluripotent stem cells into functional oligodendrocytes. 
Glia, 59(6), 882-92. doi: 1 0. 1 002/glia.2 1 159 
Deaton, A. M., & Bird, A. (20 1 1 ) . CpG islands and the regulation of transcription. Genes & development, 
25( 10), 1010-22. doi: 1 0. 1 1 01/gad.20375 1 1  
Elkabetz, Y., Panagiotakos, G., Al Shamy, G., Socci, N. D., Tabar, V., & Studer, L .  (2008). Human ES 
cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes & 
development, 22(2), 1 52-65. doi: 1 0. l  10 1 /gad. 16 16208 
Espejel, S., Roll, G. R., McLaughlin, K. J., Lee, A. Y., Zhang, J. Y., Laird, D. J., Okita, K., et al. (2010). 
Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative 
capabilities needed for liver regeneration in mice. The Journal of clinical investigation, 120(9), 
3120-6. doi: 10. 1 172/JCl43267 
Fouse, S. D., Shen, Y., Pellegrini, M., Cole, S., Meissner, A., Van Neste, L., Jaenisch, R., et al. (2008). 
Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, 
PcG complex, and histone H3 K4/K27 trimethylation. Cell stem cell, 2(2), 1 60-9. doi: 1 0. 10 16/j. 
stem.2007. 12 .0 1 1 
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., et al. (2007). 
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. 
Science (New York, N. Y), 318(5858), 1 920-3. doi: 1 0. 1 1 26/science. 1 152092 
Hargus, G., Cooper, 0., Deleidi, M., Levy, A., Lee, K., Marlow, E., Yow, A., et al. (201 0). Differentiated 
Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and 
reduce motor asymmetry in Parkinsonian rats. Proceedings of the National Academy of Sciences of 
the United States of America, 107(36), 1 5921 -6. doi: 1 0. 1073/pnas. 10 10209107 
Illingworth, R. S., Gruenewald-Schneider, U., Webb, S., Kerr, A. R. W., James, K. D., Turner, D. J., Smith, 
C., et al. (2010). Orphan CpG islands identify numerous conserved promoters in the mammalian 
genome. PLoSgenetics, 6(9). doi: 10. 1371/journal.pgen. 1001 1 34 
Jacobs, F. M. J., van Erp, S., van der Linden, A. J. A., von Oerthel, L., Burbach, J. P. H., & Smidt, M. P. (2009). 
Pitx3 potentiates Nurrl in dopamine neuron terminal differentiation through release of SMRT­
mediated repression. Development (Cambridge, England), 136(4), 531 -40. doi: 1 0. 1242/dev.029769 
Karumbayaram, S., Novitch, B. G., Patterson, M., Umbach, J. A., Richter, L., Lindgren, A., Conway, A. 
E., et al. (2009). Directed differentiation of human-induced pluripotent stem cells generates active 
motor neurons. Stem cells (Dayton, Ohio), 27(4), 806- 1 1. doi: 1 0. 1002/stem.31  
Kawasaki, H., Mizuseki, K. ,  Nishikawa, S., Kaneko, S., Kuwana, Y., Nakanishi, S., Nishikawa, S .  I., et 
al. (2000). Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived 
inducing activity. Neuron, 28(1), 3 1 -40. 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., et al. (2010). Epigenetic memory in 
induced pluripotent stem cells. Nature, 467(73 1 3), 285-90. doi: 1 0. 1 038/nature09342 
Klose, R. J., & Bird, A. P. (2006). Genomic DNA methylation: the mark and its mediators. Trends in 
biochemical sciences, 31 (2), 89-97. doi: 1 0. 1016/j.tibs.2005. 12.008 
-
GENETIC AND EPIGENETIC FEATURES OF IN VITRO GENERATED DA N EU RONS 101 
Krueger, F., & Andrews, S. R. (2011). Bismark: a flexible aligner and methylation caller for Bisulfite-Seq 
applications. Bioinformatics (Oxford, England), 27(11), 1571-2. doi:10.1093/bioinformatics/btrl67 
Kuzmenkin, A., Liang, H., Xu, G., Pfannkuche, K., Eichhorn, H., Fatima, A., Luo, H., et al. (2009). 
Functional characterization of cardiomyocytes derived from murine induced pluripotent stem 
cells in vitro. The FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology, 23(12), 4168-80. doi:10.1096/fj.08-128546 
Laemmli, U. K. ( 1970 ). Cleavage of structural proteins during the assembly of the head of bacteriophage 
T4. Nature, 227(5259), 680-5. 
Lee, S.-H., Jeyapalan, J. N., Appleby, V., Mohamed Noor, D. A., Sottile, V., & Scotting, P. J. (2010). 
Dynamic methylation and expression of Oct4 in early neural stem cells. Journal of anatomy, 
21 7(3), 203-13. doi:10.1111/j.1469-7580.2010.01269.x 
Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., et al. (2007). Directly 
reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. 
Cell stem cell, 1 (1), 55-70. doi:10.1016/j .stem.2007.05.014 
Meissner, A., Gnirke, A., Bell, G. W., Ramsahoye, B., Lander, E. S., & Jaenisch, R. (2005). Reduced 
representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. 
Nucleic acids research, 33(18), 5868-77. doi:10.1093/nar/gki901 
Mohn, F., Weber, M., Rebhan, M., Roloff, T. C., Richter, J., Stadler, M. B., Bibel, M., et al. (2008). Lineage­
specific polycomb targets and de nova DNA methylation define restriction and potential of 
neuronal progenitors. Molecular cell, 30(6), 755-66. doi:10.1016/j.molcel.2008.05.007 
Nishina, K., Toyoda, M., Yamazaki-Inoue, M., Fukawatase, Y., Chikazawa, E., Sakaguchi, H., Akutsu, H., 
et al. (2011). DNA Methylation Dynamics in Human Induced Pluripotent Stem Cells over Time. 
PLoSgenetics, 7(5), el002085. doi:10.1371/journal.pgen.1002085 
Ohi, Y., Qin, H., Hong, C., Blouin, L., Polo, J. M., Guo, T., Qi, Z., et al. (2011). Incomplete DNA 
methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nature cell 
biology, 13(5), 541-9. doi:10.1038/ncb2239 
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., et al. (2011). A 
more efficient method to generate integration-free human iPS cells. Nature methods, 8(5), 409-
12. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 
doi:10.1038/nmeth.1591 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., & Yamanaka, S. (2008). Generation of mouse 
induced pluripotent stem cells without viral vectors. Science (New York, N. Y.), 322(5903 ), 949-53.  
doi:10. l 126/science.1164270 
Perrier, A. L., Tabar, V., Barberi, T., Rubio, M. E., Bruses, J., Topf, N., Harrison, N. L., et al. (2004). Derivation 
of midbrain dopamine neurons from human embryonic stem cells. Proceedings of the National 
Academy of Sciences of the United States of America, 101 (34), 12543-8. doi:10.1073/pnas.0404700101 
Pinheiro, J. C., & Bates, D. M. (2000). Mixed Effects Models in S and S-Plus (p. 528). Springer. 
Ren, Y., Lee, M. Y., Schliflke, S., Paavola, J., Amos, P. J., Ge, X., Ye, M., et al. (2011). Small molecule 
Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human 
pluripotent stem cells. Journal of molecular and cellular cardiology, 51 (3), 280-7. doi:10.1016/j. 
yjmcc.2011.04.012 
Roessler, R., Boddeke, E., & Copray, S. (2012). Induced Pluripotent Stem Cell Technology and 
Direct Conversion: New Possibilities to Study and Treat Parkinson's Disease. Stem cell reviews. 
doi: 10.1007 /s12015-012-9369-4 
Sher, F., Boddeke, E., Olah, M., &Cop ray, S. (2012). Dynamic Changes in Ezh2 Gene Occupancy Underlie 
Its Involvement in Neural Stem Cell Self-Renewal and Differentiation towards Oligodendrocytes. 
PloS one, 7(7), e40399. 
Smallwood, S. A., Tomizawa, S.-1., Krueger, F., Ruf, N., Carli, N., Segonds-Pichon, A., Sato, S., et al. 
(2011). Dynamic CpG island methylation landscape in oocytes and preimplantation embryos. 
Nature genetics, 43(8), 811-4. doi:10.1038/ng.864 
Smallwood, S. a, Tomizawa, S.-1., Krueger, F., Ruf, N., Carli, N., Segonds-Pichon, A., Sato, S., et al. 
(2011). Dynamic CpG island methylation landscape in oocytes and preimplantation embryos. 
Nature genetics, 43(8), 811-814. Nature Publishing Group. doi:10.1038/ng.864 
102 CHAPTER 4 
Smidt, M. P., Smits, S. M., Bouwmeester, H., Hamers, F. P. T., van der Linden, A. J. A., Hellemons, A. J. C. 
G. M., Graw, J., et al. (2004). Early developmental failure of substantia nigra dopamine neurons in 
mice lacking the homeodomain gene Pitx3. Development (Cambridge, England), 131 (5), 1 145-55. 
doi: 1 0. 1 242/dev.O 1022 
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M. S., Cheng, L., & Zeng, X. (2010). Efficient generation 
of functional dopaminergic neurons from human induced pluripotent stem cells under defined 
conditions. Stem cells (Dayton, Ohio), 28(10), 1 893-904. doi: 10. 1002/stem.499 
Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell, 126( 4), 663-76. doi: 1 0. 1 0 16/j.cell.2006.07.024 
Watanabe, D., Uchiyama, K., & Hanaoka, K. (2006). Transition of mouse de novo methyltransferases 
expression from Dnmt3b to Dnmt3a during neural progenitor cell development. Neuroscience, 
142(3), 727-737. doi: 10. 10 16/j.neuroscience.2006.07.053 
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'.Alessio, A. C., Sharma, S., Seek.I, J. R., Dymov, S., 
et al. (2004). Epigenetic programming by maternal behavior. Nature neuroscience, 7(8), 847-54. 
doi: 1 0. 1038/nn1276 
Wernig, M., Zhao, J. -P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V., et al. (2008). Neurons 
derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve 
symptoms of rats with Parkinson's disease. Proceedings of the National Academy of Sciences of the 
United States of America, 1 05( 1 5), 5856-61.  doi: 1 0. 1073/pnas.0801677105 
Yamaguchi, M., Saito, H., Suzuki, M., & Mori, K. (2000). Visualization of neurogenesis in the central 
nervous system using nestin promoter-GFP transgenic mice. Neuroreport, 1 1 (9), 1991 -6. 
van de Merbel, N. C., Hendriks, G., Imbos, R., Tuunainen, J., Rouru, J., & Nikkanen, H. (20 1 1 ) . 
Quantitative determination of free and total dopamine in human plasma by LC-MS/MS: the 
importance of sample preparation. Bioanalysis, 3( 1 7), 1949-61 .  doi: 10.41 55/bio. 1 1 . 1 70 
-
GENETIC AND EPIGENETIC FEATURES OF IN VITRO GENERATED DA NEURONS 103 

Supp lementa ry i nformation for chapter 4: 
GENETIC AN D EP IG ENETIC FEATURES 
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Suppl. Fig. I: Generation of iPSCs from Pitx311rpt+ MEFs. (A) Characterization of iPSC clone 3 
and 5 using immune reactivity for selected pluripotency markers. (B) Endogenous expression of 
pluripotency markers comparing iPSC clones 3 and 5 with embryonic stem cells (ES) and MEFs. (C) 
Protein expression of selected pluripotency markers comparing iPSC clones 3 and 5 with ES cells. (D) 
Bisulfite sequencing of promoter regions of Nanog and Oct4 comparing Pitx3srpt+ iPSCs with Pitx3sfpt+ 
MEFs. Open circles represent unmethylated CpG dinucleotides, whereas closed circles indicate 
methylated CpG dinucleotides. 




Suppl. Fig.2: In vitro generation and differentiation of neural precursors. (A-C) Transgenic nestin­
GFP iPSC-derived neural precursors show characteristic neural rosette formation with an intense 
GFP expression within this subpopulation. (D and E) Co-expression of NP markers nestin, Pax6 and 
Sox2. (F) FACS results in a purification of 40% GFP-positive cells. The GFP-negative cell population 
consists of MSS feeder cells and non-NP iPS derived cells. (G) Gene expression patterns: nestin-GFP 
positive fraction versus nestin-GFP negative fraction. (H and I) GFP-positive sorted cells contain a 
subpopulation that appears to be positive for Map2 and TH. 
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A B C 
Suppl. Fig.3: Heat maps from gene expression array show a high overall similarity between iPSC­
derived mdDA neurons and primary isolated mdDA neurons (E12.5-p0). (A) Extended mdDA 
neuron marker set. (B) Ion channel expression. (C) Axonal guidance factors. 
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Suppl. Fig.4: DNA methylation status for pluripotency, neural precursor markers and DA specific 
markers. (A) Average methylation for CGis found in pluripotency-related genes compared in 
different cell types. (B) Average methylation for CGis found in neural precursor markers compared 
in different cell types. (C-E) Average methylation for CGis found in early, intermediate and late DA 
genes compared in different cell types. 
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Suppl. Fig.6: Global and promoter associated DNA methylation. (A) Violin plot depicting 
proportions of global DNA methylation. (B) Violin plot depicting proportions of DNA methylation 
restricted to annotated transcription start sites (TSS). *** represents a p-value smaller then 0,05 (linear 
regression model) . 
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A B STRACT 
Induced pluripotent stem cell (iPSC) derived dopaminergic (DA) neurons have been 
successfully grafted and functionally integrated in parkinsonian animal models. However, 
iPSC-derived grafts always contain a significant proportion of non-dopaminergic cells. 
Only grafting of purified iPSC-derived DA neurons would allow solid conclusions about 
their actual functionality. Therefore, we generated iPSCs from Pitx3-GFP knock-in mice, 
which subsequently have been differentiated towards mesodiencephalic dopaminergic 
(mdDA) neurons. This eventually enabled us to purify in vitro differentiated Pitx3-GFP 
positive DA neurons by fluorescence activated cell sorting (FACS) for implantation 
studies. In this pilot study we show that low numbers of purified mdDA neurons drastically 
improved amphetamine-induced rotation behavior in 6-0HDA rats, indicating that even 
limited restoration of dopamine and structural reestablishment in the striatum by a 
purified mdDA neuron population results in measurable beneficial effects in this animal 
model of Parkinson's disease. 
Key words: induced pluripotent stem cells, dopaminergic neurons, purified grafts, 
parkinsonian rats. 
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INTRODU C TION 
Cell replacement therapy has been proposed and tested as approach to treat PD already 
more than two decades ago (Lindvall et al., 1989; Madrazo et al., 1988). Compared to 
conventional PD treatment with e.g. levo-dopa but also to deep brain stimulation, a cell­
based regenerative approach has major advantages, particularly regarding the reinnervation 
of brain regions that lost DA signaling (for review see (Tsui & Isacson, 2011)). 
To date a series of clinical grafting studies, using embryonic midbrain explants, have 
been performed and showed, to some extent, promising results (Brundin et al. ,  2000; 
Freed et al., 1992, 2001; Spencer et al., 1992). However, the outcome of these studies was 
highly inconsistent. Beneficial effects seem to depend on factors such as age of the treated 
patients, responsiveness to previous L-dopa treatment and graft composition (Ma et al., 
2010). For the latter, optimization would involve the generation of a more defined or 
even purified cell population. Towards these goals many studies have been undertaken to 
generate midbrain DA neurons in vitro e.g. from ES cells, NSCs and also iPSCs(Kriks et al., 
2011; Lee, Lumelsky, Studer, Auerbach, & McKay, 2000; Roybon, Hjalt, Christophersen, 
Li, & Brundin, 2008; Rossler, Boddeke, & Copray, 2010; Soldner et al. , 2009). However, 
most of the cells generated in these studies are non-dopaminergic as percentages vary 
maximally between 10-20%. Although these highly mixed populations elicit clear effects on 
parkinsonian symptoms, it is difficult to assess to what extend other cell types besides DA 
neurons contribute to these effects or even interfere with them. Strict purification of stem 
cell-derived DA neurons would help to shed light on these questions. Moreover, the chance 
to retain remaining proliferating and potentially teratoma-forming cells would be reduced 
to a minimum. In 2008 a study by Hedlund and colleagues utilized ESCs from Pitx3-GFP 
knock-in mice to generate DA neurons. In this study, researchers couldshow that it was 
possible to purify ESC-derived midbrain DA neurons and subsequently transplant this cell 
population in a Parkinson rat model where purified cells functionally integrated into the 
host striatum (Hedlund et al. , 2008). 
Pitx3 is a homeobox transcription factor and within the CNS it is selectively expressed 
in mesodiencephalic DA (mdDA) neurons (M P Smidt et al., 1997; Marten P Smidt, Smits, 
& Burbach, 2004). These properties make this factor a highly suitable marker to select 
specifically for mdDA neurons. 
As for ESCs, the risk of generating undesired cell types in a graft and the possibility to 
retain a certain population of tumorigenic pluripotent cells is also a major hurdle for the 
use of iPSCs in potential cell based therapy. It has been shown that mouse and human iPSCs 
can sufficiently differentiate towards DA neurons (Kriks et al., 2011; Soldner et al., 2009; 
Wernig et al., 2008) and chapter 3 and chapter 5 of this thesis), however, so far no purified 
iPSC-derived mdDA neuron population has been functionally tested in an in vivo model 
for PD. In this pilot study we make use of the 6-0HDA rat model for Parkinson's disease, 
which upon unilateral injection of the neurotoxin allows to quantify a characteristic motor 
behavior as a reflection of the specific loss of DA substantianigra projections to the striatum. 
We find that even small numbers of surviving, purely mdDA neurons, show beneficial 
effects on asymmetric motor behavior. Our study provides evidence that enrichment or 
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purification of iPSC-derived mdDA neurons efficiently improves PD symptom-associated 
behavior in 6-OHDA rats. These findings might be instrumental for future studies on cell­
based replacement therapies for PD. 
M ATER I ALS AN D METHODS 
Cell culture and in vitro differentiation 
IPSC clones of Pitx3grpt+ fibroblasts have been generated and expanded as described in chapter 
IV. Briefly, retro-viral transduction with Oct4, Sox2, Klf4 and cMyc resulted in iPSC colonies 
approx. 2-3 weeks after proviral gene expression. Several independent iPSC clones have been 
characterized in terms of marker expression, differentiation capacity and promoter DNA 
methylation (see chapter IV) . DA specific in vitro differentiation has been introduced by 
co-culture with MS5 stromal feeders (Kawasaki et al., 2000) combined with dual SMAD 
inhibition (Chambers et al., 2009) .  Neural patterning has been established by exposure to 
Shh (200ng/ml, Peprotech) and FGF8 (l00ng/ml, R&D systems) in a gradually changing 
basic medium (serum replacement to N2). Subsequent DA differentiation has been initiated 
by withdrawing of Shh and FGF8 and in the presence of BDNF (20ng/ml, R&D), GDNF 
(20ng/ml, R&D), ascorbic acid (0,2mM, Sigma) and cyclic AMP (0,5mM, Sigma) . 
FACS 
Undifferentiated as well as differentiated iPSCs were dissociated using the Papain 
dissociation Kit (Worthington Biochem. Products, LK003 1 50) Dissociated cells were 
collected in colorless DMEM (Gibco) and sorted on a MoFlo-XDP or MoFlo-Astrios sorter. 
All cell types were sorted with a 1 00µm nozzle at a pressure of 1 5- 1 7  psi. Cells were collected 
in physiologic salt solution for grafting in 6-OHDA rats (6-8µ1/samples containing approx. 
20.000-25.000 Pitx3gfpt+ cells) . Pitx3 negative cells have been collected and prepared for 
grafting in equal numbers. 
l ntrastriatal cell grafting in unilateral 6-0HDA lesion rat model 
Surgical procedures were performed as described by Fornari et al., 201 2. Briefly, animals were 
anesthetized by subcutaneous injection of ketamine (37,5mg/kg) and dexmedetomidine 
(0,25mg/kg). Rats were placed in a stereotaxic apparatus and with a small incision the skull 
was exposed. After detecting Bregma, proper coordinates were established and the tip of an 
injection needle was positioned into the medial forebrain bundle of the left substantianigra. 
Two injection sides were defined (coordinates: first injection side: -4mm (AP axis); -0,8mm 
(LM axis) ; -8,0mm (vertical axis) and 3,4mm (incisor bar); second injection side: 4,4mm 
(AP axis); 1 ,2mm (LM axis); -7,8 (vertical axis) and 2,4mm (incisor bar)) .  Two injections 
of 1 ,5µ1 of 6OHDA (3µg/µl in 0,02% ascorbic acid in saline solution) were performed. Rats 
recovered for a week and were subsequently tested for lesion-related amphetamine induced 
rotation behavior (see figure l A  and section rotation behavior below) . 
Two days after the initial rotation test, rats received cell grafts. 3 rats received Pitx3sfpt+ 
positive cells, 3 rats received Pitx3srrt+ negative cells and 3 rats received no cells. All grafts 
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consisted of approx. 20.000-25.000 cells. Grafts were injected into the striatum ipsilateral 
to the 6OHDA lesion using the following coordinates (based on Bregma as reference point: 
+0,9mm (AP-axis); -2,6mm (LM-axis); -5,lmm and -4,0mm (vertical axis) and 0mm 
{incisor bar). Two volumes of 3-4µ1 were injected into the two different vertical positions. 
Graft infusion rate was manually adjusted to approx. 0,5µ1/min and the injection needle was 
retracted Smin after the injection was completed. Functional integration of the grafts has 
been analyzed 6 and 9 weeks post-grafting (see figure IA). 
Rotation behavior 
Animals received an i.p. injection of dexamphetamine sulfate (Smg/kg body weight, 
pharmacy, UMCG) and were placed in a rotameter (rota-8), a set-up that allowed to 
quantify induced rotation behavior. Unilaterally injected 6OHDA selectively depletes 
dopaminergic neurons in the left substantianigra, which results in loss of dopaminergic 
projections to the ipsilateral striatum. Upon amphetamine administration, the stimulated 
strictly contralateral dopamine release will cause asymmetric rotational motor behavior, 
which allows assessment of the severity of DA depletion. DA neuron graft injection into 
the left striatum subsequently will equalize DA levels compared to the contralateral side. 
Functional graft integration can then be measured by reduced rotation behavior. Individual 
rats were measured in a rotation test for 90min/session. In total 3 rotation sessions were 
performed, 1 pre-grafting and two post-grafting (6 and 9 weeks, see scheme fig. IA). 
l mmunoh i stochemica l  procedures 
After the final rotation test (9 weeks post-grafting), explanted brains were dehydrated 
for 24h in 20% sucrose in PBS. l 4µm thick coronal cryo-sections of the striatum and the 
substantianigra were generated. Tissue-slices were immunohistologically stained for GFP 
(anti-GFP antibody, 1:500), tyrosine hydroxylase (anti-TH antibody, 1:200) and Iba-1 
(anti Iba-1 antibody, 1:300). Fluorescently labeled secondary antibodies (Alexa-488, 1:500, 
Invitrogen; Cy3, 1 :500, Jackson ImmunoResearch) were used for fluorescent microscopy 
analysis. Hoechst nuclear staining was used for general cell identification. 
Stati stica l  a na lys i s  
Amphetamine-induced rotation scores were obtained using Rota-8 software. Statistical 
analysis of the raw data was done with Microsoft Excel. 
RES U LTS 
Specific depletion of the n ig rostriata l pathway 
In order to selectively deplete dopaminergic neurons that project from the substantianigra 
to the striatum selective toxicity of 6-OHDA can be utilized. If this neuroto:xin is injected 
into the substantianigra, DA neurons that send their projections to the caudate nucleus 
and the putamen will selectively die. This causes massive interruption in a signaling loop 
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in the basal ganglia that are important for motor control. The disturbance in left/right 
balance of striatal dopamine release due to unilateral depletion of SN DA neurons will 
lead to spontaneous asymmetric rotation behavior, which can be triggered and intensified 
by application of amphetamine stimulating dopamine release. Decrease in amphetamine 
induced rotation behavior after grafting of DA neurons can be considered as a measure for 
re-establishment of the dopamine level in the 6-OHDA denervated striatum. We inflicted 
6-OHDA lesions on day 0 of the transplantation experiment (see fig. lA for experimental 
setup). Unilateral injection caused selective depletion of SNc DA neurons while leaving 
VTA DA neurons largely intact (fig lC). As a result dopaminergic synapses in the striatum 
were almost completelyabsent in the injected hemisphere (fig IC). Functional impairment 
was assessed in a pre-grafting rotation test (see scheme in fig. IA and fig. 3B). Stable 
amphetamine induced rotation behavior was established one week after lesioning. 
A lesion test 1.rotation test 2.rotation test 
6-0HDA 0 cell grafting 0 0 
Day 0 7 9 51 72 
B C 
unilateral 
control brain 6-0HDA lesion 
SNc 
Fig. 1: (A) Schematic setup of the experiments. (B) Effects of 60HDA lesioning. In the control 
condition, DA neurons from the substantianigra pars compacta (SNc) and the ventral tegmental 
area (VTA) would be unaffected. As a result, also projection to the striatum (st) would be intact. cc 
corpus callosum, ctx cortex. Unilateral 6-0HDA lesions caused selective death of SNc DA neurons 
and their projections. (C) TH immunostaining shows the result of 6-0HDA injections in the SN and 
its consequences for the DA innervation of the striatum; contra-lateral control side vs. 6-0HDA side. 
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Pitx39fp/+i PSCs can be d ifferentiated towa rds sortab le md DA neu rons  
As described in more detail in chapter I V  of this thesis Pitx3gfpt+ knock-in iPSCs were 
differentiated towards mdDA neurons. Resulting cell populations were FACS-sorted and 
equal amounts of pure Pitx3-GFP positive cells and Pitx3-GFP negative cells were collected 
and prepared for injection in the DA neuron depleted striata. Characteristics of GFP-purified 
cells closely resemble the characteristics of mdDA neurons that can be isolated from the 
ventral midbrain (Roessler et al., manuscript in preparation, chapter IV of this thesis). Pitx3-
GFP positive cells have a clear neuronal morphology and co-express the neuronal marker 
Map2 and the DA marker TH, tyrosine hydroxylase (fig.2 A and B). We have shown before 
that Pitx3-GFP positive cells also express specific mDA neurons markers Nurrl and DAT. 
C 
undiff. Pitx3gtpt+ iPSCs diff. Pitx3gtpt+ iPSCs 
102 102 
C\1
101 1 01 
10° 10° 
10·1 10·1 
10·' 10° 101 102 103 10-1 1 0°  101 102 103 
gfp fluorescence 
Fig. 2:(A) In vitro DA-differentiated Pitx3srpi+iPSCs co-express knock-in GFP and the neuronal 
marker Map2. (B) In vitro DA-differentiated Pitx3gfp/+iPSCs co-express knock-in GFP and the DA 
neuron marker TH. (C) FACS-comparison of undifferentiated vs. differentiated Pitx38rpi+ iPSCs shows 
clearly the induction of transgenic GFP expression upon specific in vitro DA-differentiation. Obtained 
percentages of Pitx3sfpl+ positive cells vary between 1 -4%. Scale bar 40µm. 
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Moreover, as indicated in chapter IV, this purified population reveals very high similarities 
to primary mdDA neurons as far as global DNA methylation patterns and global gene 
expression levels are concerned. FACS resulted in two distinct populations (GFP pos. and 
GFP neg. cells)(fig. 2C). Optimally, the GFP pos. population contains solely iPSC-derived 
mdDA neurons, whereas the GFP neg. populations contain a highly mixed and undefined 
group of cells, including non-dopaminergic neurons but also several other cell types. The 
exact composition of the GFP neg. populations has not been assessed in this study. 
Grafti n g  of pu rified i PSC-derived md DA neurons  i n  Pa rki nson rats 
resu lts i n  i m proved motor behavior  
Sorted cell populations were injected in the lesioned striatum and motor behavior recovery 
was analyzed 6 and 9 weeks after grafting (see fig. 3A for experimental set up). Animals 
that received either Pitx3-GFP pos. or Pitx3-GFP neg. grafts were compared with animals 
that did not receive any graft. Bothgroups, Pitx3-GFP pos. and Pitx3-GFP neg., showed 
clear reduction of amphetamine-induced rotation behavior 6 weeks post grafting. 'No-graft' 
control animal (small group size of this pilot study resulted in only one 'no-graft' control 
rat) however did show an increase in rotation. 9 weeks post grafting a strong reduction of 
rotation could be observed for the Pitx3-GFP pos. group. Asymmetric motor behavior was 
reduced to 1/5 of the starting value. Also for the Pitx3-GFP neg. group a slide decrease in 
rotation could be seen after 9 weeks, however the reduction was less profound then for the 
A 
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•pre grafting 
Cl6 weeks post grafting 
cg weeks post grafting 
Pltx3 pos Pltx3 neg 
no graft 
no graft 
Fig. 3:(A) Schematic representation 
of cell grafting and DA restoration. 
(B) Quantitative analysis of 
amphetamine-induced rotation 
behavior pre- and post-grating. 
Pitx:3gfpt+ positive cells show strong 
reduction in rotation 6 and 9 weeks 
post grafting. Pitx:3grpt+ negative cells 
show a slight reduction in rotation 
6 and 9 weeks post grafting. No 
reduction in rotation was observed 
in animals that did receive no graft. 
Pitx3-GFP pos. group. The 'no graft' control animal, also after 9 weeks, only showed impaired 
motor behavior. Post-behavioral examination of antibody-labeled brain slices revealed poor 
survival of grafted cells (fig.4). However, it was possible to detect GFP-positive cells at the site 
of injection which co-expressed TH (fig. 4 panel A). As shown in fig.lC, TH-positive cells 
were depleted almost completely before cell grafting, still several TH-positive neurites could 
be observed around the grafting site. In order to assess potential rejection responses to the 
grafted cells, we analyzed the activity stages of microglia surrounding the grafting side based 
on their morphology. Iba-1 staining revealed a more activated state for microglia directly 
adjacent to the cell graft (fig. 4, panel B), whereas only resting microglia, characterized by 
a more ramified morphology, were observed in the contralateral striatum (fig. 4, panel C). 
Since we observed reduced rotation behavior also in animals that received Pitx3-GFP 
neg. cells, we reasoned that this effect might be explained by delayed maturation of DA 
precursors present in that population. In order to verify this, we also stained these brains 
for GFP. If DA maturation did occur post grafting we should be able to identify these cells 
C 
GFP 
transplanted sorted Pitx3gfp/+ cells 
l ba1  Hoechst 
Hoechst merge 
Fig. 4:Immunohistological analysis of grafts. (A) GFP- and TH-positive cells could be detected in the 
striatum of animals that received Pitx3srpi+ positive cells. Overlay shows co-expression of both markers 
in the transplanted cells. Notably, no TH-positive cells can be detected surrounding the graft. (B and 
C) The cell response towards the grafted cells was analyzed by comparing the state and phenotype of 
microglia surrounding the graft (B) vs. microglia in the contralateral striatum of the same animal (C). 
Morphology in (B) indicates a more activated state of the microglia compared to the ramified shape, 
representing a more quiescent state, in (C). Scale bar 200µm. 
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as Pitx3-GFP positive. However, analysis of immunostained brain slices did not reveal 
detectable GFP positive cells in the striatum of these animals (data not shown). 
Summarizing, our pilot study on purified iPSC-derived mdDA neurons reveals that 
functional efficiency of such a defined cell population appears to be higher compared to 
mixed cell grafts that has been depleted of Pitx3 positive cells. However the Pitx3 negative 
population might contain less mature DA neurons. At this point we cannot rule out that such 
remaining cells caused the observed reduction in rotation behavior in the Pitx3 negative 
group (fig.3B middle panel). Nonetheless, a highly characterized pure cell population (see 
also chapter IV of this thesis) seems crucial for any future clinical application. 
D I S CUSS ION 
In this study we show for the first time that purified iPSC-derived mdDA neurons functionally 
integrate in the striatum of a PD rat model.PD is one of the few neurodegenerative diseases 
that might be treatable in the future with cell replacement therapies. Human iPSCs that can 
be differentiated into DA neurons in more and more sophisticated ways might in fact provide 
a suitable tool for this approach (Soldner et al., 2009; Wernig et al., 2008). However, before 
that can be considered a realistic option, animal studies will have to show unambiguously 
their beneficial effects in Parkinson models. In this pilot study we attempted to functionally 
test purified mouse iPSC-derived mdDA neurons. Although the study presented here is to 
be considered a pilot study, with too limited experimental and control group sizes, we could 
show that purified iPSC-derived mdDA neurons could be implanted in the 6-0HDA rat 
model and that small numbers of surviving cells could induce clear motor improvement. 
Earlier studies showed that Pitx3-GFP DA neurons derived from embryonic stem cells 
survive grafting in great number and have highly beneficial effects in rodent PD models 
(Hedlund et al., 2008). In our study, we provide evidence that comparable effects can be 
achieved by purified iPSC-derived mdDA neurons. This is a crucial finding that could be 
translated into primate studies in order to approach human trials as close as possible. A 
very recent study shows that indeed human pluripotent stem cell derived DA neurons 
functionally integrate in Parkinson models of rodents and primates very efficiently(Kriks et 
al., 2011). The finding that induction of specific embryonic patterning (Fasano, Chambers, 
Lee, Tomishima, & Studer, 2010), as observed during embryogenesis in floor-plate tissue, 
drastically improves the generation of midbrain DA neurons from iPSCs, resulted in high 
numbers of DA neurons, which could be grafted in animal models. Nonetheless, even such an 
efficient generation of a specific neuronal cell type does not solve the issue of the presence of 
different, undefined cell types in the graft. Before pluripotent stem cell-derived DA neurons 
would be suitable for clinical trails, not only the safety issues that are intrinsic to pluripotent 
cells (as discussed in chapter I& II), but also issues regarding the purity of a cell graft needs 
to be addressed. Recently, genome editing methods (Hockemeyer et al., 2009, 2011) have 
been developed that might make it possible to create human iPSC-derived neurons that can 
be purified the same way as we showed in our present study for murine cells. However, to 
date, no study has yet reported the generation of sortable DA neurons from human iPSCs. 
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Such a procedure would certainly strengthen the point that cell replacement therapy could 
lead to more profound clinical improvements in PD patients, e.g. compared to L-Dopa 
administration or deep brain stimulation (for review see (Tsui & Isacson, 2011). A major 
argument for that notion is that properly integrating stem cell-derived DA neurons will be 
able to restore not only dopamine levels in the striatum but also reinnervate original target 
areas of the lost nigro-striatal projections. However, most grafting reports to date show 
rather limited axonal and dendritical branching of the injected cells. Therefore, the ability 
to innervate specific target areas is far from optimal. Several studies addressed that issue 
with the utilization of neural cell adhesion molecules such as L1 or PSA-NCAM, two well 
characterized immunoglobulin superfamily members crucially involved in axonal guidance 
and neuronal migration (Maness & Schachner, 2007). Particularly, L1 overexpression in 
ESCs seems to improve survival and axonal and dendritic branching of transplanted cells 
and additionally enhances DA differentiation (Cui et al., 2010). L1 also showed beneficial 
effects when overexpressed in neural stem cells, which subsequently have been grafted in 
PD mouse models (Ourednik et al., 2009). However, functional studies still need to prove 
that such modified cells, particularly mature DA neurons; indeed improve parkinsonian 
symptoms more efficiently. 
As a continuation of the study described here we plan to lentivirally overexpress both 
adhesion molecules (Ll and PSA-NCAM) in PitxJcfphiPSCs at a relatively early neural 
precursor stage. These modified cells will then be further differentiated towards Pitx3-GFP 
expressing neurons, sorted as described here and subsequently transplanted in 60HDA 
rats. This may provide novel information about the potential beneficial properties of 
neural adhesion molecules in a purified population of iPSC-derived DA neurons to be 
grafted intrastriatally. 
Studies in experimental animal models for PD with purified DA neuron grafts generated 
from mouse and human iPSCs will be crucial in helping to optimize a possible future cell­
based therapy for PD with iPSCs. The new exciting developments in genetic engineering 
will definitely help to improve the capacities of the iPSC-derived DA neurons to mature 
and integrate as bona fide DA neurons in the host striatum drastically boost their symptom­
reducing efficiency and the acceptance of cell transplants as PD treatment. 
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ABSTRAC T 
In vitro generation of bona fide midbrain dopaminergic (mDA) neurons from human 
induced pluripotent stem cells (hiPSCs) presents most valuable opportunities to study 
and treat Parkinson's disease (PD). Generation of such cells requires sophisticated in 
vitroimitation of in vivo midbrain conditions during development. Human midbrain 
development, however, is poorly understood due to inaccessibility of developing tissue. 
Here we describe that recapitulation of the niche of embryonic floor plate (FP) precursors 
during early in vitro differentiation with small molecules that efficiently mimic sonic 
hedgehog (SHH) and Wnt-signaling, results in highly efficient generation of subject­
specific midbrain DA neurons. These neurons can be maintained in culture for a substantial 
time span, show proper mDAmarker expression, secret dopamine and reveal neuron-like 
electrophysiological properties. Such autologous, patient-tailored mDA neurons might 
serve as crucial tool for potential future cell-based therapies and also will be indispensable 
to study the molecular pathology of PD in a patient-specific fashion. 
Key words: subject-specific iPSCs, dopaminergic differentiation, floor-plate tissue, 
Parkinson's disease 
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INTROD U CTION 
Generation of human iPSC-derived dopaminergic (DA) neurons with bona fide midbrain 
identity will provide valuable tools to study and treat Parkinson's disease (PD). After the key 
finding that somatic cells indeed can be reversed to a pluripotent ground state (Takahashi et 
al., 2007; Takahashi & Yamanaka, 2006), many groups reported the successful generation of 
DA-like neurons (for review see (Roessler, Boddeke, & Copray, 2012)). Human iPSC-derived 
DA neurons showed expression of several typical markers such as FoxA2, Nurrl, Pitx3 
and TH. Additionally, these cells elicited some improvement in PD-associated behavior in 
animal PD models (Hargus et al., 201 O; Rhee et al., 2011). However, the efficiency of in vitro 
DA differentiation and the functional efficacy was drastically lower then found earlier for 
DA neurons derived from mouse iPSCs(Wernig et al., 2008). 
In order to generate correct midbrain DA neurons, it is necessary to recapitulate human 
embryonic midbrain development as closely as possible. Compared to mouse development 
relatively little is known about exact temporal and spatial actions of specific signaling 
molecules during human midbrain generation. An important organizing structure for 
proper development of midbrain precursors is the floor-plate, a specialized group of cells 
that is located along the ventral midline (M Placzek, 1995; Marysia Placzek & Briscoe, 
2005). This particular organizer crucially regulates neuronal and glial identities by specific 
secretion of sonic hedgehog (SHH). Floor-plate cells are characterized by expression of 
netrin-1 and FoxA2. FoxA2, a winged helix transcription factor, regulates SHH expression 
and represents a central factor in DA development. FoxA2 appears to be sufficient and 
required for in vivo DA development and it promotes specific DA differentiation of 
embryonic stem cells (ESCs) in vitro(Ferri et al., 2007; Hynes, Poulsen, Tessier-Lavigne, 
& Rosenthal, 1995; Kittappa, Chang, Awatramani, & McKay, 2007). Besides, FoxA2 might 
function within a SHH-independent pathway, since blocking of SHH signaling in FoxA2 
overexpressing ESCs only caused 50% loss of DA neurons (Kittappa et al., 2007). Moreover, 
in ESCs, FoxA2 takes part in interconnected feedback loops, with Lmxla as parallel central 
player, in DA differentiation (Chung et al., 2009). Also Lmxla has been shown to be 
crucially involved in DA neuron differentiation in vivo and in vitro(Andersson et al., 2006; 
Roybon, Hjalt, Christophersen, Li, & Brundin, 2008; Rossler, Boddeke, & Copray, 2010). 
Noteworthy, both transcription factors are usually expressed in very distinct positions: 
FoxA2 in the floor-plate and Lmxla in the roof-plate. Only the developing midbrain is 
exposed to a subtle coexpression of these two markers (for FoxA2 reviews: (Ang, 2009; 
Arenas, 2008); for Lmxla review: (Burbach & Smidt, 2006)). 
A recent study showed that human ESCs can efficiently form functional floor-plate tissue 
upon very early and highly potent SHH exposure (Fasano, Chambers, Lee, Tomishima, & 
Studer, 2010). In vitro generated floor-plate tissues showed specific up-regulation of FoxA2, 
SHH and netrin-1, whereas dorsal markers such as Lmxla or anterior markers such Dkk-1 
were down-regulated. Following up on this specific in vitro generation of floor-plate tissue 
Kriks et al. (2011) showed that additional activation of Wnt- signaling by small molecules 
drastically improved specifically DA differentiation capacity and expandability (Kriks et 
al., 2011). Floor-plate protocol-based pluripotent stem cell-derived DA neurons generated 
-
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in this study have successfully been grafted in several PD animal models, and caused very 
solid improvements in PD symptom-associated behavior. 
In our study we generated humaniPSCs and studied the functionality and applicability 
of this floor-plate based DA differentiation protocol for the generation of subject-specific, 
autologous DA neurons. We found a very robust in vitro generation of DA neurons with 
bona fide midbrain identity. Floor-plate based human iPSC-derived DA neurons expressed 
midbrain DA markers, showed DA specific electrophysiological properties and secreted 
dopamine. Our study confirms the value of floor-plate based in vitro generation of midbrain 
DA neurons. Not only might this be instrumental for future cell-based regenerative 
medicine but it will also allow more sophisticated in vitro disease modeling. 
MATERIA LS A ND MET H ODS 
h u m a n  i PSC i nd uct ion 
HiPSCs were generated from human dermal fibroblasts ( obtained from the department of 
dermatology UMCG) using lentiviral transduction. Lentivirus was produced in HEK293T 
cells (10 cm cell culture dish) following transfection with EFla-STEMCCA-RedLight-LoxP 
plasmid (contains Oct4, Klf4, Sox2 and mCherry genes), together with pMD2-VSV-G and 
pCMV-�8.91 plasmids. Lentivirus containing medium was collected 48h posttransduction, 
filtered through 0,45 um filter and concentrated using Amicon Ultra 100,000 MWCO 
centrifugal filters (2000xg, 30 min) (Millipore). Entire concentrated supernatant diluted with 
1ml of fresh fibroblast medium containing 8µg/ml polybrene, was used to transduce circa 
100.000 human fibroblasts plated the day before in 1 well of 6-well plate. Lentivirus containing 
medium was washed away the next day and cells were cultured in fibroblast medium for 
another 3 days. Transduced cells were then trypsinized, seeded onto irradiated mouse 
embryonic fibroblasts (MEF) and cultured in hES medium (DMEM/Fl2, 20%KSR, 1 %NEAA, 
PIS, 0,lmM �-mercaptoethanol, Sng/ml bFGF) until hiPSC colonies appeared and were ready 
to be picked. Around 28 days post-transduction largehiPSC colonies were fragmented and 
plated on matrigel coated dishes with mTESR medium (StemCell technologies). Subsequent 
hiPSC passages were done mechanically and cells were further propagated in mTESR medium. 
DA specific i n  vitro d ifferentiat ion 
DA-specific floor-plate based in vitro differentiation has been extensively described by Kriks 
et al., (2011). Briefly, hiPSC colonies cultured on matrigel were switched to knockout serum 
replacement (KSR) medium (as described by Perrier et al., 2004) for lday. After, sequentially 
timed exposure to LDN193189 (lO0nM, Stemgent), SB431542 (lOµM, Tocris), SHH 
(l00ng/ml, Peprotech), purmorphamine (2µM, Calbiochem), FGF8 (l00ng/ml, R&D) and 
CHIR99021 (3µM, Stemgent) were used to induce floor-plate induction. Between day 1 and 
day 11 medium was gradually changed from KSR to N2. On day 11 medium was changed to 
neural basal medium (NBM, Gibco) containing L-glutamate and B27 (Invitrogen). Medium 
was supplemented with CHIR99021 until day 13, with BDNF (20ng/ml, R&D), GDNF 
(20ng/ml, R&D), ascorbic acid (0,2mM, Sigma), TGF� (lng/ml, R&D) and dibutyrylcAMP 
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(0,SmM, Sigma). At day 20, cells were dissociated using accutase(Sigma) and replated 
on matrigel under high cell density conditions (approx. 400.000-500.000 cells/cm2) and 
continuously cultured under NBM-B27 conditions. Cells were collected at different time 
points for qPCR characterization and fixated and immunocytochemically stained around 
day 30 of in vitro differentiation. 
Di rect b i su lfite sequenc ing 
Genomic DNA was purified by  proteinase K digestion followed by  phenol-chloroform 
extraction. Sodium bisulfite conversion was carried out with the Zymo EZ DNA 
methyaltion Kit. PCRs were performed for Nanog (FW: S'TGG TTA GGT TGG 
TTT TAA ATT TTT G 3'; BW: S'AAC CCA CCC TTA TAA ATT CTC AAT TA 3'). 
Sequence analysis of converted fragments was done using Quma Quantification tool 
for methylation analysis ( quma.cdb.riken.jp). 
q PCR 
Total RNA was extracted during the differentiation at day 0 ,  2 ,  6 ,  11, 20  and 30  using 
standard RNA extraction methods. Each data point represents nine technical replicates 
from three biological samples. Primers were used for Nanog, Oct4, Otx2, FoxA2, Lmxla, 
Msx l, Nurrl, Pitx3 and TH. Primer sequence information is given in table 1. 
LC-MS/MS 
Dopamine was essentially determined as described in (van de Merbel et al., 2011). Instead 
of plasma we analyzed 1 00µl of supernatant or cell homogenate for the derivatization step. 
E lectrophys io logy 
Electrophysiological recordings were performed as described earlier (Balasubramaniyan et 
al., 2006). Briefly, standard whole-cell patch clamp technique was used to measure currents 
at room temperature (22-24°C) with the use of an Axopatch 200B amplifier, Digidata 1320A, 
and pClamp version 8.2 software (Axon Instruments, Foster City, CA). The extracellular 
primers forward backward 
Nanog CAGCTACAAACAGGTGAAGAC CACACCATTGCTATTCTTCGG 
Oct4 GAAGCAGAAGAGGATCACCC CTGAATACCTTCCCAAATAGAACC 
Otx2 CATCTTCATG C GAG AG GAGG GCTCTTCGATTCTTAAACCATACC 
FoxA2 GGAGCAGCTACTATGCAGAG CTCATGTACGTGTTCATGCC  
Lmx 1 a  GACTACGAGAAGCTGTTTGCT GCAGCTCAGGTGGTATACAC 
Msx 1 AGACGCAGGTGAAGATATGG GCTCTGCCTCTTGTAGTCTC 
Nurr1 ATTAGCATACAGGTCCAACCC ACAATGGAATCAATCCATTCCC 
Pitx3 GACGCACTAGCCCTCCCTCCA GCCAGCGTCTGACAGCGACA 
TH GAGATCGCCTTCCAGTACAG TGGTGTAGACCTCCTTCCAG 
-
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(bath) solution contained (mmol/L) 140 NaCl, 4 KCl, 5 glucose, 2 CaC12, 1 MgCl2• and 1 0  
HEPES, pH adjusted to 7.4 with NaOH. The pipette solution contained (mmol/L) 1 40 KCl, 
10 EGTA, 1 CaCl2• 1 MgC12 and 10 HEPES,2 Na2ATP pH adjusted to 7.2 with KOH and a 
osmolarity of 290-300 mOsm- 1 .Microelectrodes were made of GC 1 20F- 10  borosillicate glass 
(Harvard Apparatus) and pulled on a P-87 puller (Sutter Instruments, Novato, CA) having a 
final resistance of 4-5 M.O. Series resistance was compensated by 80%-85%. Currents were 
filtered at 5 kHz and digitized at 1 0  kHz. Data were analyzed using 
Clampfit (Axon Instruments) and Excel (Microsoft) . In current clamp mode, the cells 
membrane potential was held at -50 m V by injecting a steady holding current through the 
pipette. The cells were activated with a 500 ms pulse of depolarizing current. 
l m m u nocytochemistry, confoca l  i mag ing  & t issue faxs 
In vitro differentiated human iPSCs have been fixated with 4% paraformaldehyde after 35-40d 
of differentiation. Cells were blocked in 5% normal goat serum and 2% FCS, subsequently 
samples were probed with primary antibodies: anti-Map2 ( 1:500, Sigma), anti-TH ( 1:500, 
Millipore) and anti-Nurr l ( 1:250, Santa Cruz). Alexa488 and Cy3-conjugated secondary 
antibodies were used and combined with Nuclei Hoechst staining. Confocal imaging was 
performed with Zeiss LSM confocal laser scan microscope. TissueFAXS analysis has been 
performed with TissuegnosticsTissueFAXS microscope and integrated software. 
RES U LTS 
Reprogra m m i ng of patient-d erived sk in  fi b rob l asts 
We reprogrammed patient-derived skin fibroblasts ( obtained from the Dermatology Department, 
UMC Groningen) by infection with lentiviruses expressing the reverse tetracycline transactivator 
(FWU-M2rtTA) combined with DOX-inducible lentiviruses providing Oct4, Sox2, Klf4 and 
cMyc as described elsewhere(Soldner et al., 2009). Two independent iPSC clones were generated 
(GriPScc1onct and GriPSCc1°nc2) from which clone 1 (fig. IA) was analyzed in detail. This clone 
expressed pluripotency markers such as alkaline phosphatase, Nanog, Oct4, Sox2 and SSEA4 
as shown by immunohistochemistry (fig.lB-F) . Additionally marker expression patterns were 
compared between human adult fibroblasts, GriPScc1onc1 , GriPSCC10"c2 and L-iPSCs(human iPSC 
line obtained from the group of Prof. C. Mummery, University of Leiden) by RT-PCR (fig. lG). 
All iPSC lines analyzed consistently expressed pluripotency markers, whereas the expression 
pattern of the control fibroblasts clearly differed. 
To test for successful reprogramming to pluripotency, cells were subcutaneously 
injected into SCID mice. GriPSCs formed teratomas after 7-8 weeks post-injection and all 
analyzed teratomas contained cell types from all three germ layers ( ectoderm, mesoderm 
and endoderm) (fig. l .H-K). 
The combination of assays shown here, indicates a sufficient generation of subject­
specific iPSCs upon DOX-inducible delivery of the aforementioned reprogramming 
factors. In order to assess their capacity to generate autologous DA neurons, we employed 
specifically designed in vitro DA differentiation protocols. 
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Fig.I :  Characterization of human iPSCs. (A) Phase contrast image of a typical hiPSC colony. (B) 
Alkaline Phosphatase staining of a hiPSC colony. (C-D)Immunocytochemical staining of hiPSCs for 
pluripotency markers Nanog, Oct4, Sox2 and SSEA4. (G) RT-PCR comparison of two GriPSC lines 
with human control fibroblasts and with a positive control line (Leiden iPSC line). (H-L) Injected 
hiPSCs formed teratomas containing cell types from all three germ layers. 
DA specific in vitro d ifferentiation 
Several studies have provided evidence that human iPSCs can be differentiated into DA 
neurons (Rhee et al., 2011; Soldner et al., 2009). Two recent studies showed that a in vitro 
recapitulation of floor-plate cells derived from pluripotent stem cells results in strikingly 
high amounts of neurons with bona fide midbrain DA neuron characteristics (Fasano et al., 
2010; Kriks et al., 2011). 
Here we subjected our humaniPSCs ( GriPScc1onc 1) to this floor plate-based differentiation 
protocol. This long-term protocol uses a combination of specific signaling factors such as 
SHH and FGF8 as well as small molecules that selectively activate SHH and Wnt-signaling 
pathways (see fig. 2A, modified from (Kriks et al., 2011). 
We differentiated our subject-derived iPSCs according to the given scheme, compared 
DNA methylation patterns for the Nanog promoter (fig.2B) and analyzed expression 
profiles for pluripotency genes and DA specific gene at day0, 2, 6, 11, 20 and 30 by real-time 
PCR. Expression of pluripotency markers was drastically reduced quickly after floor-plate 
induction (fig.2C). After 6 days of differentiation Nanog and Oct4 expression was reduced 
by a factor of 100 and Oct4 expression levels continued to decrease (more than a 1000-
fold) during further differentiation. In parallel we analyzed expression profiles of early 
and late DA specific genes (fig.2D and E). Markers were subdivided in these two groups 
based on their appearance during midbrain DA neuron generation in vivo. Strikingly 
FoxA2, as crucial marker for floor-plate cells and developing mDA neurons, was drastically 
-
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induced as early as day 6 of the differentiation and was maintained high during the whole 
differentiation process. This is in perfect accordance to earlier findings (Fasano et al., 
2010) and characterizes the potency of this in vitro differentiation protocol. At around day 
11 the specific early markers Lmxla and Mxsl significantly increased. Lmxla and Msxl 
have been shown to be crucially involved in the generation of DA neurons (for review 
see Burbach & Smidt, 2006). Moreover, in chick embryos Lmxla appears to be sufficient 
to ectopically induce DA neurons (Andersson et al., 2006). Although both factors were 
found to be increased, the induction level clearly differed, with an approx. 10 times higher 
level of Lmxla (and with that equal to FoxA2 levels). Denominated late DA markers also 
increased during in vitro differentiation (fig.2E). Most profound is the induction of tyrosine 
hydroxylase (TH) expression, the rate-limiting enzyme of intracellular DA production. But 
also Nurrl and Pitx3, two crucial transcription factors involved in differentiation processes 
and maintenance were strongly increased between day 11-20 of in vitro differentiation. 
So far this detailed analysis of DA specific marker expression patterns indicates 
the generation of proper mDA neurons. In order to further characterize these human 
iPSC-derived cells we determined their identity by immunocytochemistry, their 
electrophysiological properties with patch clamping and their capacity to generate and 
release dopamine with HPLC. 
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Fig. 2: in vitro differentiation and evaluation of human iPSC-derived DA neurons.(A) Floor-plate 
based differentiation scheme (modified from Kriks et al., 201 1) .  {B) Bisulfite sequencing of a Nanopg 
promoter area for human fibroblasts, hiPSCs and floor-plate based DA neurons. (C) QPCR evaluation 
of pluripotency markers Nanog and Oct4 upon differentiation. (D)qPCR evaluation of floor-plate and 
early DA markers FoxA2, Otx2, Lmxla and Msxl upon differentiation. (E)qPCR evaluation of late DA 
markers Nurrl ,  Pitx3 and TH upon differentiation. 
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Patient-derived i PSCs can generate bona fide midbra i n  DA neu rons 
A major concern for  in vitro generation of patient-specific mDA neurons is the efficiency 
by which pluripotent, but e.g. also multipotent stem cells can differentiate into bona fide 
cells. Earlier studies for mouse as well as for human stem cells have reported a rather limited 
capacity for the formation of mDA neurons (Hargus et al., 2010; Roybon et al., 2008; Rossler 
et al., 2010; Wernig et al., 2008). Here we found a comparably high number of neurons that 
co-express DA specific markers TH and Nurrl (fig.3). Fig.3A provides an overview of the 
contribution of TH positive cells as subset ofMap2 positive neurons. All TH-expressing cells 
co-expressed Map2 (fig.3B-B"). Moreover, the majority of Map2 positive neurons appeared 
to be also positive for Nurrl (fig.3C-C"). TissueFAXS analysis confirmed a predominant 
co-expression of Nurrl and Map2 (fig.3D). For TH and Map2 expression however, this 
analysis indicated two distinct populations (fig. 3E). This might be explained by differences 
in antibody properties and by the difficulties of this automated quantification to correctly 
identify and therefore quantify neuron-like morphology. Careful visual evaluation of 
double-labeled TH and Map positive neurons reveal widely co-expression. 
HPLC experiments revealed that differentiated hiPSC-derived DA neurons secreted 
dopamine, which was measurable in the supernatant as well as in cell lysates. More 
maturated DA neurons showed increased DA release (fig. 3F).Patch clamp experiments 
with 35-45 day old neurons showed clear Ca2+ flux and to a lesser extend also activity of 
Na+ channels. Action potential-like activities could be measured, however, the stability and 
magnitude of measured spike indicated still neuronal immaturity (fig. 3G-I). 
Together, our data, characterizing individual-specific floor-plate tissue-derived DA neurons, 
provide evidence for in vitro generation of bona fide mDA neurons at a pre-mature stage. 
DISCUSSI ON 
In this study we evaluated the suitability of a floor-plate based DA-specific in vitro 
differentiation protocol for humaniPSCs. Recent studies provided evidence that early 
exposure to high concentrations of SHH and properly orchestrated induction of Wnt­
signaling results in cells that resemble floor-plate tissue characteristics at an early stage 
of in vitro differentiation, which subsequently show robust and very efficient capacity to 
differentiate into mDA neurons (Fasano et al., 2010; Kriks et al., 2011). Earlier studies 
described the paramount importance of the interplay between SHH- and Wnt-signaling 
for correct mouse midbrain development (Joksimovic et al., 2009; Ono et al., 2007). Also, 
the downstream effectors FoxA2 and Lmxla have been described as crucial for DA neuron 
generation during development but also for in vitro generation ( Chung et al., 2009; Deng et 
al., 2011; Friling et al., 2009; Kittappa et al., 2007). 
Our study, in accordance to the findings of Fasano et al. (2010) and Kriks et al. (2011), 
now shows that both, FoxA2 and Lmxla, play important roles during the in vitrogeneration 
of DA neurons derived from humaniPSCs. We demonstrated the sequential activation of 
several DA-specific markers that strongly suggested the recapitulation of human midbrain 
development. The drastic increase ofFoxA2 correlates with a most pronounced induction of 
-
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Fig. 3: Human iPSC-derived DA neurons show correct cellular DA characteristics. (A) Random 
selection ofMap2- and TH-positive neurons, indicative for the amount of DA producing cells; (B) Co­
labeling of Map2- and TH-positive neurons with higher magnification; (C) Co-labeling of Map2- and 
Nurrl-positive neurons. (D) Tissues FAXS analysis revealed a high correlation of Map2 and Nurrl 
positive cells. (E) Tissues FAXS analysis revealed yet weak correlation of TH and Map 2, additionally two 
distinct populations can be seen. (F) HPLC analysis shows functional dopamine secretion of human iPSC­
derived mDA neurons after 35 and 45 days of in vitro differentiation. Panel (G-H) Electrophysiological 
properties of human iPSC derived mDA neurons. (G) Representative phase contrast image of a patched 
neuron. (H) I-V curve indicative for co-expression of voltage-independent Ca++ channels and voltage 
dependent Na+ channels. (I) Action-potential recordings from human iPSC-derived DA neurons. 
TH. Lmxla expression seems to follow up on increased Foxa2 expression and, shortly after, 
levels up with the winged helix transcription factors, where it remains comparably highly 
expressed during the time of observation. While TH expression continues to rise, late DA 
markers such as Nurr 1 and Pitx3 show increased expression only after coordinated induction 
of FoxA2 and Lmxla. Timed induction of several crucial DA-specific markers combined 
with mDA neuron typic morphology, DA secretion and proper electrophysiological 
properties points towards the generation of bona fide human iPSC-derived mDA neurons. 
136 CHAPTER 6 
Such in vitro generated neurons will serve as important tool to study the pathology of PD 
and moreover, might help to push forward future cell replacement therapies. 
A remaining issue of floor-plate based DA neurons, however, is the purity of the generated 
cells. It is likely that many other non-DA cell types are generated as well. Purification of mouse 
ESCs- and iPSCs-derived DA neurons has been achieved (Hedlund et al., 2008 and chapter IV 
and V of this thesis) but comparable generation of purified human pluripotent stem cell derived 
DA neurons has not been reported yet. To that end, two studies describe genome editing by 
zinc finger nucleases (ZNFs) and transcription activator-like effector nucleases (TALENs), 
which would allow generation of equally sortable human DA neurons (Hockemeyer et al., 
2009, 201 I). These studies report integration of a GFP reporter in the Pitx3 locus, generating 
heterozygous Pitx3grpt+ human iPSCs. Actual generation of Pitx3 expression hiPSC-derived DA 
neurons with these iPSCs, that would eventually allow purification of mDA neurons, remains 
still to be shown. However, pure human iPSC-derived mDA neurons that might be obtained 
in follow-up research will enable us to study in detail DA neuron specific cell pathogenesis 
and might shed light on molecular causes and consequences of PD-specific mutations. 
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CHAPTER 7 
SUMMARY AND PERSPECTIVE 

The cardinal symptom of PD is selective loss of dopaminergic (DA) neurons in the 
substantianigra pars compacta (SNc). Deprivation of these neurons and their projections 
to the striatum leads to the well-known physiological symptoms of PD, including tremor, 
rigidity, bradykinesia, postural instability and difficulties in gait often accompanied with 
noticeable psychological problems. Despite decades of intensive research, neither the 
ultimate underlying cause nor an efficient lasting cure has been found yet. 
Stem cells are considered one of the most promising tools to study pathogenic cellular 
and molecular events in PD in detail. Moreover, much attention has been put on basic 
research regarding their use in cell replacement therapy. Regardless of the technical 
difficulties of such surgical interventions, the regionally confined nature of cell loss in PD 
makes replacement strategies highly attractive. Both applications of stem cells, disease 
modelling as well as cell replacement, are however dependent on proper in vitro generation 
and strict characterization of stem cell-derived DA neurons. 
In this thesis we evaluate the DA differentiation capacity of various stem cell types 
including neural stem cells, mouse induced pluripotent stem cells and human induced 
pluripotent stem cells. 
In chapter I, we provided a survey on environmental and genetic factors eventually 
contributing to PD and we summarized and outlined as to why SNc DA neurons appear 
to be selectively susceptible in Parkinson's disease pathology. Moreover, we compiled an 
overview of past and currently applied therapies with a focus on cell-based replacement 
therapies. First approaches in the 1980s with embryonic ventral midbrain grafts resulted in 
rather poor beneficial effects (Lindvall et al., 1989; Madrazo et al., 1988). Also technically 
more sophisticated trials did not result in robust improvements in graft-receiving patients 
(Brundin et al., 2000; Freed et al., 1992; Spencer et al., 1992). However, beneficial effects 
observed in some recipients pointed towards the survival of a functional DA cell population 
within the grafted tissue. Next to embryonic ventral midbrain neurons, also neural stem 
cells (NSCs) were considered potential toolsfor graft-induced restorative approaches. 
Chapter I summarizes how NSCs but also pluripotent embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs) can be manipulated to specifically differentiate 
towards DA neuronsin vitro. In chapter II we elaborated on the ground-breaking recent 
discovery that somatic cells can be reprogrammed to a state of pluripotency. This finding 
had a massive impact on research regarding in vitro disease modelling and cell based 
therapeutic approaches, since it allows generation of autologous DA neurons, e.g. from 
individual PD patients and it completely obviates the use of ESCs. Moreover, the exciting 
possibility to directly convert skin fibroblasts into DA neurons is introduced and evaluated. 
In chapter III of this thesis we first set out to analyse the DA-specific differentiation 
capacity of non-mesencephalic NSCs that were isolated from embryonic mouse brains. In 
this study, we tested the effects of mitogens, like sonic hedgehog, fibroblast growth factor 8 
and Wnt-1, on guided DA differentiation. Several studies have shown that these particular 
growth factors are crucially involved in physiological embryonic development of midbrain 
DA neurons as well as in in vitro differentiation of pluripotent and multipotent neural 
stem cells (Andersson et al., 2006; Chung et al., 2009; Cooper et al., 2010; Joksimovic et al., 
2009). However, the ability of NSCs to generate bona fide midbrain DA neurons seemed 
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to be hampered when they have passed a distinct window of neural development ( Chung 
et al., 2006; Roybon, Hjalt, Christophersen, Li, & Brundin, 2008). In our experiments we 
show that a combination of extrinsic and intrinsic DA neuron specific factors and histone 
deacetylase inhibitors facilitate in vitro DA neuron generation of non-mesencephalic NSCs. 
We found that approximately 1 /3 of the differentiating NSCs adopted a midbrain DA-like 
phenotype. The robustness of this particular differentiation protocol, however, appeared 
to be less in comparison to e.g. ESC-based DA induction methods. So, also in view of the 
extreme sensitivity and limited availability of human autologous adult NSCs, obtained via 
stereotactic endoscopic harvesting along the ventricular wall, it became clear that large-scale 
application of autologous adult NSCs for biomedical research should be considered not 
feasible. Nonetheless, it remains interesting to analyse which characteristics in adult NSCs 
inhibit specific neuronal linage differentiation, since, e.g. the introduction of Oct4 (as in the 
iPSC reprogramming procedure) seemed to recover the ability of NSCs to differentiate into 
midbrain DA neurons (Deleidi, Cooper, Hargus, Levy, & Isacson, 201 1 ; J. B. Kim et al., 2009) . 
The importance of induced pluripotency in somatic cells became more and more evident 
and in particular for PD-related in vitro disease modelling and cell replacement strategies 
this cell type holds major promises. Earlier ESC studies provided ample evidence that 
pluripotent stem cells can efficiently be differentiated into DA neurons (Chambers et al., 
2009; Cho, Hwang, & Kim, 2008; Kawasaki et al., 2000; D.-W Kim et al., 2006; Lee, Lumelsky, 
Studer, Auerbach, & McKay, 2000). This knowledge was effectively translated to iPSCs and 
by now several studies have reported the generation of DA neurons derived from mouse 
and human iPSCs(Hargus et al., 201 0; Soldner et al., 2009; Wernig et al., 2008). However, 
before PD-specific mutations and their molecular pathogenic consequences, as for example 
found in the gene for a-synuclein or LRRK2, can be selectively studied in iPSC-derived DA 
neurons it will be inevitable to purify such in vitro generated DA neurons. Purification will 
also be crucial for cell populations that might be considered for possible future regenerative 
medicine strategies. In chapter IV, we generated transgenic mouse iPSC lines that allowed the 
purification of in vitro generated neural precursors (NPs) and of mature DA neurons. IPSC­
derived NPs were purified based on transgenic nestin-GFP expression and iPSC-derived DA 
neurons underwent purification based on knock-in Pitx3gfpt+. Focusing on the latter, Pitx3gfpt+ 
sorting allowed extensive comparison with primary isolated mesodiencephalic dopaminergic 
(mdDA) neurons. MdDA neurons, with SNc neurons as specific subpopulation, have been 
extensively characterized during rodent development (Smits, Burbach, & Smidt, 2006) and 
Pitx3 has been identified as highly specific marker within the CNS (Smidt et al., 1997) . 
Its specificity makes Pitx3 an optimal marker to select for iPSC-derived mdDA neurons. 
Therefore, our study provides the first strict in-depth characterization of iPSC-derived mdDA 
neurons. Chapter IV focuses on genetic and epigenetic features of Pitx3grpt+ purified cells. 
We analysed global gene expression and DNA methylation patterns of iPSC-derived mdDA 
neurons and compared these with those of primary mdDA neurons. This detailed analysis 
has provided unique novel information about iPSC-derived DA neurons and showed to what 
extent such in vitro generated DA neurons resemble the original cell type. 
In vitro generation of midbrain DA neurons is considered promising for future cell 
replacement in PD patients. Mixed iPSC-derived cultures or NP-selected cell populations 
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have been successfully implanted in rodent models for PD (Hargus et al., 201 O; Wernig et al., 
2008). However, such undefined cell populations carry several risk factors. First, unknown 
cell types within the graft might mask or modulate the efficacy of DA neurons within that 
population. Second, incomplete differentiation of pluripotent stem cells harbours the risk 
of teratoma formation in the host tissue. In chapter V we described a pilot study showing 
grafting of Pitx3gfp/+ purified iPSC-derived mdDA neurons in 6-OHDA Parkinson rats. Our 
results indicate that comparably low numbers of purified mdDA neurons drastically improve 
neurotoxin-induced rotation behaviour. Even though the outcome of this study should be 
considered only preliminary, we provide promising evidence regarding the functionality of 
pure iPSC-derived mdDA neurons in an animal model for PD that might be translatable to 
human iPSCs and therefore may become instrumental for cell-based therapy in the future. 
To date human iPSCs are the most promising cell types to model and study human 
disease (Vogel, 2010). In order to generate bona fide human iPSC-derived midbrain DA 
neurons, it is crucial to recapitulate tissue-specific development in vitro. As indicated above, 
several established protocols used to differentiate ESCs could be applied to iPSCs. Two 
recent studies reported that ESCs can efficiently be differentiated into floor-plate tissue (the 
floor plate is a crucial organizing structure in the developing embryo, located along the ventral 
midline), which eventually gives rise to midbrain DA neurons. (Fasano, Chambers, Lee, 
Tomishima, & Studer, 2010; Kriks et al., 2011). In chapter VI we generated human iPSCs 
and studied the efficacy of this particular floor-plate based protocol for the generation of 
autologous DA neurons. Our findings confirmed the potential of this tissue-specific DA 
induction protocol. We found high amounts of neurons with bona fide DA characteristics. 
Early during in vitro differentiation, these cells revealed gene expression traits of floor­
plate tissue and sufficiently adopted DA identity at later in vitro differentiation stages. 
Furthermore, these humaniPSC-derived neurons showed typical electrophysiological 
properties (indicative for young neurons) and secreted dopamine. Thus, tissue-specific 
patterning apparently provides a robust DA induction method and will be very helpful for 
patient-specific in vitro disease modelling. If further experimental developments will lead 
to stringent purification of human iPSC-derived midbrain DA neurons, then floor-plate 
based DA neurons might become the cell type of choice for cell replacement therapies. 
The tremendous success of induced pluripotency led researchers to revisit the question 
whether direct conversion from one somatic cell type to another would be as easily possible. 
Classical nuclear transfer experiments but also expression of single transcription factors 
indicated that differentiated somatic cells are not terminally committed to a specific fate 
(Gurdon, Elsdale, &Fischberg, 1958; Gurdon, 2006; Weintraub et al., 1989). As a result 
of this combined knowledge, three recent studies reported direct lineage programming of 
skin fibroblast to neurons, to cardiomyocytes and to blood cell progenitors with a more 
pronounced biomedical focus (Ieda et al., 2010; Szabo et al., 2010; Vierbuchen et al., 2010). 
Such directly programmed cells types would have the advantage of skipping a pluripotent 
'intermediate' state and would therefore be more suitable for any type of clinical application. 
Specifically the generation of induced neurons (iNs) by Vierbuchen et al. (2010) must 
be considered of interest for PD related cellular research. This study reported efficient 
generation of neurons by lentiviral delivery of three neurogenic factors (Brn2, Asel! and 
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Pitx391P1+ fibroblasts 
control fibroblasts 
6d + dox 
1 0d + dox 
�rn2, 8scll, ,Mytll 
(+ Lmxla, Pitx3) 
Pitx391P1+ neurons 
Additional fig. I :  Direct programming of Pitx3gfp/+ fibroblasts into iDA neurons. (A) Schematic 
representation of a trans-differentiation experiment. (B) BAM-transduced fibroblasts before 
doxycycline (DOX) exposure. (C) iNs 6 days after DOX exposure. (D) iNs 10 days after DOX exposure. 
(E) Expression profile comparison of control fibroblasts and iNs. (F) DOX-driven 'BAM' expression 
causes efficient generation of Map2 positive neurons. (G-1) A subpopulation of Map2 neurons 
expresses tyrosine hydroxylase (TH) and Pitx3-GFP. scale bar: S0µm. 
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Mytll). Quickly after this finding, three additional reports described the direct induction of 
DA-like (iDA) neurons from fibroblasts (Caiazzo et al., 2011; J. Kim et al., 2011; Pfisterer et 
al., 2011). Kim et al. (2011) reported the generation of iDA neurons from Pitx3-GFP mice. 
Kim and colleagues used 11 factors (Brn2, Ascll, Mytll, Pax6, Soxl, Ngn2, Lmxla, Lmxlb, 
Nurrl, Pitx3 and Enl) that had been lentivirally integrated in the genome of isolated mouse 
embryonic fibroblast. Eventually the highest efficiency to generate Pitx3-GFP positive cells 
was found when Pax6 Soxl and Ngn2 were omitted. Crucially required on the other hand, 
seemed to be Acsll and Pitx3 for the induction of Pitx3-GFP expressing cells. Cell sorting 
experiments revealed that up to 9% of the total resulting cell population expressed GFP. 
However, the aforementioned potential supremacy of directly converted iDA neurons 
seems to be drastically undermined by these high proviral genome modifications. 
In order to reduce proviral contribution to this direct programming, we started 
experiments using Pitx36rpt+ fibroblasts (avoiding contamination of tissue of neural origin 
- see additional fig.IA) in which only Brn2, Ascll and Mytll (BAM) were lentivirally 
transduced (as previously described) and DA specific factors Lmxla and Pitx3 were 
only transiently overexpressed. Our preliminary results, show (this section) efficient iN 
induction upon BAM transduction. Additionally, we found small amounts of neuron-like 
cells that showed Pitx3-GFP expression (see additional fig.I). However we did not succeed 
to increase DA-like iNs by transient expression of Lmxla and Pitx3 (data not shown). 
Although the data presented here do not comprise a completed study they still provide 
a very interesting angle concerning in vitro disease modelling and cell therapy. Future 
experiments will show whether directly induced or transdifferentiatediDA neurons are able 
to sufficiently recapitulate primary midbrain DA neurons. 
In conclusion, the discovery of induced pluripotent stem cells has drastically changed 
and boosted the research area of regenerative medicine. IPSCs have been proven to be 
truly pluripotent. As a result they have comparable differentiation capacities as ESCs but 
leap the controversies that classically hampered ESC research. Not only does that cell type 
facilitate the 'disease in a dish' approach that allows patient-specific cellular and molecular 
modelling, it also generates immense opportunities to obtain autologous, patient-tailored 
cell types that may allow treatment in the future. Primary neural stem cells (adult or 
embryonic) have taught us how to manipulate stem cells in general in order to form a 
specific subset of neural cell, however their large-scale application for biomedical research 
seems to be restricted, mainly due to their high sensitivity and their lack of availability. 
An interesting novel aspect is the ability to generate sustainable NSCs directly from 
fibroblasts (Han et al., 2012; Thier et al., 2012). Future experiments will have to show 
whether these directly programmed NSCs have a more robust and efficient differentiation 
capacity towards dopaminergic neurons in comparison to primary NSCs. Parallel, direct 
generation of neurons from fibroblast offer some sort of short cut, however it still needs to 
be proven that these iDA neurons are truly dopaminergic neurons. 
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NEDERLANDSE SAMENVAT TING 
Het selectief afsterven van dopaminerge (DA) neuronen in de substantia nigra pars compacta 
(SNc) is het belangrijkste kenmerk van de ziekte van Parkinson. Het verloren gaan van deze 
groep neuronen en hun verbindingen naar het striatum en andere hersenregio's leidt tot veel 
van de karakteristieke symptomen van "Parkinson': zoals tremor, spierstijfheid, bradykinesie, 
problemen met houding en lopen, vaak uiteindelijk ook vergezeld met mentale stoornissen. 
Ondanks jarenlang intensief onderzoek is de primaire oorzaak nog steeds onbekend 
en bestaat er geen afdoende behandeling. Er is al geruime tijd belangstelling voor het 
therapeutisch gebruik van stamcellen als bron voor te implanteren nieuwe vervangende 
dopaminerge neuronen; het feit <lat slechts een relatief kleine lokale homogene groep 
neuronen aangetast is, maakt intracerebrale celtransplantatie een interessante optie, 
waarvan de mogelijkheden, ondanks de aanzienlijke technische problemen, in het 
verleden met het implanteren van uit abortus verkregen humane foetale dopaminerge 
neuronen zijn aangetoond. Recentelijk zijn stamcellen ook in beeld gekomen als unieke 
beloftevolle werktuigen om in detail de cellulaire en moleculaire pathogene mechanismes 
van "Parkinson" te ontrafelen. Voor beide toepassingen, celvervanging en "Parkinson-in-a­
dish" onderzoek, is het essentieel <lat de dopaminerge neuronen die uit stamcellen verkregen 
kunnen worden volledig gekarakteriseerd zijn en liefst identiek zijn aan de dopaminerge 
neuronen in het brein. 
In <lit proefschrift wordt verslag gedaan van onderzoek naar de differentiatiecapaciteit 
van verschillende types stamcellen, waaronder neurale stamcellen en muizen en humane 
induced pluripotente stamcellen (IPS cellen), tot dopaminerge neuronen. 
In hoofdstuk 1 wordt allereerst een overzicht gegeven van de omgevings- en genetische 
factoren die een belangrijke rol lijken te spelen bij het ontstaan van de ziekte van Parkinson 
en de vraag komt aan de orde waarom de dopaminerge neuronen in de SNc selectief worden 
aangetast. Daarnaast geven wij een overzicht van oudere en recente behandelingsstrategieen 
voor de ziekte van Parkinson, met speciale nadruk op celvervangingstherapieen. In 
de 80-er jaren van de vorige eeuw vonden de eerste trials plaats met het transplanteren 
van embryonale dopaminerge neuronen gei'soleerd uit foetale ventrale middenhersenen: 
de heilzame effecten waren in eerste instantie gering (Lindvall et al., 1989; Madrazo et 
al.,1988). Ook het doorvoeren van een aantal technische verbeteringen in de procedures 
leidden vooralsnog niet tot grootschalige, robuuste veranderingen in de symptomen van 
de ontvangende Parkinson patienten (Brundin et al., 2000; Freed et al., 1992; Spencer et 
al., 1992). Echter de opmerkelijke verbeteringen in sommige Parkinson patienten maakten 
duidelijk <lat een deel van de gei'mplanteerde dopaminerge neuronen na implantatie in het 
striatum overleefde en dopamine produceerde. Vanwege aanzienlijke praktische en ethische 
problemen met het gebruik van uit abortusweefsel verkregen cellen, werd er gezocht naar 
andere bronnen voor transplanteerbare dopaminerge neuronen, met name stamcellen, 
en kwam het onderzoek naar de mogelijkheden om neurale stamcellen en embryonale 
stamcellen in vitro specifiek te laten differentieren tot dopaminerge neuronen op gang. In 
hoofdstuk 2 gaan we uitgebreid in op de recente grensverleggende ontdekking <lat gewone 
lichaamscellen gereprogrammeerd kunnen worden tot een pluripotente stamcelstatus, de 
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induced pluripotent stamcel (IPS eel). De mogelijkheid om van individuele Parkinson 
patienten autologe ("eigen") pluripotente stamcellen, vergelijkbaar met embryonale 
stamcellen (maar zonder de ethische en praktische bezwaren), te genereren heeft een nieuwe 
stimulans gegeven aan het onderzoek naar de mogelijkheid van celvervangingstherapieen 
en naar pathogene mechanismes in dopaminerge neuronen van Parkinson patienten. De 
recent ontdekte mogelijkheid van directe conversie van huidfibroblasten tot dopaminerge 
neuronen lijkt een volgende stap te zijn in <lit onderzoeksgebied. 
In hoofdstuk3 beschrijven wij ons onderzoek naar de mogelijkheid om nonmesencephale 
neurale stamcellen, i.e. neurale stamcellen die normaliter geen dopaminerge neuronen 
genereren, te induceren tot specifieke differentiatie tot dopaminerge neuronen. Daartoe 
testten wij een aantal groei- en inductiefactoren, zoals Shh, FGF8 en Wnt- 1 ,  waarvan de 
rol in de embryonale ontwikkeling van mesencephale dopaminerge neuronen overtuigd 
is aangetoond (Andersson et al., 2006; Chung et al., 2009; Cooper et al., 2010; Joksimovic 
et al., 2009) . In onze experimenten met nonmesencephale neurale stamcellen uit muizen 
vonden we <lat deze extrinsieke factoren slechts in combinatie met de geforceerde expressie 
van enkele dopaminerge transcriptiefactoren en inhibitie van histone deacetylases, 
uiteindelijk dopaminerge differentiatie konden bewerkstelligen in een deel (± 30%) van 
de nonmesencephale neurale stamcellen. De moeilijkheid om voldoende dopaminerge 
neuronen te verkrijgen uit neurale stamcellen die normaliter niet <lit type neuronen 
genereren, heeft het mogelijk gebruik van autologe neurale stamcellen, ge'isoleerd uit de 
ventrikelwand met behulp van fijne endoscopische neurochirurgie, op een dood spoor gezet 
(Chung et al., 2006; Roybon, Hjalt, Christophersen, Li, & Brundin, 2008). De reden voor de 
weerstand van dergelijke neurale stamcellen te differentieren tot dopaminerge neuronen is 
nog onduidelijk; opmerkelijk genoeg blijkt de geforceerde expressie van Oct4 (zoals tijdens 
IPS-reprogrammering) het vermogen van neurale stamcellen tot dopaminerge differentiatie 
weer te kunnen herstellen (Deleidi, Cooper, Hargus, Levy, & Isacson, 20 1 1 ; J. B. Kim et 
al., 2009). In eerdere studies met embryonale stamcellen was aangetoond <lat pluripotente 
stamcellen efficient dopaminerge neuronen kunnen genereren (Chambers et al., 2009; Cho, 
Hwang, & Kim, 2008; Kawasaki et al., 2000; D.-W Kim et al., 2006; Lee, Lumelsky, Studer, 
Auerbach, & McKay, 2000) . Gebruikmakend van de protocollen uit deze studies, konden ook 
uit muizen en humane IPS cellen dopaminerge neuronen verkregen worden met wisselende 
efficientie (Hargus et al., 2010 ;  Soldner et al., 2009; Wernig et al., 2008). Ten einde de uit IPS 
verkregen dopaminerge neuronen te kunnen gebruiken, hetzij voor transplantatie, hetzij 
voor onderzoek aan moleculaire pathogene mechanismes, is celzuivering essentieel. Ook 
slechts aan zuivere celsuspensies van uit IPS verkregen dopaminerge neuronen kunnen 
cruciale analyses betreffende de volledigheid en stabiliteit van de differentiatie verricht 
worden. In hoofdstuk 4 hebben wij daartoe IPS cellijnen gemaakt uit fibroblasten afkomstig 
van transgene Pitx3gfpt+ muizen, waarbij green fluorescent prote'ine (GFP) gekoppeld is aan 
de expressie van de transcriptiefactor Pitx3, een specifieke marker voor mesodiencephale 
dopaminerge neuronen (Smidt et al., 1997; Smits, Burbach, & Smidt, 2006). Door middel 
van FACs-sorting, konden we zuivere, uit IPS cellen gegenereerde dopaminerge neuronen 
suspensies verkrijgen, waarop we unieke, grondige ("in-depth") genetische en epigenetische 
karakteriseringen konden uitvoeren die we konden vergelijken met die van primaire 
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dopaminerge neuronen, ook met behulp van FACs gei'soleerd uit de transgene Pitx3gfpt+ 
muizen. Onze extensieve analyses hebben unieke informatie opgeleverd over de genetische 
en epigenetische status van uit JPS verkregen dopaminerge neuronen en laten zien hoezeer 
deze neuronen vergelijkbaar zijn met primaire dopaminerge neuronen in het brein. Ten 
aanzien van de functionaliteit van de Pitx3gfpt+ gezuiverde dopaminerge neuronen hebben 
we enkele pilot transplantatie-experimenten uitgevoerd met een ratmodel voor de ziekte 
van Parkinson, het 6-OHDA gei'nduceerde rotatiemodel (hoofdstuk 5). Tot nu toe waren in 
vergelijkbare studies met <lit diermodel slechts ongezuiverde celsuspensies getransplanteerd 
en getest. Het transplanteren van ongezuiverde celsuspensies brengt een aanzienlijk risico 
mee op teratoma-vorming door contaminerende, ongedifferentieerde JPS cellen; daarnaast 
kan de aanwezigheid van allerlei andere celtypes het effect van de dopaminerge neuronen 
maskeren of zelfs teniet doen. De eerste voorlopige resultaten van onze rotatie-experimenten 
laten zien dat al met een relatief klein aantal zuivere dopaminerge neuronen, gegenereerd 
uit JPS cellen, drastische verbeteringen teweeg gebracht kunnen worden. Als extrapolatie 
naar humane cellen mogelijk is, betekent dat een belangrijke ontwikkeling voor mogelijke 
toepassing van celtransplantatietherapie voor Parkinson-patienten. 
Het genereren van bona fide dopaminerge neuronen uit humane JPS cellen vereist het 
recapituleren van de normale embryonale dopaminerge ontwikkeling in-vitro. Protocollen 
daarvoor zijn reeds opgesteld voor embryonale stamcellen en recentelijk is een nieuwe, zeer 
efficiente differentiatie strategie, via de formatie van een embryonale floor-plate structuur, 
voor deze embryonale stamcellen ontwikkeld (Fasano, Chambers, Lee, Tomishima, & 
Studer, 201 O; Kriks et al., 2011). In hoofdstuk 6 hebben we <lit nieuwe differentiatie protocol 
gebruikt voor het genereren van dopaminerge neuronen uit humane JPS cellen. Onze 
resultaten bevestigden de potentie van deze methode ook voor JPS cellen en de verkregen 
dopaminerge neuronen vertoonden elektrofysiologische eigenschappen specifiek voor 
dopaminerge neuronen en produceerden dopamine. 
In het vervolg op de revolutionaire ontwikkelingen rond de JPS cellen kwam de vraag 
aan de orde of het niet ook mogelijk is om een somatische eel direct te converteren tot een 
andere somatische eel, zonder de omweg langs het pluripotente tussenstadium. Aanwijzingen 
daarvoor (e.g. transdifferentiaties van lever- en fibroblastcellijnen tot myoblasten d.m.v. 
geforceerde MyoD expressie) waren al jaren eerder gepubliceerd maar enigszins genegeerd 
(Gurdon, Elsdale, & Fischberg, 1958; Gurdon, 2006; Weintraub et al., 1989). In de afgelopen 
2 jaar zijn een aantal studies gepubliceerd waarin de directe reprogrammering van 
huidfibroblasten tot cardiomyocyten, bloedcellen en neuronen (induced neurons of iNs) 
door middel van de geforceerde expressie van specifieke combinaties van celtype relevante 
transcriptiefactoren werd aangetoond (Ieda et al., 201 O; Szabo et al., 201 O; Vierbuchen 
et al., 2010). In 3 recente publicaties is beschreven hoe huidfibroblasten zelfs direct tot 
dopaminerge neuronen geconverteerd kunnen worden ( Caiazzo et al., 2011; J. Kim et al., 
2011; Pfisterer et al., 2011). In eerste voorlopige studies hebben wij ook getracht om onze 
Pitx3gfp/+ fibroblasten direct te converteren tot dopaminerge neuronen, waarbij een aantal 
modificaties, met name ter reductie van de virale belasting, werden doorgevoerd. Met dat 
aangepaste protocol bleken wij inderdaad ook in staat een klein aantal Pitx3gfp/+ neuronen te 
genereren. De toekomst zal uitwijzen of directe conversie van huidfibroblasten inderdaad 
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stabiele, volledig gedifferentieerde en volledig functionele dopaminerge neuronen kan 
leveren, geschikt voor therapeutische doeleinden. 
Samenvattend, de ontwikkeling van autologe induced pluripotent stamcellen heeft de 
regeneratieve geneeskunde drastisch veranderd. Autologe IPS cellen komen wat betreft 
pluripotente eigenschappen overeen met die van embryonale stamcellen, maar missen de 
ethische bezwaren en, in geval van transplantatiegebruik, immuunreactie-complicaties. De 
mogelijkheid om op relatief eenvoudige wijze onbeperkte aantallen autologe IPS cellen te 
verkrijgen van individuele patienten biedt ongekende mogelijkheden voor celtransplantatie 
( al dan niet na genetische modificatie) en verschaft unieke onderzoekswerktuigen om 
onderliggende cellulaire pathogene mechanismes te ontrafelen. De resultaten van de 
extensieve analyses in <lit proefschrift laten zien <lat de uit IPS verkregen dopaminerge 
neuronen vrijwel identiek zijn aan primaire dopaminerge neuronen. Het lijkt erop 
<lat de JPS cellen ( en wellicht de directe conversie van huidcellen tot dopaminerge 
neuronen) hernieuwde interesse zullen opwekken voor celtransplantatie als therapie 
voor Parkinson patienten. De belangrijkste bezwaren tot nu toe tegen een mogelijke 
dopaminerge celtransplantatietherapie (i.e. variabele en ongedefinieerde samenstelling 
van het celtransplantaat, zeer beperkte en onzekere beschikbaarheid, onmogelijkheid tot 
standaardisering van optimale implantatieprocedure, noodzaak tot immunosuppressie 
en ethische problematiek), lijken door IPS cellen weggenomen te worden: de onbeperkte 
aantallen autologe IPS cellen bieden de mogelijkheid tot optimalisering en standaardisering 
van de productie van zuivere dopaminerge celsuspensies en daarmee systematisch 
onderzoek naar de optimale implantatieprocedure. 
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DEU TSC HE Z USAM MEN FASSUNG U N O  
SC H L U SSFO LG ERU NG EN 
Das Hauptsymptom von Parkinson ist der selektive Verlust von dopaminergen (DA) 
Neuronen in der substantia nigra pars compacta (SNc). Daraus resultierender Verlust der 
neuronalen Projektionen zum Striatum fiihrt zu den allgemein bekannten Merkmalen der 
Erkrankung. Diese umfassen Tremor, Steifheit, Bradykardie und Haltungsinstabilitat oft 
kombiniert mit Schwierigkeiten im Gang. Dariiber hinaus ist Parkinson haufig assoziiert 
mit psychopathologischen Symptomen. Ungeachtet der intensiven, jahrzehnte langen 
Forschung sind weder die zugrundeliegenden Ursachen bekannt noch stehen effektive, 
langanhaltende Therapien zur Verfiigung. 
Stammzellen gehoren derzeit zu den vielversprechendsten Moglichkeiten um Parkinson­
spezifische zellulare und molekulare Ereignisse im Detail zu untersuchen. Dariiberhinaus besteht 
groBes Interesse an der potentiellen Nutzbarkeit von Stammzellen fiir zukiinftige Zelltherapie. 
Aufgrund des regional sehr definierten und begrenzten Gehirngebiets, welches unter zuvor 
erwahntem Zellverlust leidet, ist Zelltherapie, trotz einer Vielzahl technischer Hiirden, eine sehr 
attraktive Behandlungsperspektive. Beide Anwendungen, in vitro-modelling von Parkinson auf 
zellularer Ebene und Zelltherapie, hangen maBgeblich von effizienter Generierung und strenger 
Charakterisierung der aus Stammzellen erzeugten DA Neurone ab. 
In dieser Dissertation wird die DA-spezifische Differenzierungskapazitat von 
verschieden Stammzell-typen untersuchen und evaluiert. Zu den analysierten Zellen 
gehoren neuronale Stammzellen und induziert pluripotente Stammzellen, sowohl der Maus 
als auch des Menschen. 
In Kapitel I wird eine Ubersicht gegeben iiber Umweltfaktoren sowie auch genetische 
Faktoren die zu Parkinson beitragen konnen. Dariiberhinaus werden Moglichkeiten 
dargelegt um die spezifische Sensitivitat von SNc DA Neuronen zu erklaren. Weiterhin liefert 
dieses Kapitel eine Ubersicht iiber friihere und moderne klinisch angewendete Therapien, 
wobei der Fokus bei dieser Betrachtung auf Zelltherapie fiir Parkinson liegt. Erste Versuche 
in den achtziger Jahren mit embryonalen ventral-mesencephalen Transplantaten ergaben 
wenig zufriedenstellende Resultate mit relativ geringer symptomaler Versbesserung 
fiir die behandelten Patienten. Auch technisch-methodisch verbesserte klinische 
Transplantationen lieferten zunachst keine robusten Verbesserungen fiir die meisten 
der Patienten. Nichtsdestotrotz konnte in einigen wenigen Patienten Verbesserung nach 
Zellinjektion beobachtet werden. Dies gab erste Hinweise darauf, dass die eingebrachte 
Zellpopulation funktionelle DA Neurone enthielt, die sich dariiberhinaus auch adaquat zu 
integrieren schienen. Neben embryonalen mesencephalen Neuronen wurden auch neurale 
Stammzellen als potentielle Werkzeuge fiir regenerative Therapien angesehen. Kapitel I 
fasst ebenfalls zusammen inwieweit derartige neurale Stammzellen aber auch pluripotente 
embryonale Stammzellen und induzierte pluripotente Stammzellen derartig manipuliert 
werden konnen um spezifisch DA Neurone zu generieren. 
In Kapitel II gehen wir detaillierter auf die bahnbrechende Entdeckung ein, <lass 
somatische Zellen umprogrammiert werden konnen zu einem pluripotenten Stadium. 
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Diese Entdeckung hatte enorme Auswirkungen auf Forschung fiir ,,disease-modelling" in 
vitro und Zellersatztherapie, da es so zum ersten Mal moglich war korpereigene, Patienten­
spezifische DA Neurone zu generieren, und das unter kompletter Vermeidung von ethisch 
sehr umstrittenen embryonalen Stammzellen. Zusatzlich gehen wir in diesem Kapitel auf 
die faszinierende Moglichkeit ein, DA Neurone direkt aus Hautzellen zu gewinnen. 
In Kapitel III dieser Dissertation beginnen wir mit der Analyse der DA-spezifischen 
Differenzierungs-kapazitat von neuralen Stammzellen die nicht aus dem Mesencephalon 
isoliert wurden. In dieser Studie untersuchen wir die Auswirkungen von spezifischen 
Mitogenen, wie z.B. Sonic Hedgehog, Fibroblast Growth Factor-8 und Wnt-1, auf eine 
zielgerichtete DA-Differenzierung. Mehrere Studien haben bereits gezeigt, <lass bestimmte 
Wachstumsfaktoren eine wesentliche Rolle spielen wahrend der embryonalen Entwicklung 
von mesencephalen DA Neuronen aber auch wahrend der kiinstlichen Generierung dieser 
Neurone aus pluripotenten oder multipotenten Stammzellen. Ungeachtet <lessen scheinen 
die Differenzierungsfahigkeiten von neuralen Stammzellen eingeschrankt zu sein wenn 
ein bestimmtes zeitlich Fenster der neuralen Entwicklung verstrichen ist. In den hier 
vorgestellten Experimenten konnten wir zeigen, <lass eine spezielle Kombination von 
extrinsischen und intrinsischen Faktoren, kombiniert mit Histone-Deacetylase Inhibitoren, 
die Differenzierungskapazitaten von ,,non-mesencephalen" neuralen Stammzellen 
signifikant verstarkt. Ungefahr 1/3 der sich differenzierenden neuralen Stammzellen 
zeigen einen Dopamin-Neuron typischen Phanotyp. Die Stabilitat und Effizienz dieses 
Differenzierungsprotokolls scheint jedoch geringer zu sein fiir neurale Stammzellen als fiir 
embryonale Stammzellen. Angesichts der extrem hohen Sensitivitat und der begrenzten 
Verfiigbarkeit von autologen humanen neuralen Stammzellen erscheint es unwahrscheinlich, 
<lass dieser Zelltyp in gro:Bem AusmaB fur eine biomedizinische Anwendung geeignet 
ist. Es bleibt jedoch, ungeachtet <lessen, interessant zu untersuchen welche spezifischen 
Eigenschaften von adulten humanen neuralen Stammzellen eine Linien-spezifische 
Differenzierung inhibieren. In diesem Zusammenhang konnte z.B. gezeigt werden, <lass eine 
Induktion von Oct4 (wie es auch fiir iPSC Erzeugung benutzt wird) in neuralen Stammzellen 
die Fahigkeit zur DA-spezifischen Differenzierung wieder herstellt. 
Die Tragweite von induzierter Pluripotenz in somatischen Zellen wurde im Laufe der Zeit 
immer deutlicher und erweist sich speziell im Fall von Parkinson als sehr vielversprechendes 
Werkzeug. Vorausgehende Studien an embryonalen Stammzellen lieferten bereits zahlreiche 
Hinweise auf DA-spezifische Differenzierungskapazitaten von pluripotenten Stammzellen. 
Dieses Wiss en konnte effizient aufiPSCs iibertragen werden, wodurch zum jetzigen Zeitpunkt 
mehrere Studien die Generierungvon DA Neuronen sowohl von Mauszellen als auch humanen 
Zellen bestatigt haben. Es war jedoch noch nicht moglich Parkinson-spezifische Mutationen 
und deren molekulare pathologische Konsequenzen in aufgereinigten Zellpopulationen zu 
untersuchen. Eine Aufreinigungsprozedur ist des weiteren unvermeidlich wenn derartig 
generierte Zellen in der Zukunft als therapeutische Option in Erwagung gezogen werden 
sollen. In Kapitel 4 haben wir transgene iPSC Linien generiert die sowohl eine Aufreinigung 
von neuralen Vorlauferzellen als auch eine Aufreinigung von ausgereiften DA Neuronen 
erlaubt. Speziell letztere wurden einer umfassenden vergleichenden Charakterisierung mit 
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primaren mesencephalen DA Neuronen unterzogen um zu evaluieren zu welchem Ausmafi 
die kiinstlich generierten DA Neuronen echten, aus dem Hirn isolierten DA Neuronen 
entsprechen. Dies ist die erste Studie die eine sehr detaillierte Beschreibung von iPSC­
generierten DA Neuronen liefert und damit Auskunft iiber genetische und epigenetischen 
Eigenschaften von iPSC-generierten DA Neuronen gibt. 
In vitro-Herstellung von mesencephalen DA Neuronen wird als vielversprechende 
Option zur Behandlung von Parkinson angesehen und gemischte Populationen von 
neuralen Vorlauferzellen wurden bereits erfolgreich in Ratten-Modelle fiir Parkinson 
transplantiert. Derartige multipotente Zellimplantate tragen allerding einige Risiken. 
So ist z.B. nicht bekannt wie unbekannte Zelltypen innerhalb einer solchen Population 
die Wirksamkeit von DA Neuronen maskieren oder modulieren. Des Weiteren besteht 
bei unvollstandiger Differenzierung <las Risiko auf Teratomaformierung innerhalb des 
Transplantationsbereiches. In Kapitel 5 stellen wir eine Pilot-Studie vor in der aufgereinigte 
iPSC-generierte DA Neurone in 6-0HDA Parkinson-Ratten transplantiert wurden um 
deren Funktionalitat zu evaluieren. Unsere Resultate weisen darauf hin, <lass selbst relativ 
geringe Mengen von aufgereinigten DA Neuronen zu einer drastischen Verbesserung von 
Neurotoxin-induziertem Rotationsverhalten fiihren. Wenngleich diese Studie zuniichst als 
unvollstandig anzusehen ist liefert sie dennoch vielversprechende Ergebnisse hinsichtlich 
der Funktionalitat der von uns generieren und transplantierten DA Neurone. Es besteht 
daher die Hoffnung, <lass die Ergebnisse aus diesen Modelversuchen iibertragbar auf 
zukiinftige klinische Zelltherapie sind. Bevor allerdings derartige Therapien in Frage 
kommen bedarf es jedoch noch ausgedehnter Forschung. 
Derzeit sind humane iPSCs der Zelltyp der Wahl um Erkrankungen zu modellieren 
und zu studieren. Im Fall von Parkinson ist es daher iiufierst wichtig DA Neurone so exakt 
wie moglich zu generieren. Dafiir ist es unausweichlich den Vorgaben der in vivo DA­
Entwicklung so genau wie moglich zu folgen. Neue Studien haben gezeigt, <lass embryonale 
Stammzellen, die zuvor zu sogenannten ,,floor-plate" Zellen (Als ,,floor plate" wird eine 
Struktur im sich entwickelnden Embryogehirn bezeichnet die sich entlang der ventralen 
Mittellinie ausbreiten.) differenziert wurden, sehr effizient zu DA Neuronen differenzieren. 
In Kapitel 6 beschreiben wir die Generierung von humanen iPSCs und untersuchen deren 
Kapazitat zur DA-Differenzierung unter Verwendung des zuvor genannten ,,foor-plate" ­
Protokolls. Unsere Resultate bestiitigen <las hohe Potential dieses Gewebe-spezifischen 
DA-Induktionsprotokolls. Wir konnten hohe prozentuale Anteile von korrekt gebildeten 
DA Neuronen finden. Daher lasst sich schlussfolgernd sagen, <lass ein gewebespezifisches 
,,priming" von pluripotenten Stammzellen zu robuster Formierung von DA Neuronen 
fiihrt. Dieses Protokoll konnte sich in Zukunft als sehr niitzlich erweisen um Parkinson 
zellular und Patienten-spezifisch zu modellieren. Wenn dariiberhinaus weitere Forschung 
zu humanen DA Populationen fiihrt, die sich in ahnlicher Weise aufreinigen lassen wie hier 
in Kapitel 4 und 5 beschrieben, konnten diese Zellen potenziell fiir Patienten-spezifische 
Zelltherapie Verwendung finden. 
Zusammenfassend lasst sich sagen, <lass die Entdeckung von induzierten pluripotenten 
Stammzellen immensen Einfluss hatte auf <las Forschungsgebiet der regenerativen Medizin. 
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Es konnte iiberzeugend gezeigt werden, <lass iPSCs wahrhaft pluripotent sind und damit 
vergleichbare Differenzierungskapazitaten aufweisen als embryonale Stammzellen. 
Mit iPSCs ist es jedoch moglich die an embryonale Stammzellen gekniipften ethischen 
Hiirden ganzlich zu umschiffen. Dieser kiinstlich generierte Zelltyp erlaubt nicht nur das 
Patienten-spezifische modellieren von molekularen und zellularen Konsequenzen einer 
speziellen Pathologie, sondern ermoglicht zudem die Erzeugung von maBgeschneiderten 
Patient-eigenen Zellen (wie z.B. DA Neurone) , welche sich in Zukunft als wertevolle 
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bachelor student and I have to say that the Med Fys is truly something special. Obviously 
the atmosphere and dynamics of a group is made by the people in it and you guys created a 
terrific work environment. 
Trix, the statement 'zonder Trix gebeurd er nix' is absolutely true. Thanks for helping 
to arrange endless numbers of things during the last five years. With your kind and always 
positive attitude you manage even to make administration pleasant. 
Itje, thanks for helping out when cryosections became important. Your friendly and 
helpful spirit majorly contributes to the positive dynamics of the whole group. 
Loes, as the most important person in the cell culture you always make sure that things 
are running as smooth as possible. Thanks for providing this crucial environment. Besides 
that I very much enjoined our non-work related conversations on several occasions. 
Michel, THE MAN when it comes to microscopy. I think, with your help, we managed 
to capture some nice pictures. By the way, you are the only person I know who dug a ditch 
at the beach. ;-) 
Eef, I really cannot thank you enough for all your help with cloning, qPCRs and bisulfite 
sequencing (probably I forgot something in this list). You were extremely cooperative and 
you came up with solutions when I ran out of ideas. Working with you was always fun. 
Nieske, I was looking for a term that describes you and the role you play (at least in my 
eyes) in the department. I believe it could be 'gray eminence'. As you know, this is a person 
with tremendous influence and importance because of wisdom and knowledge, who acts 
behind the scenes and actually does not like the spotlight. 
Bart, we had several work but also non-work related conversations, which I enjoyed very 
much. I profited a lot from your molecular biology knowledge and the inspiring discussions 
we had around it. You also (knowingly or not) provided a different perspective for me 
regarding the successful fusion of work and private life. 
Kumar, over the years you became a real friend. You always have some interesting story 
to tell and I will never forget our beer-bet (which I lost) at noorderzon. And we still need to 
have that bbq, by the way. Yes, this is an invitation! 
The Phd fellows: As all of you guys certainly know, the road to reach the degree that we are 
all striving for can be a stony one. Nonetheless, I am sure you agree that some of the biggest 
fun we have during this endeavor is with the fellow PhD students. So in my case you guys. 
Marcin, you too became a good friend. I always had lots of fun in all the pubs in 
Groningen we went together, during the football matches we watched and particularly 
during the legendary bbq at your place. I wish you and Kasia all the best and who knows . . .  
you always meet twice in life. 
Arun, you joined late but our 'obsession' with sports provided a quick link. I enjoyed 
our squash competition. I guess some of this attitude is helpful in science too. Don't get me 
wrong but some day I' ll kick your butt on the court. 
Divya, as my long-time roommate we had plenty of conversations about almost 
everything. I liked that a lot. Good luck with the last couple of meters. 
Wandert, man, I think after you joined the lab I never won the bowling cup again. Keep 
up that relaxed attitude, this comes in handy, especially towards the end. 
Ming-San, when I looked at you I realized that I really don't have soo much to do. 
Incredible, how you manage so many things at once. Hope that everything turns out fine. 
Suping, it was really fun working with. Your seemingly endless positive charisma and 
cleverness was very refreshing. Keep that up . . .  I guess this will bring you far. And remember 
Irish Coffee is not only Coffee. ;-) 
Duco, as the newcomer in the lab and as a new roommate you integrated very quickly. I 
enjoyed our coffee/tea breaks. Whish you good luck with the huge exome sequence project. 
Vishnu, there is a saying in german, which literally translated goes something like that: 
'good things come to those who wait'. On this note: Take it easy! And now you can use my 
pipettes. ;-) 
Ilia, it's always good to have somebody around who takes care of the next movie night. 
Good luck with your projects. 
Inge, good luck with starting the bioinformatics branch in the department. Hope things 
will go well with the planned RRBS experiments. 
Ria, whether it was our bowling competition, at noorderzon or during the lab trips, we 
always had a relaxed time. Thanks for that. 
Xhilin, thanks for the interesting stories about China. Hope you enjoyed watching 
football matches with us. Good luck with the PhD in the Netherlands. Keep looking for 
food you like in the super market. 
Other members of the Med Fys: 
Although we did not directly work together I would like to extend my gratitude to Wieb, 
Rob (particularly form your advice with my patch-clamp experiments), Inge and Tjalling. 
As I said, a group is defined by the people and all of you contributed extensively to a great 
atmosphere. Thanks for this important facet of a satisfying work environment. 
Former Med Fys members: 
Hilmar, we figured out quickly that we both enjoyed a coup of coffee and fresh air 
(partially polluted by your cigarette smoke). And it didn't take long to find out that we 
shared the same affection for good beer and even better pizza. These were the pillars for, 
what I would call a great friendship. Let's keep in touch. So far that went pretty good. 
Sham, bro! We had a fantastic time. We went almost equally through ups and downs 
during our PhD, be it failing experiments or accepted paper. But besides that we had a lot of 
fun e.g. while you were learning how to swim ;-), in several pubs and clubs in the city, during 
moving all your stuff from one house to another several times or during our visit in Rome. 
Most of those things created unforgettable memories. Hope to see you soon in the US. 
Sander, as my first roommate (or actually I became your roommate) you, Hilmar and 
me enjoyed many coffee breaks together. Thanks for the distraction when it was needed. 
Marta & Falak, see you guys soon somewhere in Boston. 
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Marjolein, the coolest cell culture chief I know. Hope things are going fine for you. 
Michiel, the DJ, the time before and after we shared an office was never as lively (and a 
little chaotic) again. Keep going master of the turntables. 
Serena & Jonathan, thanks for cooking authentic Italian food on several occasions and 
for great company. We had a lot of fun during poker sessions at your place ( even though 
I lost badly), in many different pubs and restaurants and of course while renovating your 
house. ;- ) All the best for both of you and for the little ones. 
Old friends (Till and Daniel): Jungs, wir kennen uns ja j etzt schon einige Zeit und ich 
habe festgestellt das ein paar Tage Ablenkung mit euch beiden, sei es auf nem Hausboot 
in Amsterdam, im Backpacker in London oder in Kopenhagen, Wunder wirken. Fast wie 
richtiger Urlaub. Ich war hinterher meist kaputt aber hab auch mehr gelacht in drei Tagen 
als normalerweise in nem Monat. Das machen wir demnachst wieder! 
The Beachers: One of the things I am passionate about is playing beach volleyball with like­
minded people. You guys (Petros, Paul, Eelke, Jarno and Dennis) made that possible. Thanks a lot 
for this great time we had during hours of training and during several tournaments we went to. 
The Pintelier Crew: Another thing I am passionate about is a nice beer with good company. 
Luckily we had established the Pintelier night early on and now there are waiters who know 
what we would order before we even say a word. Big thank you Carlos, Ulrike, Arne, Golnar, 
Fany, Areg, Nekeia, Sham, Marcin, Kasia, Maxi and all the others that joined regularly or 
occasionally for refreshing beverages. Those were great nights. 
Next to colleagues and friends, moral support from the family is of utmost importance. 
Therefore I would like to express deepest thankfulness to my family in this very last part. 
Ohne familiare Unterstiitzung ware eine Doktorarbeit vermutlich ganzlich unmoglich. 
Anders als fiir die meisten Wegbegleiter zu diesem Abschluss beginnt hier die Anteilnahme 
und Unterstiitzung schon weit friiher. Als allererstes mochte ich in diesem Zusammenhang 
meiner Mutter danken. Ohne deine unermesslichen Beitrage zu vielzahligen Fassetten 
ware mein Studium und die darauffolgende Doktorarbeit wahrscheinlich nicht erfolgreich 
verlaufen. Ebenso unschatzbar und wertvoll war der Einfluss meiner Grofieltern. Eure 
grenzenlose Liebe und Zuneigung und das eroffnen von neuen Perspektiven hat im grofiem 
Mafie zu meinem Werdegang beigetragen. Ich weifi, dass meine beiden Grofivater gerne 
bei diesem grofien Etappenende dabei gewesen waren. Ich mochte auch meiner Schwester 
danken. Eva, auch du warst immer sehr unterstiitzend und die Tatsache, dass du dich schon 
friih fiirs Ausland entschieden hast hat sicher in gewisser Weise meine Entscheidungen 
beeinflusst. Und das zum Besseren! Hoffe wir sehen uns in Zukunft wieder haufiger, 
schliefilich wohnen wir ja bald auf der gleichen Seite des atlantischen Ozeans. Weiterhin 
mochte ich auch meinem Yater und Gabi danken. Lange Gesprache am Kamin oder zum 
Pferdeweihnachten mit nem Glasschen Wein haben, wenn sich die Gelegenheit ergab, 
immer fiir willkommene Abwechslung und Ablenkung gesorgt. 
Zu allerletzt mochte ich Romy danken. Du warst und bis mein engster und wichtigster 
Begleiter auf dem Weg zum Doktortitel. Wir haben uns in Groningen kennengelernt und 
aus Freundschaft wurde eine besondere Beziehung. Durch deine tiefe Zuneigung, deine 
Geduld und <lurch eine Vielzahl von Ratschlagen wurden schwierige Zeiten um vieles 
leichter. Danke furs ausbalancieren von Arbeits- und Privatleben. Ich freu mich sehr auf 
unsere gemeinsame Zukunft und auf die Abendteuer die anstehen. 
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